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Abstract 
In Friedreich’s ataxia (FRDA), abnormal GAA repeat expansions in intron 1 of the 
frataxin gene (FXN) cause epigenetic changes and reduce FXN mRNA levels in averaged 
cell samples though a poorly understood mechanism. Dissecting the silencing mechanism 
in FRDA in situ is crucial to improve our understanding of the disease. 
Here, I use novel FRDA human cell models suitable for screening compounds able 
to upregulate FXN expression and to analyse the link between FXN nuclear localisation 
and expression in single cells. FXN-Luc, FXN-GAA-Luc, FXN-MS2-Luc and FXN-GAA-
MS2-Luc stable human clones carry a site-specific integration of a single copy of the whole 
FXN locus with either 6 (FXN-Luc and FXN-MS2-Luc) or ~310 (FXN-GAA-Luc and FXN-
GAA-MS2-Luc) GAA repeats in intron 1. To fluorescently label the transgenic FXN 
mRNA, I inserted MS2 binding sites into exon 2 of FXN-MS2-Luc and FXN-GAA-MS2-
Luc transgenes by homologous recombination. The ~310 GAA repeats recapitulate the 
characteristic FXN gene repression and epigenetic changes seen in FRDA. 
I report a single-cell analysis of FXN repression in which I identify the nuclear 
lamina (NL) as a novel and key player in FXN transcriptional impairment and silencing. 
Using a multidisciplinary approach, including analysis in both fixed and living single cells, 
I show that expanded GAA repeats increase FXN positioning at the NL, leading to 
decreased numbers of FXN mRNA molecules and slower transcription kinetics in the FXN-
GAA-MS2 cell model. Restoring histone acetylation reverses NL positioning. I observe the 
same abnormal repositioning to the NL in carrier and FRDA patient cells and show that 
this tightly correlates with a marked decrease in the number of actively expressing FXN 
alleles. Furthermore, I show that those few active expanded FXN alleles located at the NL 
express at a significantly lower level than the alleles located in the interior of the nucleus. 
Finally, I demonstrate that expanded GAA repeats predominantly disrupt FXN 
transcription initiation. 
Collectively, these results suggest repressive epigenetic modifications at the 
expanded GAA-FXN locus may lead to NL relocation, where further repression may occur. 
The mechanisms described may extend to other genetic diseases mediated by repeat 
expansions within regions of non-coding DNA. 
 
Keywords: Friedreich’s ataxia, GAA repeat expansion, single-cell resolution, 
heterochromatin, transcription. 
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Resumo 
Na Ataxia de Friedreich (FRDA), uma expansão de repetições trinucleotídicas GAA, 
presentes no intrão 1 do gene que codifica a proteína frataxina (FXN), causa mudanças 
epigenéticas e reduz os níveis médios de RNA do gene FXN em amostras celulares através 
de um mecanismo pouco conhecido. Com o intuito de melhor perceber a patogénese 
inerente à doença e, em última análise, desenvolver terapias eficientes para a FRDA, é 
importante criar modelos celulares que traduzam as características repressivas da doença 
ao mesmo tempo que permitem quantificar eficientemente os níveis de expressão do gene 
FXN.  
As linhas celulares reporter FXN-GAA-Luc, FXN-Luc, FXN-GAA-MS2-Luc e FXN-
MS2-Luc, descritas nesta Tese, foram especificamente criadas de modo a permitir a 
comparação directa entre o efeito das repetições GAA normais e expandidas na expressão 
do gene FXN. Para o efeito usei: (i) todo o locus FXN com o seu promotor, intrões e exões 
originais e todos os elementos necessários para a expressão fisiológica do transgene, com 
inserção do gene luciferase no final do exão 5a; e (ii) uma única cópia de cada BAC 
integrado num sítio FRT especificamente localizado no cromossoma 1 de células HEK 
FRT, de modo a excluir efeitos contraditórios na expressão do gene FXN devido a 
integração de ambos os vectores em sítios diferentes. 
Análise das modificações das histonas no promoter do gene FXN e regiões que 
ladeiam as repetições GAA a montante e a jusante revelou um decréscimo da acetilação de 
H3K9 e H4K8 e um aumento da metilação de H3K9me2 e H3K9me3 nas três regiões nas 
células FXN-GAA-Luc. Adicionalmente, as regiões a montante e a jusante das repetições 
GAA das células FXN-GAA-Luc apresentam um aumento da metilação do DNA em CpG 
específicos. As células FXN-GAA-Luc foram usadas num rastreio de compostos 
terapêuticos e permitiram identificar uma molécula capaz de aumentar a expressão do gene 
FXN-GAA-Luc para níveis similares aos das células FXN-Luc. A análise usando a técnica 
de imunoprecipitação da cromatina em células derivadas de pacientes depois de tratadas 
com esta molécula revelou o restauro para níveis normais de acetilação de H3K9 e H4K8 
nas regiões que ladeiam as repetições GAA. Estes resultados sugerem que as repetições 
GAA induzem a repressão do gene FXN nas células FXN-GAA-Luc através da alteração da 
estrutura da cromatina no transgene, fazendo com que estas células sejam consideradas 
excelentes para o rastreio de moléculas capazes de aumentar a expressão do gene FXN. 
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No entanto, o modelo FXN-GAA-Luc apenas apresenta o estado provável do gene 
FXN visto que os resultados provêm de experiências onde se efectuam medições médias 
resultantes de amostras contento milhões de células. Consequentemente, o modelo FXN-
GAA-MS2-Luc foi criado para dissecar o mecanismo repressivo de FRDA in situ, 
permitindo a visualisação e análise da localização e repressão de FXN em células fixas e 
vivas usando o sistema MS2. 
Neste trabalho, desenvolvi um modelo celular humano para analisar a associação 
entre a localização e a expressão do gene FXN ao nível da célula. Os clones celulares 
estáveis FXN-MS2-Luc e FXN-GAA-MS2-Luc foram gerados por integração dos transgenes 
num local específico e contêm todo o locus FXN de 80 kb, o gene repórter luciferase no 
exão 5a e seis repetições ou uma expansão de ~310 tripletos GAA no intrão 1, 
respectivamente. Para efectuar uma marcação fluorescente do mRNA FXN transgénico e 
quantificar o efeito da expansão de tripletos GAA na transcrição do gene, inseri 24 
repetições de locais de ligação da proteína MS2 (MBS) no exão 2 por recombinação 
homóloga. A expansão de ~310 GAA na linha celular FXN-GAA-MS2-Luc traduz as 
características repressivas do gene FXN em FRDA. 
A localização do transgene FXN nas linhas FXN-MS2-Luc e FXN-GAA-MS2-Luc 
foi determinado por Immuno-FISH. FXN contactou com a lâmina nuclear (NL) em ~44% 
das células FXN-GAA-MS2-Luc quando comparado com apenas ~10% das células FXN-
MS2-Luc. Após tratamento das células com inibidores das desacetilases de histonas, apenas 
o transgene FXN-GAA-MS2-Luc se reposicionou longe da NL. No entanto, ocorreu um 
aumento da expressão do mRNA FXN transgénico nas duas linhas celulares, sugerindo que 
existe uma associação complexa entre repressão do gene FXN e a sua localização 
intranuclear. Para aprofundar o conhecimento sobre a repressão do gene FXN, analisei o 
output de transcrição de alelos FXN transgénicos individuais nas células FXN-MS2-Luc e 
FXN-GAA-MS2-Luc por RNA FISH e recuperação de fluorescência após a fotodegradação 
(FRAP). As células FXN-GAA-MS2-Luc contêm ~5 ± 2 mRNAs por célula e as células 
FXN-MS2-Luc cells contêm ~9 ± 4 mRNA por célula, indicando que ~310 tripletos GAA 
reduzem o número de moléculas de mRNA em 44% ao nível celular. As curvas FRAP 
mostram que o tempo necessário para a recuperação completa da fluorescência após a 
fotodegradação é diferente nas duas linhas celulares. O transgene FXN-MS2-Luc 
apresentou um tempo total de recuperação de 120 segundos, enquanto o transgene FXN-
GAA-MS2-Luc apresentou uma cinética mais lenta com recuperação total de 260 segundos. 
Devido ao facto de a estabilidade do mRNA de FXN não apresentar diferenças entre as 
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células FXN-GAA-MS2-Luc e FXN-GAA-MS2-Luc, os resultados de RNA FISH e FRAP 
indicam que a expansão de GAA diminui a quantidade de moléculas de mRNA de FXN-
GAA-MS2-Luc através do impedimento da iniciação e/ou elongação da transcrição por 
parte da polimerase de RNA II. De modo a elucidar a relação entre a localização e 
repressão do gene FXN, analisei a intensidade fluorescente de transgene activos em células 
FXN-MS2-Luc e FXN-GAA-MS2-Luc vivas. A intensidade fluorescente de locais de 
transcrição foi significativamente menor quando os transgenes estavam a expressar na 
periferia nuclear comparando com o nucleoplasma em células FXN-MS2-Luc e FXN-GAA-
MS2-Luc. Estes dados indicam que os dois transgenes expressam quando localizados na 
periferia nuclear, embora o façam em quantidades mais pequenas. Quando comparados 
com transgenes FXN-MS2-Luc activos, a intensidade dos locais de transcrição dos 
transgenes FXN-MS2-GAA-Luc foi significativamente mais baixa apenas no interior do 
núcleo. No seu conjunto, estes resultados sugerem que a expansão de GAA aumenta a 
localização do transgene FXN-GAA-MS2-Luc na NL, onde os níveis de expressão são 
reduzidos quando comparados com o interior nuclear ou com os níveis de expressão do 
transgene FXN-MS2-Luc.  
Em seguida, analisei a localização do gene no seu ambiente genómico natural em 
células derivadas de pessoas saudáveis, de portadores heterozigóticos de um alelo FXN 
mutante e de pacientes. Em células derivadas de portadores heterozigóticos, o alelo FXN 
contendo a expansão de GAA localiza-se preferencialmente mais próximo da periferia 
nuclear do que o alelo normal e contacta mais vezes com a NL. Quando se compara a 
localização do gene FXN em células saudáveis com células derivadas de pacientes, os 
resultados indicam que a expansão de GAA aumenta a probabilidade de um alelo se 
encontrar associado à NL e consequentemente a probabilidade de estar silenciado. 
Adicionalmente, quando os alelos FXN expandidos se encontravam a expressar, os níveis 
de expressão eram significativamente reduzidos quando se encontram no nucleoplasma, 
mas especialmente quando localizados na periferia nuclear. Estes resultados indicam uma 
relação directa entre o posicionamento do gene FXN na NL e a repressão da transcrição 
mediada pela expansão de GAA. A realização de uma quantificação ao nível cellular 
mostrou ainda que a expansão das repetições de GAA induz um défice na expressão 
maioritariamente ao nível da iniciação da transcrição do gene FXN, mas também induz um 
pequeno bloqueio na elongação da polimerase de RNA II.  
No seu conjunto, estes resultados sugerem que as modificações epigenéticas 
repressivas no locus FXN expandido podem induzir a relocalização do gene para a NL, 
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onde uma repressão adicional pode ocorrer. O efeito combinado da presença da expansão 
de GAA e relocalização do gene para a NL resultam numa redução catastrófica dos níveis 
de transcrição, levando à redução dos níveis da proteína frataxina e, em última análise, à 
manisfestação de FRDA. O trabalho descrito nesta Tese apresenta novos conhecimentos 
sobre as causas moleculares subjacentes à FRDA e poderá ser aplicável a outras doenças 
genéticas causadas por expansões de nucleótidos em regiões não codificantes do DNA. 
 
Palavras-chave: Ataxia de Friedreich, expansão de repetições GAA, resolução ao nível da 
célula, heterocromatina, transcrição. 
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1.1 Unstable expanded repeat diseases 
Abnormally expanded DNA repeats are associated with several neurodegenerative 
diseases (Table 1.1). The majority of these diseases are caused by expanded trinucleotide 
repeats, but tetra-, penta-, and hexanucleotide repeat expansions have also been identified. 
Expanded repeats can be found either in coding or non-coding regions of a given locus. In 
the first group, exonic repeats code for amino acid homopolimers, as occurs in diseases 
mediated by polyglutamine and polyalanine runs in proteins, for example Huntington’s 
disease (HD) and oculopharyngeal muscular dystrophy, respectively. In the second group, 
repeats can be located in: (i) the 5ʹ untranslated regions (5ʹ UTRs), as in fragile X 
syndrome (FRAXA), fragile X mental retardation associated with the FRAXE site 
(FRAXE), fragile X tremor and ataxia syndrome (FXTAS), and spinocerebellar ataxia 
(SCA) 12; (ii) the 3ʹUTRs, as in myotonic dystrophy (DM) 1, SCA8 and HD-like 2; (iii) 
introns, as in DM2, Friedreich’s ataxia (FRDA), SCA10, SCA31; SCA36 and C9ORF72-
related frontotemporal dementia and amyotrophic lateral sclerosis (FTD/ALS) (reviewed in 
Gatchel & Zoghbi, 2005; Mirkin, 2007; La Spada & Taylor, 2010; Polak et al, 2013). 
Although each particular disease is caused by a mutation in a different locus, several 
features are shared. Alleles are present in three states: normal, premutated and fully 
mutated. While healthy individuals carry less than 30 repeats, patients harbor longer and 
unstable tracts of repeats on mutant alleles, with a strong tendency to expand rather than 
contract. Repeats show intergenerational and somatic instability. As longer repeat tracts are 
transmitted through generations, disease symptoms become more severe and appear at an 
earlier age, a phenomenon known as anticipation (reviewed in Dion & Wilson, 2009; 
Castel et al, 2010). Repeat instability seems to be triggered by formation of unusual DNA 
structures, such as hairpins, slipped-strand structures, triplexes and quadruplexes, during 
DNA replication, repair, recombination and transcription, where there is a transient 
separation of complementary DNA strands, or exposure of a single DNA strand. The DNA 
repair machinery is then thought to bind to these aberrant structures, stabilizing instead of 
repairing them, which results in repeat expansions or contractions (Mirkin, 2007; Polak et 
al, 2013). Changes in the epigenetic landscape of the mutated locus, such as aberrant DNA 
methylation, histone modifications, and chromatin remodelling also play a role in the 
molecular pathogenesis of several unstable expanded repeat diseases (reviewed in Evans-
Galea et al, 2013). 
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Table 1.1 List of unstable repeat expansion neurodegenerative diseases (Gatchel & Zoghbi, 2005; La 
Spada & Taylor, 2010; Walsh et al, 2014). 
    Repeat length 
Disease Main clinical features Mutation Location Normal Expanded 
Loss of protein function 
FRDA Ataxia, sensory loss, 
weakness, diabetes 
mellitus, cardiomyopathy 
(GAA)n FXN (Intron 1) 6–32 70–1700 
FRAXA MR, facial dysmorphism, 
autism 
(CGG)n FMR1 (5′ UTR) 6–52 >200 
FRAXE MR, hyperactivity (GCC)n FMR2 (5′ UTR) 4–39 200–900 
Toxic gain of RNA function 
SCA10 Ataxia and seizures (ATTCT)n ATXN10 (Intron 9) 10–29 400–4500 
SCA31 Ataxia, dysarthria, 
nystagmus 
(TGGAA)n TK2/BEAN (Intron) 0 ≥100 
SCA36 Ataxia, eye movement 
abnormalities, tongue 
fasciculations, upper and 
lower motor neuron 
disease 
(GGCCTG)n NOP56 (Intron 1) 3–14 650–2500 
DM1 Muscle weakness, 
myotonia, cardiac 
conduction deficit, MR 
(CTG)n DMPK (3′ UTR) 5–37 50–1000 
DM2 Muscle weakness, 
myotonia, cardiac 
conduction deficit 
(CCTG)n ZNF9 (Intron 1) 10–26 75–11,000 
FXTAS Ataxia, intention tremor, 
parkinsonism, cognitive 
deficit 
(CGG)n FMR1 (5′ UTR) 6–52 55–200 
Toxic gain of protein function 
DRPLA Ataxia, epilepsy, 
choreoathetosis, dementia 
(CAG)n ATN1 (Exon 5) 7–34 49–88 
HD Severe movement 
abnormalities, chorea, 
dystonia, cognitive 
decline, psychiatric 
features 
(CAG)n HTT (Exon 1) 6–28 36–180 
SBMA Motor weakness, 
swallowing difficulty, 
gynecomastia, 
hypogonadism 
(CAG)n AR (Exon 1) 9–36 38–62 
SCA1 Ataxia, dysarthria, 
spasticity, cognitive 
impairment 
(CAG)n ATXN1 (Exon 8) 6–39 41–83 
SCA2 Ataxia, slow eye 
movement, hyporeflexia, 
polyneuropathy, motor 
neuropathy, infantile 
variant 
(CAG)n ATXN2 (Exon 1) 15–24 32–200 
SCA3 
(MJD) 
Ataxia, dystonia, lower 
motor neuron disease 
(CAG)n ATXN3 (Exon 10) 13–36 61–84 
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SCA6 Ataxia, dysarthria, 
nystagmus, tremor 
(CAG)n CACNA1A (Exon 47) 4–20 20–33 
SCA7 Ataxia, retinal 
degeneration, cardiac 
involvement in infantile 
variant 
(CAG)n ATXN7 (Exon 3) 4–35 37–306 
SCA17 Ataxia, behavioural 
changes or psychosis, 
intellectual deterioration, 
seizures 
(CAG)n TBP (Exon 3) 25–44 47–63 
Toxic gain of function at both the protein and RNA levels 
SCA8 Ataxia, dysarthria, 
nystagmus 
(CTG)n*(CAG)n ATXN8OS (3′ UTR) 
and ATXN8 (Exon 1) 
15–50 71–1300 
Haploinsufficiency and toxic gain of function at both the protein and RNA levels 
FTD/ALS Cognitive impairment, 
psychosis/Upper and lower 
motor neuron disease, 
paralysis 
(GGGGCC)n C9ORF72 
(5’UTR/Intron 1) 
2–19 30–2000 
Unknown pathogenic mechanism 
SCA12 Ataxia, tremor, dementia (CAG)n PPP2R2B (5′ UTR)  7–28 55–78 
HDL2 Similar to HD (CTG)n*(CAG)n JPH3 (exon 2A) 7–28 66–78 
Abbreviations: AR, androgen receptor; ATXN, ataxin; BEAN, brain-expressed, associated with Nedd4; 
CACNA1A, calcium channel, voltage-dependent, P/Q type, α1A subunit; DM1, myotonic dystrophy type 1; 
DM2, myotonic dystrophy type 2; DMPK, dystrophia myotonica protein kinase; DRPLA, dentatorubral-
pallidoluysian atrophy; DM, dystrophia myotonica; FMR1, fragile X mental retardation 1; FMR2, fragile X 
mental retardation 2; FRAXA, fragile X syndrome; FRAXE, fragile X mental retardation associated with the 
FRAXE site; FRDA, Friedreich ataxia; FTD/ALS, frontotemporal dementia and amyotrophic lateral sclerosis; 
FXN, frataxin; FXTAS, fragile X tremor/ataxia syndrome; JPH3, junctophilin 3; HD, Huntington’s disease; 
HDL2, Huntington’s disease-like 2; HTT, huntingtin; MJD, Machado–Joseph disease; MR, mental 
retardation; NOP56, nucleolar protein 56; PPP2R2B, protein phosphatase 2 (formerly 2A) regulatory subunit 
B; SBMA, spinal and bulbar muscular atrophy; SCA, spinocerebellar ataxia; TBP, TATA box binding 
protein; TK2, thymidine kinase 2; ZNF9, zinc-finger protein 9. 
 
There are three key pathological mechanisms by which expansions result in disease: 
(i) loss of function typically by disrupting transcription of the mutated gene (FRDA, 
FRAXA, FRAXE); (ii) RNA toxic gain of function through aberrant interactions of the 
respective RNAs with proteins controlling RNA metabolism (SCA10, SCA31, SCA36, 
DM1, DM2, FXTAS); and (iii) protein toxic gain of function via abnormal protein 
interactions and accumulation of aggregates (polyglutamine diseases, for example HD) 
(reviewed in Nelson et al, 2013). Interestingly, some diseases have more than one repeat-
mediated mechanism at play, for example SCA8 and C9ORF72-related FTD/ALS. In 
SCA8, two overlapping genes expressed in opposite directions are affected by the 
expansion, with a (CAG)n expansion in the ataxin 8 gene (ATXN8) and a (CTG)n expansion 
in the non-coding 3’ UTR of the ataxin 8 opposite strand gene (ATXN8OS). As a result, 
ATXN8 expresses a polyglutamine expansion protein, and ATXN8OS produces non-coding 
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CUG expansion mRNAs which accumulate as RNA foci and sequester RNA-binding 
proteins (Moseley et al, 2006; Daughters et al, 2009). In C9ORF72-related FTD/ALS, the 
(GGGGCC)n hexanucleotide repeat expansion leads to disease by: (i) formation of DNA 
and RNA G-quadruplexes and RNA/DNA hybrids (R-loops) which lead to abortive 
transcription; (ii) formation of RNA foci that bind to ribonucleoproteins, preventing RNA-
processing factors from functioning normally in the nucleus; and (iii) repeat-associated 
non-ATG (RAN) translation, which results in the production of dipeptide repeat proteins 
that also form inclusions in affected cells (DeJesus-Hernandez et al, 2011; Renton et al, 
2011; Mori et al, 2013; Haeusler et al, 2014). 
In the following sections, I review the major findings in FRDA and also highlight the 
similarities with other repeat expansion diseases with special emphasis on non-coding 
repeats at the DNA and RNA level. 
 
1.2 Friedreich’s ataxia 
Friedreich’s ataxia (FRDA; OMIM 229300) is a progressive neurodegenerative 
disease and the most common form of recessive ataxia (Campuzano et al, 1996). The 
disease is named after Nikolaus Friedreich (1825–1882), a German pathologist and 
neurologist, who first described its clinical features (Friedreich, 1863a, 1863b, 1863c) and 
hereditary nature (Friedreich, 1876, 1877). An abnormal GAA trinucleotide–repeat 
expansion in intron 1 of the frataxin gene (FXN) causes FRDA. Approximately 96% of 
FRDA patients are homozygous for a GAA repeat expansion and the remaining patients 
(4%) are compound heterozygous with one expanded allele and a classical mutation 
(nonsense, missense, deletions, insertions) in the second allele (Campuzano et al, 1996; 
Bidichandani et al, 1997; Cossée et al, 1999). FXN alleles in healthy individuals contain 
<36 GAA repeats, whereas in FRDA patients GAA expansions ranging from ~70 to 1700 
GAA repeats lead to FXN mRNA deficiency and subsequent reduced levels of frataxin, a 
nuclear-encoded mitochondrial protein essential for life (Campuzano et al, 1996; Cossée et 
al, 2000).  
 
1.2.1 Etiology 
Normal FXN alleles are divided in 2 groups: short normal (SN, <10 GAA repeats) 
and long normal (LN, from 12 to 60 GAA repeats). LN FXN alleles account for ~17% of 
normal alleles. Haplotype analysis of five markers (FAD1-ITR4-F5225-ITR3-CS2) close 
to the GAA repeats revealed that a single founder event that occurred on the major AT2CC 
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haplotype is at the origin of the LN alleles and the expanded alleles. The two second most 
frequent haplotypes AT3CC and AT2CT are most likely derived from the major haplotype 
by marker mutation rather than by independent events on different haplotypes (Cossée et 
al, 1997). Expanded FXN alleles are thought to have arisen through a two-step process. A 
singular event was responsible for the transition of SN to LN GAA repeats as these alleles 
only share the same haplotype rarely. This is thought to have occurred through DNA 
polymerase “stuttering” during DNA replication, originating LN alleles of (GAA)18 by 
duplication of SN alleles of (GAA)8. After a number of small increases in size because of 
slippage events, larger LN alleles served as a pool for further repeat expansions once the 
instability threshold (~34 GAA repeats) was reached (Montermini et al, 1997a; Labuda et 
al, 2000). Therefore, repeat numbers between 35 and 66 are referred as premutations. In 
line with this, all LN and expanded alleles share a common haplotype (Cossée et al, 1997). 
A single initial event is also thought to have occurred in DM1, HD, DRPLA and 
MJD where haplotypes associated preferentially or uniquely with expanded alleles are also 
preferentially associated to LN alleles (Imbert et al, 1993; Rubinsztein et al, 1995; 
Takiyama et al, 1995; Yamagata et al, 1996; Yanagisawa et al, 1996). Furthermore, as 
observed in FRDA, the prevalence of DM1, HD and DRPLA in a given population is 
correlated with the frequency of the LN alleles (Novelli et al, 1994).  
The FRDA founding mutation is dated between 9,000 and 24,000 years ago and went 
through a population bottleneck (Colombo & Carobene, 2000) which coincides with the 
glacial period in Europe. This may provide an explanation for the highest prevalence of 
FRDA in the surviving northern Spain ice age refuge (Polo et al, 1991). Further support 
comes from the observed distribution of FRDA in the remaining European regions where 
the prevalence decreases from west to east and correlates with the frequency gradient of 
the chromosomal R1b marker, a genetic marker for the population that originated from the 
Cantabrian refuge (Tambets et al, 2004). It has been hypothesized that the FRDA 
distribution in Europe is derived from Palaeolithic migrations out of the Franco-Cantabrian 
ice age refuge (Vankan, 2013). 
 
1.2.2 Epidemiology 
FRDA is detected in individuals from Europe, the Middle East, North Africa and 
India (Labuda et al, 2000). The prevalence of the disease is closely correlated with the 
frequency of LN FXN alleles in the population, and is highest in Western Europe, with 
more than 1 case per 30,000 individuals (1/30,000) reported in north-west Spain and 
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Ireland (Schulz et al, 2009; Vankan, 2013). LN alleles are virtually absent in individuals 
from East Asia and in American Indians (Labuda et al, 2000). 
The frequency of heterozygous mutation carriers in Europe shows a decreasing 
gradient from south to north-east, ranging from 1:78 in France to 1:89 in Germany and 
1:500 in Finland (Cossée et al, 1997; Epplen et al, 1997; Labuda et al, 2000; Juvonen et al, 
2002; Schulz et al, 2009; Vankan, 2013). The prevalence of FRDA in Caucasians is shown 
in Table 1.2. 
 
Table 1.2 Prevalence of FRDA in Caucasians (source: Schulz et al, 2009; Vankan, 2013). 
Country Prevalence of FRDA 
Cantabria, Spain 4.7/100,000 
Denmark 0.5-1/100,000 
Finland 0.13/100,000 
France 4.2/100,000 
Germany 3.1/100,000 
Norway 1/100,000 
Portugal 0.95/100,000 
Sweden 0.23/100,000 
United Kingdom 1.8/100,000 
 
1.2.3 Clinical features of FRDA 
The healthy FXN gene is expressed in all cells but at variable levels. In adult humans, 
FXN mRNA is most abundant in the heart and spinal cord, mild in the cerebellum, 
pancreas, liver, brown fat and skeletal muscle, and low in other tissues, such as the cortex 
(Campuzano et al, 1996; Koutnikova et al, 1997). In FRDA, residual levels of frataxin 
vary according to the length of the expansion and the cell type. Affected cells, such as 
sensory neurons and cardiomyocytes, are known to have a high mitochondrial content and 
high metabolic rate, making them more sensitive to frataxin deficiency. 
The first neurologic symptoms usually appear around puberty, but early-onset and 
late-onset variants also exist. Patients experience progressive gait and limb ataxia, 
dysarthria and lower limb areflexia, resulting from the loss of large sensory neurons in the 
dorsal root ganglia (DRG), atrophy of the large sensory fibres in peripheral nerves, 
degeneration of the posterior columns, spinocerebellar and corticospinal motor tracts in the 
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spinal cord and dentate nucleus in the cerebellum (Fig. 1.1). Hearing disability and loss of 
vision are also common. Non-neurological symptoms include hypertrophic 
cardiomyopathy, diabetes mellitus, kyphoscoliosis and pes cavus. Life expectancy is 
reduced to an average of 40-50 years (Filla et al, 1990; Dürr et al, 1996; Pandolfo, 2009; 
Schulz et al, 2009). 
In most cases, compound heterozygous patients are clinically indistinguishable from 
patients that are homozygous for the GAA repeat expansions, but a few missense 
mutations (e.g., G130V, D122Y, R165P, L106S) may cause an atypical or milder clinical 
phenotype due to an adverse effect on protein expression, function and/or stability (Cossée 
et al, 1999; Gellera et al, 2007). 
 
Figure 1.1 Main sites of organ dysfunction in FRDA. Large dots indicate more severe neuronal loss. 
Pathological features are shown for the brain, spinal cord (SC), heart (H) and pancreas (P). Loss of large 
primary neurons in dorsal root ganglia is a prominent and early hallmark. As the disease progresses, the 
posterior columns of the spinal cord degenerate. This associated with atrophy of the spinocerebellar tracts, 
the corticospinal motor tracts of the spinal cord and the large sensory fibers in peripheral nerves. Non-
neurological symptoms include hypertrophic cardiomyopathy and diabetes (adapted from Taroni & 
DiDonato, 2004). 
 
In homozygous patients, the GAA repeat length of the shorter of the 2 FXN expanded 
alleles correlates with residual frataxin protein levels, earlier onset (Fig. 1.2) and 
confinement to a wheelchair, and increased phenotypic severity of the disease (Dürr et al, 
1996; Filla et al, 1996; Montermini et al, 1997b). The GAA expansion length only 
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accounts for ~50% of the variability in age of onset (Filla et al, 1996). Phenotypic 
variability among FRDA patients and within affected families can be also due to 
intergenerational instability of the GAA expansion, somatic mosaicism, interruptions in the 
repeat sequence, changes in expansion size over life and other modifying genes or 
environmental factors (Dürr et al, 1996; Montermini et al, 1997b; Pandolfo, 2009). 
 
Figure 1.2 Correlation between age at onset and the number of GAA repeats in the smaller FXN allele. 
Larger GAA expansions in the smaller FXN allele correlates with earlier age at onset (Dürr et al, 1996). 
 
For most of the unstable expanded repeat diseases, the repeat sequence shows 
intergenerational and age-dependent somatic instability. In FRDA, DM1, FRAXA and 
SCA8, expansions and contractions are equally likely after maternal transmission, whereas 
contractions are favoured after paternal transmission (Malter et al, 1997; Monrós et al, 
1997; Pianese et al, 1997). In FRDA, expanded alleles are highly unstable in somatic cells 
in vivo. While expanded FXN allele with <250 GAA repeats tend to expand, FXN alleles 
with >500 GAA repeats show contractions in peripheral leukocytes from FRDA patients. 
Due to somatic instability, carriers carrying LN FXN alleles (44–66 triplets) can develop a 
FRDA phenotype (Sharma et al, 2002, 2004). Somatic instability in FRDA is mostly 
postnatal, progresses throughout life and is tissue-specific (De Biase et al, 2007a, 2007b). 
Expanded GAA repeats undergo progressive expansion in tissues primarily affected in 
FRDA: the DRGs, cerebellum and heart of FRDA patients (De Biase et al, 2007a), and in 
the DRGs, cerebellum and brain of mouse models (Al-Mahdawi et al, 2004; Clark et al, 
2007; Anjomani Virmouni et al, 2015). Therefore, the progressive accumulation of large 
expansions coupled with a lower frequency of large contractions in specific cell types, such 
as DRGs, suggests that somatic instability may contribute to the selective vulnerability of 
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these cells in FRDA. Although the molecular mechanism of somatic instability in FRDA is 
still poorly understood, a few studies have suggested that mismatch repair (MMR) proteins 
may be involved (section 1.3.2.1.1). 
In FRAXA and DM1, large expansions arise in non-dividing oocytes during arrest in 
meiotic prophase I, and in terminally differentiated somatic cells in females; in males, the 
full mutation alleles tend to contract in the dividing male spermatogonia, during weeks 13–
17 of fetal development, and small gains and losses in the pre-mutation range can be 
observed in both spermatogonia and in somatic cells (McMurray, 2010). 
 
1.3 The FXN locus 
 
1.3.1 FXN in healthy individuals 
The human FXN locus is located on the positive strand of chromosome 9q21.11 and 
contains seven exons (1–4, 5a, 5b, and non-coding 6). Alternative splicing results in 
multiple transcript variants with exons 1–5a generating the 1.3 kb major transcript that 
encodes the 210-amino acid frataxin protein (Campuzano et al, 1996). Two major 
transcription start sites (TSS) were identified: TSS1 is located 221 bp upstream of the ATG 
translation start site (Campuzano et al, 1996), whereas TSS2 is located 62 bp upstream of 
the ATG and is considered the major TSS in Epstein Barr virus-transformed 
lymphoblastoid cell lines. (Kumari et al, 2011). 
The FXN promoter (Fig. 1.3) is enriched in repetitive DNA elements. These include 
L2 (LINE) and Alu (SINE) elements as well as MIRb and mariner DNA transposon 
downstream of TSS1 and in intron 1 (Greene et al, 2005). The presence of these different 
retroelements suggest that the FXN promoter sequence has been remodelled repeatedly 
during the evolution of mammals and fairly recently in the primate lineage (Greene et al, 
2005). Although their contribution to FXN regulation is unclear, deleting these elements 
significantly impairs FXN expression (Greene et al, 2005). Alu and MIR elements are 
transcribed from internal RNA polymerase (RNAP) III promoters and may exert a positive 
cis-acting enhancer effect on RNAPII-transcribed genes (Oliviero & Monaci, 1988; 
Tomilin, 1999). Moreover, Alu elements are also thought to affect gene expression by 
altering nucleosome positioning (Englander & Howard, 1995) and providing direct binding 
sites for hormone receptors (Norris et al, 1995) and transcription factors (Deininger, 2011). 
The region between 121-221 bp upstream of the start of the frataxin open reading frame 
(ORF) shows homology between primates and rodents and contains important regulatory 
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elements for FXN expression (Greene et al, 2005). Interestingly, the FXN promoter does 
not present typical motifs of most mammalian promoters, such as a TATA box, and is not 
controlled by either the initiator or the downstream promoter-like elements found 24 bp 
downstream of TSS1 (Greene et al, 2005; Kumari et al, 2011).  
 
Figure 1.3 The 5' end of the FXN gene. Schematic representation of the the 5’end FXN gene showing its 
regulatory elements and protein binding sites. The repetitive DNA elements identified at the FXN locus 
include L2 (LINE) and Alu (SINE) elements as well as MIRb and mariner DNA transposon (MER). FXN is 
transcribed from TSS1, which is located 221 bp upstream of the ATG, and TSS2, located 62 bp upstream of 
the ATG. TSS2 is the major TSS in lymphoblastoid cell lines. The region between TSS1 and exon 1 is 
thought to be a TATA-less downstream promoter, which contains the initiator/downstream promoter-like 
elements (Inr/DPE). Binding sequences were identified for transcription factors SRF, TFAP2 and EGR3, and 
for the insulator protein CTCF. An E-box is present in the region upstream of the GAA repeats and can 
potentially be a target for MyoD or c-myc (adapted from Kumari & Usdin, 2012). 
 
A few studies have identified transcription factors that influence FXN expression 
(reviewed in Yandim et al, 2013). Li and colleagues showed that SRF (serum responsive 
factor) and TFAP2 (transcription factor AP2) directly bind to sequences within and 
immediately downstream of the FXN promoter region conserved between rodents and 
primates due to the presence of the L2 retrotransposon-like sequence (Greene et al, 2005; 
Li et al, 2010). TFAP2 upregulates FXN mRNA expression in several cell lines (Li et al, 
2010) and is important in the balance between cell proliferation and differentiation during 
embryogenesis (Eckert et al, 2005). SRF increases FXN expression only in specific cell-
lines and activate genes involved in synaptic activity and plasticity (Knöll & Nordheim, 
2009). Moreover, the chromatin insulator CCCTC-binding factor (CTCF) binds between 
154–173 bp downstream of TSS1 (De Biase et al, 2009). CTCF is implicated in diverse 
roles in gene regulation, including context-dependent promoter activation/repression, 
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enhancer blocking and/or barrier insulation, hormone-responsive silencing, genomic 
imprinting, and long-range chromatin interactions (reviewed in Phillips & Corces, 2009). 
The intronic region downstream of exon 1 is also important for FXN regulation. 
Deletion of the binding site for the early growth response factor EGR3 (Li et al, 2010) or 
of an E-box element (Greene et al, 2007) induced a decrease in FXN expression using 
reporter assays. The E-box element can potentially be bound by proteins of the large 
family of basic Helix-Loop-Helix that includes the muscle-specific factor MyoD and c-
myc (Greene et al, 2007). 
A polymorphic (GAA)n repeat sequence located approximately 1.3 kb downstream of 
TSS2 is embedded in the centre of an Alu element in intron 1 and is preceded by a poly(A) 
tract characteristic of Alu elements. FXN alleles in healthy individuals contain <36 GAA 
repeats, whereas in FRDA patients GAA expansions ranging from70 to 1700 GAA repeats 
lead to FXN mRNA deficiency (Campuzano et al, 1996; Cossée et al, 1997; Clark et al, 
2004; Monticelli et al, 2004). 
 
1.3.2 Molecular basis of FRDA 
 
1.3.2.1 GAA expansion-mediated transcriptional dysregulation 
In FRDA, expanded GAA repeats in intron 1 of the FXN gene reduce steady-state 
FXN mRNA levels to 4% to 29% of normal (Campuzano et al, 1997) through a still poorly 
understood mechanism. This severe decrease in FXN mature mRNA content could 
potentially be due to impairment in transcription, pre-mRNA processing or decay.  
RNA splicing differences between normal and expanded FXN alleles have only been 
shown when using a FXN minigene construct containing a human cytomegalovirus (CMV) 
promoter, FXN exon 1, part of intron 1 and all of exon 2, transfected into mammalian cells 
(Baralle et al, 2008); or when inserting expanded GAA repeats into an intron of the URA3 
gene in yeasts (Shishkin et al, 2009). However, these results failed to replicate when 
studying the endogenous FXN transcript in FRDA patient cells (Bidichandani et al, 1998; 
Punga & Bühler, 2010). Moreover, there is no evidence showing differences in the decay 
rate of mature FXN transcripts from normal and expanded FXN alleles (Punga & Bühler, 
2010).  
Therefore, it seems plausible to assume that the FXN mRNA decrease seen in FRDA 
results from FXN transcriptional impairment. However, how the mutation interferes with 
the transcription machinery at the FXN gene remains unclear. Two non-exclusive 
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hypotheses have been proposed (reviewed in Kumari & Usdin, 2012; Yandim et al, 2013). 
Firstly, expanded GAA repeats may form non-B DNA structures, such as triplexes or 
sticky DNA (Bidichandani et al, 1998; Sakamoto et al, 1999), and RNA/DNA hybrids (R-
loops; Grabczyk et al, 2007; Groh et al, 2014) which impair RNAPII elongation. Secondly, 
GAA repeat expansions can induce the formation of heterochromatin (Saveliev et al, 2003; 
Herman et al, 2006), leading to increased DNA methylation at specific CpG sites (Greene 
et al, 2007; Al-Mahdawi et al, 2008; Evans-Galea et al, 2012), reduced histone acetylation 
(H3/H4ac) and increased levels of methylated histones H3K9me2 and H3K9me3 (Herman 
et al, 2006; Al-Mahdawi et al, 2008). It has been suggested that these epigenetic changes 
surrounding the GAA expansion impair RNAPII elongation (Punga & Bühler, 2010), but 
also spread upstream towards the FXN promoter, inducing a non-permissive chromatin 
configuration for transcription initiation, altering nucleosome positioning and preventing 
insulator protein CTCF binding (De Biase et al, 2009; Kumari et al, 2011; Chutake et al, 
2014; Groh et al, 2014). 
 
1.3.2.1.1 Abnormal DNA structures 
Repetitive DNA sequences are prone to adopting unusual DNA secondary structures 
due to sequence symmetry, base composition, DNA supercoiling and cellular ambient 
conditions (Mirkin, 2007). These structures contribute to the instability of disease-
associated repeats by impacting on DNA metabolism, for example stalling replication, 
altering repair or causing unusual recombination, inducing the formation of hairpins, 
triplexes and quadruplexes. During transcription, repeats can form RNA/DNA hybrids 
(Castel et al, 2010). 
Of all the repeat expansions associated with unstable expanded diseases, only GAA 
repeats do not form hairpins. Single-stranded CNG repeats form hairpin structures that 
consist of both Watson–Crick base pairs and mismatched base pairs, with a decreasing 
stability in the order CGG > CTG > CAG = CCG. In addition to hairpins, single-stranded 
CGG, CCG and GGGGCC repeats can fold into G-quadruplexes (Fry & Loeb, 1994; 
Marquis Gacy et al, 1995; Haeusler et al, 2014).  
Expanded GAA repeats form non-B DNA conformations, such as triplexes, that can 
affect FXN transcription in a length and orientation-dependent manner (Bidichandani et al, 
1998; Ohshima et al, 1998). Triplexes are three-stranded DNA structures formed at 
polypurine·polypyrimidine (R·Y) tracts, where the third strand forms Hoogsteen base pairs 
between the R or Y bases with the purines already paired with pyrimidines in the duplex 
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DNA. R·R·Y triplexes, unlike Y·R·Y, form more rapidly and at neutral pH. In FRDA, 
GAA repeat expansions form a R·R·Y triplex containing two GAA repeat strands along 
with a single strand of TTC repeats (Mariappan et al, 1999; Grabczyk & Usdin, 2000; 
Potaman et al, 2004). These structures are stabilised by negative supercoiling and can self-
associate, forming complexes known as sticky DNA which can only be resolved at high 
temperatures (80°C) and with the addition of EDTA to remove divalent metal ions 
(Sakamoto et al, 1999; Wells, 2008). Sticky DNA can impede virtually all biological 
processes in vitro, including transcription, replication, repair and recombination (Wells, 
2008). 
Another model suggests that expanded GAA repeats can form R-loops, a shared 
feature with CGG, CCG, CAG, CTG and GGGGCC repeats (Reddy et al, 2011; Colak et 
al, 2014; Groh et al, 2014; Reddy et al, 2014). These RNA/DNA hybrids are formed 
during transcription when the nascent RNA hybridizes to the DNA template behind the 
elongating RNAPII. Indeed, R-loops have been shown to form at expanded GAA repeats 
following in vitro transcription (Reddy et al, 2011), in E. coli (Grabczyk et al, 2007), and 
on endogenous FXN alleles from FRDA patients cells (Groh et al, 2014).  
All these unusual structures could impair FXN transcription by creating a physical 
blockage to the RNAPII elongation through the GAA repeat sequence and act as an initial 
trigger to promote FXN silencing (Sakamoto et al, 2001; Groh et al, 2014). 
Repeat-mediated aberrant DNA structures may be subsequently processed by 
proteins of the DNA repair machinery, potentially inducing repeat instability (reviewed in 
Castel et al, 2010; Iyer et al, 2014). In healthy conditions, these proteins stabilize the 
genome by correcting DNA replication errors, attenuating chromosomal rearrangements, 
and mediating the cellular response to certain types of DNA damage. Eukaryotic MutS 
homologs (MSHs) detect specific lesions by distinct heterodimeric complexes: human 
MSH2 forms a heterodimer in solution with MSH6 (MutSα) or MSH3 (MutSβ). MutSα 
recognizes and initiates removal of base–base mispairs, a subset of insertion–deletion loops 
and certain types of lesions caused by DNA damaging agents, whereas MutSβ almost 
exclusively recognizes loops. Mismatch recognition by MutSα or MutSβ is followed by 
recruitment and activation of a latent endonuclease function in MutLα (heterodimer of 
MLH1 and PMS2) in the presence of ATP and DNA-loaded replication sliding-clamp 
proliferating cell nuclear antigen (PCNA), resulting in single-strand breaks flanking both 
sides of the mismatch in the newly synthesized DNA strand. Mismatch removal then 
occurs by processive 5’–to–3’ hydrolytic activity of MutSα-activated Exo1, which is 
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loaded at MutLα-catalyzed 5’ strand breaks or at the 5’ ends of Okazaki fragments on the 
lagging strand of DNA replication (reviewed in Li, 2008; Iyer et al, 2014).  
MMR proteins play a role in both somatic and intergenerational CTG,·CAG, CGG 
and GAA repeat instability (van den Broek et al, 2002; Lin et al, 2006; Ku et al, 2010; 
Lokanga et al, 2014). Inactivation of MSH2 and MSH3, but not MSH6, resulted in the 
stabilization or reduction of CAG and CTG repeats in HD and DM1 transgenic mice, 
respectively, suggesting that MutSα has a causative role and MutSβ has a preventive role 
in repeat instability (Manley et al, 1999; van den Broek et al, 2002; Savouret et al, 2003; 
Owen et al, 2005). Furthermore, PMS2 and MLH1 induced somatic instability in DM1 and 
HD transgenic mice, respectively (Gomes-Pereira et al, 2004b; Pinto et al, 2013). In 
FRDA, MMR proteins have been shown to recognise GAA expansion-containing triplexes 
and play a role in GAA repeat instability (Ku et al, 2010; Bourn et al, 2012; Ezzatizadeh et 
al, 2012; Du et al, 2012; Halabi et al, 2012; Hick et al, 2013; Ezzatizadeh et al, 2014). 
Deficit of any of the MSH2, MSH3, MSH6 or PMS2 increased GAA repeat 
intergenerational mutability (expansion and/or contraction) and loss of MSH2 or MSH6 
led to a significant reduction in somatic GAA repeat expansions in FRDA transgenic mice. 
In contrast, loss of PMS2 promoted GAA repeat expansions in transmission from parents 
to offspring (Ezzatizadeh et al, 2012) and increased GAA repeat expansions in neuronal 
tissues of these mice, particularly the cerebellum and DRG (Bourn et al, 2012). MLH1 
promoted intergenerational and somatic GAA repeat expansions (Ezzatizadeh et al, 2014). 
Furthermore, expression of the MutSβ complex, particularly the MSH3 subunit, was found 
to be necessary for expansion of GAA repeats in model cells and FRDA patient fibroblasts 
(Halabi et al, 2012), which led to the interesting possibility that inhibition of MSH3 could 
slow down GAA repeat expansions in FRDA affected tissues and stop the progression of 
the disease. 
 
1.3.2.1.2 Heterochromatinisation of the FXN gene 
Epigenetic mechanisms which include DNA methylation, post-translational histone 
modifications and non-coding RNAs, regulate gene expression without involving changes 
in the primary DNA sequence. Dysregulation of chromatin organisation and function plays 
a pathogenic role in several neurodegenerative diseases for which chromatin-modifying 
compounds may be potentially therapeutic (reviewed in Jakovcevski & Akbarian, 2012). 
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1.3.2.1.2.1 Histone modifications 
In eukaryotic cells, the nuclear DNA is packaged into a higher order structure, 
known as chromatin. The nucleosome is the fundamental unit of chromatin and consists of 
an octamer of four pairs of histone proteins H2A, H2B, H3, and H4 around which 147 bp 
of DNA are wrapped (Kornberg & Thonmas, 1974). Both unstructured histone tails and 
globular domains are subject to a vast array of post-translational modifications, namely 
methylation of arginine residues; methylation, acetylation, ubiquitination, ADP-
ribosylation, and sumolation of lysines (K); and phosphorylation of serines and threonines 
(reviewed in Kouzarides, 2007).  
Histone modifications can be involved in the establishment of global chromatin 
environments (euchromatin and heterochromatin), but also regulate DNA-related 
metabolic processes including transcription, recombination, DNA repair, replication, and 
chromosome condensation (Kouzarides, 2007). Modifications that are associated with 
active transcription, such as acetylation of histones H3 and H4 or di- or trimethylation of 
H3K4, are commonly referred to as euchromatin modifications. Heterochromatin 
modifications are associated to inactive genes or regions, such as H3K9me and H3K27me 
(reviewed in Li et al, 2007). Moreover, in actively transcribed genes, acetylation is 
distributed in distinct localised patterns in the promoter, 5’ and 3’ end of coding regions 
(Fig. 1.4); within the promoter there are two nucleosomes flanking the initiation site that 
are hypoacetylated at certain lysines and are enriched in the H2A variant Hzt1; the 
initiation site shows low nucleosome occupancy; lysine trimethylation is enriched in the 
coding region; and methylation of H3K4, H3K36, H3K79 indicates transcription initiation 
and elongation (Kouzarides, 2007; Li et al, 2007). 
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Figure 1.4 Distribution pattern of histone modifications involved in transcription regulation. The 
distribution of histones and their modifications are mapped on an arbitrary gene relative to its promoter (5′ 
end), ORF, and 3′ end. The curves represent the patterns that are determined via genome-wide approaches. 
The squares indicate that data are based on only a few case studies. With the exception of the data on K9 and 
K27 methylation, most of the data are based on yeast genes (Image adapted from Li et al, 2007). 
 
It is still unclear why certain histone modifications have different functions. 
However, histone acetylation results in a change in the net charge of nucleosomes, which 
can loosen inter- or intranucleosomal DNA-histone interactions (Reinke & Hörz, 2003). 
Moreover, individual histone modifications or modification patterns can be recognized by 
other proteins that influence chromatin dynamics and function (Strahl & Allis, 2000; 
Jenuwein & Allis, 2001). 
Histone acetylation occurs at multiple lysine residues due to a variety of histone 
acetyltransferase complexes (HATs) (Brown et al, 2000) and is removed by histone 
deacetylases (HDACs). Similarly, histone methylation is controlled by histone 
methyltransferases (HMTs) and histone demethylases (HDMs), which have been linked to 
transcriptional activation and repression (Kouzarides, 2007).  
HATs utilize acetyl CoA as cofactor and catalyse the transfer of an acetyl group to 
the ε-amino group of lysine side chains, neutralising the lysine’s positive charge and 
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potentially weakening the interactions between histones and DNA. HATs such as Gcn5, 
TAF1, and p300/CBP are recruited to the promoter upon transcription initiation (Sterner & 
Berger, 2000; Strahl & Allis, 2000) and levels of acetylation are proportional to the 
transcription rate (Pokholok et al, 2005). There are two different families: type-A HATs 
are predominantly cytoplasmic, acetylating free histones but not those already deposited 
into chromatin; type-B HATs acetylate newly synthesized histone H4 at K5 and K12 (as 
well as certain sites within H3), and this pattern of acetylation is important for deposition 
of the histones (Bannister & Kouzarides, 2011). 
HDACs reverse lysine acetylation, which restores the positive charge of the lysine, 
leading to stabilisation of the local chromatin architecture and transcriptional repression. 
There are four classes of HDACs: classes I and II contain enzymes that are most closely 
related to yeast scRpd3 and scHda1, respectively; class III (referred to as sirtuins) are 
homologous to yeast scSir2 and require a specific cofactor for its activity, NAD+; class IV 
has only a single member, HDAC11. A single HDAC is able to deacetylate multiple sites 
within histones (Bannister & Kouzarides, 2011). 
HMTs do not alter the charge of histones and are divided into lysine-specific and 
arginine-specific groups. They have great specificity and usually modify only one 
particular histone residue. All histone lysine methyltransferase catalyse the transfer of a 
methyl group from S-adenosylmethionine to a ε-amino group of a lysine.  
HDMs are classified into two distinct enzyme families: the nuclear amine oxidase 
homologs, like LSD1, and the JmjC-domain proteins. All HDMs are very specific to their 
lysine targets and sensitive to the degree of lysine methylation (Kouzarides, 2007). 
There is an increasing amount of evidence supporting a link between epigenetic 
dysregulation and unstable expanded diseases, including FRAXA, FRDA, DM1, HD, 
SCAs and SBMA. Histone modification changes generally involve transition from active 
chromatin marks (H3K4me2/3, H3K9Ac) to those associated with silenced chromatin 
(H3K9me2/3; H4K20me3, H3K27me3). This is generally associated with decreasing 
transcription and protein levels in association with increasing antisense RNAs (Evans-
Galea et al, 2013). For example, FMR1 silencing occurs together with enrichment of 
H3K9me3 and H4K20me3 in exon 1 of the expanded FMR1 allele, just downstream of the 
CGG expansion, prior to DNA methylation (Kumari & Usdin, 2010); expanded ATXN8OS 
shows increased H3K9me2 and reduced H3K14ac upstream of the CTG expansion (Chen 
et al, 2009); and in DM1, expanded CTG repeats induce the heterochromatinization of the 
DMPK locus (Otten & Tapscott, 1995).  
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Saveliev and colleagues provided the first report indicating that expanded GAA 
repeats could induce heterochromatin-mediated impairment of a gene (Saveliev et al, 
2003). In this study, long GAA repeats fused to the hCD2 gene induced heterochromatin 
silencing even when the construct was integrated into a euchromatic environment, exerting 
a phenomenon similar to position effect variegation (PEV) and implying that expanded 
GAA repeats could nucleate heterochromatin. Moreover, GAA expansion-mediated 
silencing was sensitive to dosage of the classical PEV modifier heterochromatin protein 1 
(HP1), raising the possibility that PEV modifiers could potentially play a role in FRDA 
(Saveliev et al, 2003). 
Several studies have since shown that a similar epigenetic mechanism occurs at the 
endogenous FXN gene in FRDA. Chromatin immunoprecipitation (ChIP) analysis using 
primary lymphocytes and cell lines derived from FRDA patients (Herman et al, 2006; 
Greene et al, 2007; Punga & Bühler, 2010; Rai et al, 2010; Kim et al, 2011; Kumari et al, 
2011; Groh et al, 2014) has shown that the first intron of expanded FXN alleles is enriched 
in heterochromatin marks, such as hypoacetylated histones H3 and H4, methylated 
histones H3K9me2 and H3K9me3, the latter providing the binding site for HP1 (Saveliev 
et al, 2003). These epigenetic changes are also detected in the brain, cerebellum, and heart 
from FRDA patients (Al-Mahdawi et al, 2008) and in the brain and heart of FRDA mouse 
models (Al-Mahdawi et al, 2008; Rai et al, 2008). 
While ChIP data among these studies are widely accepted for the region flanking the 
GAA expanded repeat, there are contradictory reports regarding the chromatin landscape 
of the FXN promoter. Some studies show no significant enrichment in H3K9me2 and 
H3K9me3 or hypoacetylated histones on the FXN promoter of FRDA patient-derived 
lymphoblastoid cell lines compared to healthy controls (Punga & Bühler, 2010; Kim et al, 
2011). Consistently, Punga & Bühler (2010) found similar levels of the initiating form of 
RNAPII (phosphorylated at serine 5 on its C-terminal domain) on the promoter and 
immediately upstream of the GAA repeats in lymphoblastoid-derived cells from healthy 
controls and FRDA patients. However, there is also evidence showing that histone marks 
typical of transcriptionally repressed genes can be found at the FXN promoter and change 
its accessibility to regulatory factors important for transcription initiation (Al-Mahdawi et 
al, 2008; De Biase et al, 2009; Kumari et al, 2011; Chutake et al, 2014; Groh et al, 2014). 
In line with this, expanded GAA repeats can interfere with both FXN transcription 
initiation and elongation (Kumari et al, 2011; Chutake et al, 2014; Groh et al, 2014).  
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1.3.2.1.2.2 DNA methylation 
DNA methylation results from the conversion of cytosine to 5-methylcytosine (5mC) 
predominantly in the context of CpG islands. The position of DNA methylation in the 
transcriptional unit influences its relationship to gene control. In particular, methylation in 
the immediate vicinity of a TSS blocks initiation, but methylation in the gene body does 
not block and might even stimulate transcription elongation and have an impact on 
splicing. Methylation also has a role in genome stability: it is important for chromosomal 
stability in repeat regions, such as centromeres, and is also likely to suppress the 
expression of transposable elements (reviewed in Jones, 2012).  
When genes with CpG islands at their TSS are active, their promoters are usually 
characterized by nucleosome-depleted regions at the TSS, which are often flanked by 
nucleosomes containing the histone variant H2A.Z and are marked with H3K4me3 (Kelly 
et al, 2010). Promoters containing CpG islands can be repressed by various mechanisms, 
such as repression mediated by Polycomb proteins. Methylated CpG islands at TSSs are 
associated with silent genes and cannot initiate transcription after the DNA has been 
assembled into nucleosomes. While certain forms of histone methylation cause local 
formation of heterochromatin, which is readily reversible, DNA methylation leads to a 
stable long-term repression (reviewed in Cedar & Bergman, 2009). Promoters containing 
CpG islands that are already silenced by Polycomb complexes are much more likely than 
other genes to become methylated, which suggests that the silent state precedes 
methylation. Methylation appears to serve as a ‘lock’ to reinforce a previously silenced 
gene state (Gal-Yam et al, 2008). 
Intragenic CpG islands can become extensively methylated, however this does not 
block transcription elongation despite being marked by H3K9me3 and bound by methyl-
CpG-binding protein 2 (MECP2), which are chromatin features that are associated with 
repressed transcription when they are present at the TSS. Thus, in mammals, it is the 
initiation of transcription but not transcription elongation that seems to be sensitive to 
DNA methylation silencing (Nguyen et al, 2001). It is thought that intragenic methylation 
is a mechanism for silencing repetitive DNA elements, such as retroviruses, LINE1 
elements, Alu elements and others. Methylation blocks initiation of transcription at these 
elements while at the same time allowing transcription of the host gene to run through 
them (Yoder et al, 1997). 
In mammals, DNA methyltransferase (DNMT) enzymes include three functional 
proteins: DNMT1 preferentially methylates hemi-methylated DNA and is responsible for 
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methylation during DNA replication, while DNMT3a and DNMT3b have an equal 
preference for hemi-methylated and non-methylated DNA and so have been classified as 
de novo methyltransferases. Active demethylation requires a mechanism that ultimately 
involves cell division or DNA repair and the excision of the base rather than the removal of 
the methyl group directly from the 5mC. This involves enzymes such as the ten-eleven 
translocation (TET) methylcytosine dioxygenases, activation-induced cytidine deaminase 
(AID) and thymine DNA glycosylase (TDG) in active and passive demethylation and in 
gene activation (reviewed in Jones, 2012). 
When the expansion length inscreases, distinct but variable changes in CpG 
methylation state occur in the upstream and/or downstream region of the expansion and 
also, in some cases, in the promoter region of mutated genes, causing unstable expansion 
diseases. In FRAXA, the CGG expansion triggers widespread methylation of the FMR1 
gene, where most CpG sites within the repeat are methylated, as are those in the promoter 
region upstream of the repeat. DNA methylation levels correlate with FMR1 expression 
(Evans-Galea et al, 2013). In DM1, altered DNA methylation of DMPK has been 
identified, with upstream elements being highly methylated and downstream elements 
being unmethylated (López Castel et al, 2011). 
Initial studies of DNA methylation within the FXN gene showed that expanded GAA 
repeat induced hypermethylation of specific CpG sites in the upstream region of the GAA 
repeat sequence in FRDA patient-derived lymphoblastoid cells (Greene et al, 2007). These 
results were later confirmed in the brain, heart, and cerebellum tissues from FRDA patients 
and in tissues of FRDA YAC transgenic mice (Al-Mahdawi et al, 2008). In line with these 
findings, two studies on peripheral blood mononuclear cells also reported significantly 
higher levels of DNA methylation upstream of the expanded repeats on the FXN locus, 
(Castaldo et al, 2008; Evans-Galea et al, 2012). Both found a negative correlation between 
the level of DNA methylation in this region and the age of disease onset. Castaldo and 
colleagues also reported that the degree of methylation is proportional to the length of 
GAA1, the smallest of the two expanded FXN alleles (Castaldo et al, 2008), and Evans-
Galea and colleagues suggested a positive correlation between FXN gene silencing, disease 
severity and the level of DNA methylation (Evans-Galea et al, 2012). More recently, a new 
analysis able to distinguish between 5-hydroxymethylcytosine (5hmC) and 5mC revealed 
that, for at least one CpG site within the upstream GAA repeat region, the increased level 
of DNA methylation predominantly comprises 5hmC rather than 5mC (Al-Mahdawi et al, 
2013). 
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1.3.2.1.2.3 RNA interference (RNAi) 
Antisense transcripts are common in the genome and may play important roles in 
RNA stability and transcriptional activity. Antisense transcription can generate double-
stranded RNA, which trigger RNAi, enabling post-transcriptional repression of specific 
mRNAs. Double stranded RNAs, such as microRNAs, are processed by the ribonuclease 
Dicer into 21 nucleotide fragments. These short RNAs are subsequently loaded in the 
RNA-induced silencing complex (RISC), which targets mRNAs for degradation or inhibits 
their translation (Dion & Wilson, 2009). 
Antisense transcription also plays a role in the pathogenesis of several unstable 
expanded diseases. In FRAXA, FMR1 silencing is mediated by the FMR1 mRNA, which 
hybridizes to the complementary CGG-repeat portion of the FMR1 gene to form an 
RNA/DNA duplex (Colak et al, 2014). At the DMPK locus, high levels of antisense 
transcription are associated with regional H3K9me2, HP1γ recruitment and loss of CTCF 
binding (Cho et al, 2005).  
Besides heterochromatic histone marks, the FXN promoter of FRDA fibroblasts 
shows elevated levels of HP1, increased levels of a frataxin antisense transcript 1 (FAST1) 
together with depletion of CTCF binding at the 5’ UTR region of the FXN gene (De Biase 
et al, 2009). Furthermore, increased expression of FAST1 have also been shown in FRDA 
mouse fibroblasts (Sandi et al, 2014b) and reduced CTCF binding at the 5’ UTR region of 
the FXN gene in FRDA cerebellum tissue (Al-Mahdawi et al, 2013). It is still unclear 
where the starting site of FAST1 transcription is located. However, FAST1 extends from 
the first exon and intron towards the FXN promoter (De Biase et al, 2009).  
 
1.4 Frataxin protein 
 
1.4.1 Normal frataxin function 
The frataxin protein (reviewed in Pastore & Puccio, 2013; Martelli & Puccio, 2014) 
is a small, highly conserved acidic mitochondrial protein essential for life, as demonstrated 
in experiments using knockout animals where complete absence of frataxin led to early 
embryonic death (Cossée et al, 2000). It is highly expressed in the dorsal root ganglia, the 
granular layer of the cerebellum as well as the heart, pancreas, thymus, brown fat, muscle 
and liver (Campuzano et al, 1996; Koutnikova et al, 1997). Interestingly, Xia and 
colleagues suggested that tissue-specific expression of different frataxin isoforms, 
particularly the extra-mitochondrial isoforms, may explain the pathology in other FRDA-
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affected tissues (Xia et al, 2012). In this study, two novel tissue-specific transcript variants 
were identified, encoding two isoforms of frataxin (isoform II and III) lacking the 
mitochondrial targeting sequence and were therefore different from the canonical transcript 
(encoding isoform I). Isoforms II and III were functional and were specifically localised in 
affected cerebellum and heart tissues, respectively. Functional assays revealed that isoform 
I and II protect iron-sulphur clusters (ISCs) from oxidative damage, and FXN III acts as a 
mitochondrial enhancer of ISC-biogenesis. 
Sequence alignment of human, mouse, yeast (Yfh1), and bacterial (CyaY) frataxin 
showed two distinct regions. The N-terminal (70-90 amino acids) is poorly conserved 
among eukaryotes, whereas the C-terminal (100-120 amino acids) is highly conserved in 
most organisms and contains the functionally relevant part of the protein (Huynen et al, 
2001). Although the protein is nuclear-encoded and synthesised as a precursor polypeptide, 
it is expressed in the cytoplasm and imported to the mitochondrial matrix through an 
import signal contained in the N-terminus (Koutnikova et al, 1997). To obtain the 
intermediate and mature forms of the human frataxin (Fig. 1.5), the 210-amino acid 
precursor (23 kDa) undergoes a two-step maturation process in vivo (Schmucker et al, 
2008). The mitochondrial processing peptidase (MPP) initially cleaves the precursor 
between Gly41 and Leu42, generating the intermediate form (i-FXN; 19 kDa) and then 
performs a second cleavage to generate the mature form (m-FXN) (Koutnikova et al, 
1998). The mature form was initially reported to result from cleavage between Ala55 and 
Ser56 (m56-FXN; 17 kDa) (Cavadini et al, 2000). However, two additional studies have 
reported two different mature forms resulting from cleavage sites at residues Leu78-Arg79 
(m78-FXN; 14.5 kDa) and Lys80-Ser81 (m81-FXN; 14.2 kDa) (Condò et al, 2007; Yoon et 
al, 2007). Finally, Schmucker and colleagues demonstrated that the major endogenous 
form of mature frataxin corresponds to the m81-FXN and that the m56-FXN form is not 
found in normal physiological conditions (Schmucker et al, 2008). Furthermore, m78-FXN 
was shown to be a degradation product.  
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Figure 1.5 Maturation of the frataxin protein. To obtain the intermediate and mature forms of the human 
frataxin, the 210-amino acid precursor undergoes a two-step maturation process .The intermediate (i-FXN) 
and the three processed forms m56-FXN, m78-FXN and m81-FXN are represented. The mature frataxin form 
corresponds to the m81-FXN (adapted from Schmucker et al, 2008).  
 
CyaY, Yfh1 and human frataxin are highly soluble monomeric proteins in the 
absence of iron. Under aerobic conditions and iron overload, oligomers are observed for 
both CyaY and Yfh1 (Cook et al, 2006; Adinolfi et al, 2009). Human frataxin assembles 
only under extreme conditions and in an iron-independent manner (O’Neill et al, 2005). 
Furthermore, formation of oligomers is not a requisite for m81-FXN mature form to be 
functional (Schmucker et al, 2008). 
The exact function of frataxin remains unclear, however frataxin deficiency in FRDA 
shows that it is primarily involved in the biosynthesis of ISCs (Fig. 1.6), the complexes 
that serve as prosthetic groups for a variety of enzymes involved in energy and iron 
metabolism, purine synthesis and DNA repair, making frataxin of vital importance for the 
synthesis of the mitochondrial respiratory chain complexes I, II and III enzymes and 
aconitase (Rotig et al, 1997). 
Under normal conditions, frataxin binds iron directly and can function as an iron 
chaperone during heme and ISC assembly (Aloria et al, 2004). The first step of ISC 
biogenesis involves the assembly of inorganic iron and sulphur into an ISC on a scaffold 
protein, IscU (Isu1 in yeast). In this process, sulphur is provided through a persulphide 
intermediate by a cysteine desulphurase IscS (NFS1 and ISD11). Nfs1 is a cysteine 
desulphurase that converts cysteine to alanine and a highly reactive persulphide used in the 
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synthesis of sulphur bioorganic derivatives; and Isu1 is the transient scaffold protein on 
which the cluster assembles. The constitutive Nfs1 homodimer and two copies of 
monomeric Isu1 (or their bacterial orthologs IscS and IscU) form a binary complex 
(Pastore & Puccio, 2013). Frataxin interacts with several proteins of this pathway. It was 
shown that Yfh1 and human frataxin bind to the central ISC assembly complex (Gerber et 
al, 2003; Ramazzotti et al, 2004), regulating the interaction between the scaffold IscU and 
the desulfurase IscS and to modulate the formation of [Fe4S4] clusters (Colin et al, 2013). 
Moreover, frataxin may act as an iron donor which helps to solubilize and transport iron to 
the ISC biogenesis pathway (Yoon & Cowan, 2003). 
Other functional interactions were suggested between frataxin and ferrochelatase, the 
enzyme that catalyzes the final step of heme biosynthesis by inserting the ferrous ion into 
porphyrin (Yoon & Cowan, 2004), mitochondrial aconitase (Bulteau et al, 2004), complex 
II of the mitochondrial respiratory chain (González-Cabo et al, 2005) and several 
chaperones (GRP75, Ssc1) (Shan et al, 2007). 
 
Figure 1.6 Frataxin function and oxidative stress in FRDA. Schematic representation of the postulated 
functions of frataxin, including ISC and heme biogenesis, and direct interaction with the respiratory chain 
complexes. Green arrows and text indicate molecules and pathways that have decreased activity in frataxin 
deficiency; red arrows and text indicate molecules and pathways that have increased activity in frataxin 
deficiency. Abbreviations: Aco, aconitase; C(I-V), respiratory chain complex I-V; Cys, cysteine; cyt c, 
cytochrome c; e–, electron; FECH, ferrochelatase; FRDA, frataxin; GPx, glutathione peroxidase; GSH, 
reduced glutathione; GSSG, oxidized glutathione; H2O2, hydrogen peroxide; IscS, cysteine desulfurase; IscU, 
ISC scaffold protein; IX, protoporphyrin IX; OH•, hydroxyl radical; Q, coenzyme Q; SOD, superoxide 
dismutase (Pandolfo, 2008). 
 
 
51 
 
1.4.2 Frataxin defficiency 
Consequently to the defect in ISC-containing proteins, cells derived from FRDA 
patients show mitochondrial damage, lower ATP production, and impaired iron utilization, 
leading to mitochondrial iron accumulation (Ristow et al, 2000; Michael et al, 2006; Li et 
al, 2008) and formation of free radicals, which may further reduce the levels of oxidative-
sensitive ISC proteins and cause increased cellular damage (Chantrel-Groussard et al, 
2001). In particular, accumulation of large amount of iron inside mitochondria as granular 
iron deposits have been reported in a yeast strain deficient for the yeast frataxin homolog 
(Yfh1) (Babcock et al, 1997), conditional mouse model reproducing the cardiac phenotype 
(MCK mouse) (Puccio et al, 2001), cardiomyocytes of FRDA patients (Lamarche et al, 
1980), and heart autopsies of individuals with FRDA (Michael et al, 2006). 
The cerebellar dentate nucleus contains high levels of iron, but showed no difference 
in iron concentration in FRDA patients compared with healthy controls (Koeppen et al, 
2007). However, Koeppen and colleagues observed a shift in expression of iron-related 
proteins such as transferrin receptor 1 (TFR1), ferritins (FRTs) and ferroportin (FPN), 
which suggests a change in iron metabolism (Koeppen et al, 2007). Furthermore, iron can 
relocate from neurons to microglia of the dentate nucleus in FRDA (Koeppen et al, 2012). 
Similarly, DRGs from FRDA patients do not show higher iron concentration than healthy 
controls, but the expression of the iron-storage FRT proteins increases in neighbouring 
cells (Koeppen et al, 2013). 
 
1.5 Therapeutic strategies 
There is currently no proven treatment for FRDA. Several clinical trials have been 
conducted with the most promising strategies in order to rescue the pathological deficits 
seen in FRDA patients. These potential therapies were primarily aimed at managing 
symptoms, and thus improving the quality of life, through rescue of the increased oxidative 
stress and accumulation of iron in the mitochondria. As the molecular mechanisms 
underlying FRDA pathogenesis become better understood, other strategies have been 
developed to increase FXN mRNA and protein levels. 
 
1.5.1 Antioxidants 
Treatment approaches to address mitochondrial pathogenesis include the use of 
enhancers of mitochondrial function, such antioxidants or iron chelators. Coenzyme Q10 is 
a potent antioxidant and electron carrier between the respiratory chain complexes I and II, 
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and from oxidation of fatty acids and branched chain amino acids, to complex III resulting 
in the ultimate production of ATP. Idebenone is a short-chain benzoquinone structurally 
analog to coenzyme Q10. Initial results with these antioxidants were promising, resulting in 
improvement in cardiac and skeletal muscle bioenergetics (coenzyme Q10) and reduction of 
cardiac hypertrophy (idebenone) (Schulz et al, 2009). However, larger phase III 
randomized, placebo-controlled trials failed to show disease modifying efficacy of 
idebenone treatment (Parkinson et al, 2013).  
 
1.5.2 Iron quelators 
To address the iron accumulation in mitochondria and depletion in the cytoplasm, the 
use of iron chelators was considered to act on the labile iron pools and subcellular 
compartments (such as the mitochondria) without depleting transferrin-bound iron from the 
plasma (Schulz et al, 2009). Deferiprone has been used to treat iron overload in individuals 
with hemoglobinopathies and can easily cross the blood–brain barrier and cellular 
membranes. In addition, because of its relatively low affinity for iron, it is not likely to 
cause iron depletion. These properties made deferiprone an interesting candidate as an 
FRDA therapy (Pandolfo & Hausmann, 2013). Deferiprone was tested in a pilot, open-
label study and in a randomized, placebo-controlled phase II clinical trial. Although in the 
pilot study deferiprone reduced the iron content in the dentate nucleus of FRDA patients, 
the phase II study failed to demonstrate an improvement of ataxia, which was even 
worsened by high doses of the drug. However, deferiprone was able to reduce heart 
hypertrophy at all tested doses (Pandolfo & Hausmann, 2013). 
 
1.5.3 Gene therapy 
Gene therapy can potentially increase frataxin levels and alleviated FRDA 
symptoms. Recombinant adeno-associated viral (AAV) and lentiviral vectors expressing 
frataxin cDNA were shown to partially correct sensitivity to oxidative stress in FRDA 
primary fibroblasts (Fleming et al, 2005). Herpes simplex virus type 1 (HSV-1) amplicon 
vectors expressing the whole FXN genomic locus were used to transduce FRDA primary 
fibroblasts and were able to successfully rescue sensitivity to oxidative stress (Gomez-
Sebastian et al, 2007). This same construct resulted in long-term persistent FXN expression 
in the brain of wild-type mice after injection into the adult mouse cerebellum (Gimenez-
Cassina et al, 2011). Recently, a new study achieved not only correction, but also reversal, 
of a severe cardiomyopathy phenotype in a conditional FRDA mouse model following 
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intravenous injection of AAV constitutively expressing the human FXN gene (Perdomini et 
al, 2014). Importantly, FXN expression also restored compromised ventricular function to 
healthy levels (Perdomini et al, 2014). 
Introduction of FXN into cells can also be achieved via non-viral-based vector 
delivery (reviewed in Evans-Galea et al, 2014). Bacterial and yeast artificial chromosomes 
(BACs and YACs, respectively) expressing human FXN were able to rescue the embryonic 
lethality of FXN-deficient mice (Pook et al, 2001; Sarsero et al, 2004). An exogenous 
replacement of frataxin, directed to the mitochondria via an N-terminal fusion of the 
transduction domain of the cationic peptide transactivator of the HIV transcription protein 
TAT, improved cardiac function and increased lifespan in a conditional frataxin knockout 
mouse (Vyas et al, 2012). Recently, a new study demonstrated a 1.6-fold increase in FXN 
mature mRNA and a 1.6–1.8-fold increase in frataxin protein, after nucleoinfection of 
human FRDA fibroblasts with a transcription activator-like effector protein (TALE) fused 
to a transcription activation domain (VP64) engineered to bind to the FXN promoter 
(Chapdelaine et al, 2013).  
Zinc finger nucleases (ZFNs) have been shown to specifically recognise and cleave 
CAG or CTG repeat tracts. When a single ZFN was expressed in the target cells, repeat 
contractions could readily be detected, indicating that CTG and CAG duplexes were 
formed in the cells (Liu et al, 2010). In FRDA, Li and colleagues successfully corrected 
human FRDA cells via ZFN-mediated excision of expanded GAA repeats (Li et al, 2015). 
 
1.5.4 Epigenetic therapies 
Epigenetic strategies have been used in unstable expanded diseases, for example 
treatment of FRAXA patients lymphoblastoid cells with 5-aza-2’-deoxycytidine, a DNMT 
inhibitor, either alone (Chiurazzi et al, 1998) or in combination with HDAC inhibitors 
(Chiurazzi et al, 1999), efficiently reverses the FMR1 promoter hypermethylation and 
restores mRNA and protein levels to normal. Moreover, HDAC inhibitors have been 
shown to restore the dysregulated gene expression in HD mice and ameliorate their 
neurodegenerative phenotype (Ferrante et al, 2003; Jia et al, 2012). 
In pre-clinical studies, a family of HDAC inhibitors has been shown to increase FXN 
mRNA and protein levels in cells from FRDA patients and in FRDA mouse models 
(Gottesfeld et al, 2013). Initially, Herman and colleagues treated FRDA lymphoblastoid 
cells using a selection of commercially available HDAC inhibitors and showed that the 
benzamide compound BML-210 increased FXN mRNA levels and its analog, compound 
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4b, could directly increase acetylation of specific histone marks associated with the FXN 
gene to increase FXN mRNA levels in FRDA primary lymphocytes (Herman et al, 2006). 
Compound 4b was also shown to ameliorate the phenotype and transcriptional abnormalies 
in an HD transgenic mice (Thomas et al, 2008). Three 2-aminobenzamide compounds, 
named 106, 136, and 109, were synthesised from 4b to improve their FXN-upregulating 
action in FRDA cells and minimise their effect on unaffected control cells. Compound 106 
has been shown to be an inhibitor of class I HDACs, with a preference for inhibition of 
HDAC3 (Xu et al, 2009). Compound 109 was shown to be the most promising compound 
after a long-term treatment using YG8R YAC transgenic mice (Sandi et al, 2011) as well 
as in neuronal cells derived from FRDA- induced pluripotent stem cells (iPSCs) (Soragni 
et al, 2014). This compound was taken into a Phase Ib clinical trial in FRDA patients, 
where drug treatment led to increases in FXN mRNA and histone acetylation at the FXN 
gene in peripheral blood mononuclear cells (Soragni et al, 2015). Similarly, the sirtuin 
protein deacetylase inhibitor nicotinamide (vitamin B3) also increases FXN mRNA levels 
in FRDA models (Chan et al, 2013), and recently in circulating lymphocytes from 
nicotinamide-treated FRDA patients in an exploratory, open-label, dose-escalation clinical 
trial (Libri et al, 2014). 
 
1.6 Aims of this Thesis 
In FRDA, expanded GAA repeats in intron 1 of the FXN gene reduce steady-state 
FXN mRNA levels through a poorly understood mechanism. In order to better understand 
the underlying pathogenesis and ultimately to design effective therapies for FRDA, it is 
important to generate cellular models that recapitulate the repressive hallmarks of the 
disease while providing efficient ways to quantify FXN expression. Therefore, the purpose 
of this study is to dissect the silencing mechanism of FRDA using genomic reporter 
models of FRDA and physiologically relevant carrier and FRDA patient-derived cells.  
This thesis has been structured under four main aims: 
1. Characterisation of the epigenetic silencing induced by expanded GAA repeats in a 
human cell model of FRDA (Chapter 3); 
2. Investigation of the link between FXN localisation and expression at the single-cell 
level in fixed and living cells using the MS2 system (Chapter 4); 
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3. Analysis of FXN localisation in its native genomic environment and assessment of 
FXN association with specific nuclear subdomains in carrier-derived lymphoblastoid 
cells (Chapter 5); 
4.  Elucidation of the interplay between the repressive environment at the nuclear lamina 
(NL) and FXN repression in FRDA patient-derived cells (Chapter 5). 
 
  
 
 
 
 
 
CHAPTER 2 
Materials and methods 
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2.1 Culture of human cells 
 
2.1.1 Cell culture 
Epstein Barr virus–transformed lymphoblastoid cell lines GM14519 (from an FRDA 
clinically unaffected carrier, alleles with 1285+50 and 9 GAA repeats), GM15851 (from an 
unaffected individual with normal range of GAA repeats), GM16209 (from an FRDA 
clinically affected individual, both alleles with 800 GAA repeats) and GM15850 (from an 
FRDA clinically affected individual, alleles with 1030 and 650 GAA repeats) were 
obtained from the Human Genetic Cell Repository of the Coriell Institute (USA) and 
propagated in RPMI1640 medium supplemented with 15% Fetal Bovine Serum (FBS) and 
2 mM L-glutamine. HEK FRT cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) medium supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml 
penicillin/streptomycin and 100 µg/ml Zeocin (Life Technologies). FXN-GAA-Luc, FXN-
Luc, FXN-MS2-Luc and FXN-GAA-MS2-Luc clonal cell lines were propagated in complete 
DMEM medium (see above) supplemented with 100 µg/ml Hygromycin B (Life 
Technologies). 
 
2.1.2 Routine subculture 
Cell culture was carried out under aseptic conditions in a Class II tissue culture 
cabinet. Cells were maintained in saturated humidity incubators at 37 °C with 5% CO2. 
Routine subculture of adherent cells was performed every 3 days. The growth medium was 
discarded and cells were washed with 10 mL phosphate-buffered saline (PBS). Cells were 
trypsinised using 2 mL trypsin-EDTA (Sigma) at 37 °C for 5 minutes. Trypsinisation was 
halted using 8 mL of normal growth medium and clumps of cells were broken up by 
repeated pipetting. Cell suspensions were diluted to the appropriate seeding concentration 
in fresh growth medium and distributed into new 75 cm2 flasks. Cells were allowed to 
reach 80% confluency until the next subculture. Suspension cells were mixed to disperse 
any clumps by pipetting the cell suspension up and down. Cell viability was monitored 
using trypan blue exclusion and cells were counted with a haemocytometer: 10 μL of cell 
suspension was loaded into the chamber and cells counted in eight 4 x 4 mm squares; the 
number of cells per mL of cell suspension was calculated by multiplying the average 
number of cells by 10,000. Cell suspensions were diluted to a final concentration of 2x105 
cells/mL in 20 mL of fresh growth medium and distributed into new 25 cm2 flasks. Flasks 
were incubated in an upright position until the next subculture. 
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2.1.3 Cryopreservation of cells 
Adherent cells growing in a 75 cm2 flask were trypsinised as described above, 
resuspended in 10 mL of normal growth medium, transferred to a 15 mL conical centrifuge 
tube and centrifuged at 900 x g for 10 minutes. The supernatant was aspirated and the cell 
pellet was resuspended in 1.5 mL of normal growth medium and 1.5 mL of 2x freeze mix 
(60% DMEM, 30% FBS, 10% dimethyl sulphoxide (DMSO)). One millilitre of cells was 
transferred to a previously labelled 1.8 mL cryovial (Nunc). Suspension cells were counted 
as described above. Five million viable cells/mL were centrifuged at 100 x g for 10 
minutes. The cell pellet was resuspended in 1 mL of cold freeze medium (RPMI1640 
medium with 30% FBS and 5% DMSO) and transferred to a cryovial. Cryovials were 
stored in a polystyrene box and allowed to freeze to -80 °C overnight, then transferred to a 
liquid nitrogen storage tank. 
 
2.1.4 Thawing frozen cells  
Cells were rapidly warmed in a 37 °C water bath. Thawed cells were diluted in 10 
mL of normal growth medium in a 15 mL conical centrifuge tube and centrifuged at 900 x 
g for 10 minutes. The supernatant was discarded and cells were resuspended in 8 mL of 
fresh growth medium. Cells were then distributed into 25 cm2 flasks at different dilution 
ratios and allowed to grow as described above. 
 
2.1.5 Drug treatment 
Lymphoblastoid cell lines GM15850 and GM15851 were treated with DMSO or C5 
at a concentration of 20 µM for 48 hours before ChIP analysis. Actinomycin D (ActD) 
time-course was performed by adding DMSO or 8 µg/ml ActD to the media of FXN-MS2-
Luc and FXN-GAA-MS2-Luc clonal cell lines before lysing cells every 4 hours up to 24 
hours for RNA extraction. FXN-MS2-Luc and FXN-GAA-MS2-Luc cells were treated with 
DMSO, nicotinamide (10 mM) or compound 106 (10 µM) for 48 hours before RNA 
extraction and Immuno-FISH. 
 
2.2 Bacterial cell culture 
Unless otherwise stated, all bacterial work was performed using ElectroMax DH10B 
E. coli cells (Life Technologies). Bacterial cultures were grown either in Luria broth (LB) 
or on LB agar.  
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2.2.1 Preparation of electrocompetent DH10B E. coli 
Highly electrocompetent DH10B bacteria were used for all cloning experiments. A 
single bacterial colony was inoculated into 1.5 mL LB with the appropriate antibiotic and 
incubated overnight at 37 °C with shaking at 225 rpm. The culture was tipped into 100 mL 
LB with the appropriate antibiotics in a 1 L conical flask and incubated with shaking at 37 
°C. After 1.5 hours, the optical density at 600 nm was determined using a cell density 
meter (WPA) every 15 minutes until it reached 0.35-0.36. The culture was then transferred 
to a 250 mL centrifuge flask and allowed to chill on ice at 4 °C for 40 minutes. Cells were 
pelleted at 5000 rpm for 15 minutes at 4 °C in an Avanti J-E centrifuge with a JLA-10.5 
rotor. The supernatant was discarded and the pellet was washed three times with 100 mL 
ice-cold autoclaved 10% glycerol by centrifugation at 6000, 7000 and 7500 rpm for 15 
minutes at 4 °C. After the final wash, the supernatant was carefully poured off and excess 
glycerol was removed with a clean tissue. The pellet was resuspended in the small residual 
amount of glycerol. Cells were distributed into 50 μL aliquots in microtubes and 
immediately snap-frozen in dry ice. Electrocompetent bacteria were stored at -80 °C. 
 
2.2.2 Electroporation of electrocompetent cells 
Bacterial transformation was achieved by electroporation using a Gene Pulser system 
(Bio-Rad). Electrocompetent bacteria (50 μL) were transformed in ice-cold 0.1 cm 
electroporation cuvettes according to the manufacturer’s instructions. The following 
parameters were used: potential difference of 1800 V, capacitance of 25 μF and internal 
resistance of 200 Ω. Electroporated bacteria were incubated in 450 μL SOC medium (Life 
Technologies) for 1 hour at 37 °C with shaking, subsequently 2 μL and 100 μL were plated 
on LB agar petri dishes with the appropriate antibiotics and incubated overnight at 37 °C. 
 
2.2.3 Transformation efficiency of electrocompetent cells 
To measure the competence efficiency of electrocompetent cells, 1 μL of pUC19 
plasmid DNA (10 pg/μL; Life Technologies) was electroporated into a 50 μL aliquot of 
electrocompetent cells as described above. Bacteria were plated on a LB agar petri dish 
with ampicillin (100 μg/mL) selection and allowed to grow overnight at 37 °C. Colonies 
were counted and the transfection efficiency was calculated as the number of colony 
forming units (CFU) per μg DNA using the following formula: 
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High transformation efficiencies of >1 x 109 transformants/μg pUC19 were routinely 
obtained using the described method.  
 
2.3 DNA manipulation 
 
2.3.1 Miniprep 
A 1.5 mL LB culture with the appropriate antibiotic was seeded with a single 
bacterial colony and was incubated overnight at 37 °C with shaking. The culture was then 
tipped into a 1.5 mL microtube and cells were pelleted at 5000 rpm for 10 minutes. The 
supernatant was discarded and cells were resuspended in 70 μL of STET resuspension 
buffer (8% sucrose, 5% Triton X-100, 50 mM EDTA and 50 mM Tris-Cl at pH8). Cells 
were lysed with 200 μL of alkaline SDS solution (1% SDS, 0.2 M NaOH) and immediately 
neutralized with 150 μL of 7.5 M ammonium acetate. Microtubes were inverted three times 
and placed on ice for 5 minutes. The neutralised lysate was centrifuged at 13000 rpm for 
20 minutes at 4 °C and the supernatant was transferred to a new microtube. DNA was 
precipitated by adding 250 μL isopropanol and was pelleted by centrifugation at 10000 
rpm for 8 minutes. The supernatant was discarded and the pellet washed with 200 μL of 
70% ethanol and then centrifuged at 10000 rpm for 8 minutes. The ethanol wash was 
aspirated and the DNA pellet allowed to air dry for 5-10 minutes. DNA was resuspended in 
50 μL of Tris-EDTA (TE) containing 5 μg/mL RNase A. 
 
2.3.2 Maxiprep 
To obtain larger amounts of BAC DNA, 1.5 mL LB starter cultures seeded with a 
single bacterial colony were grown for 8 hours at 37°C with shaking and then were tipped 
into 250 mL LB with appropriate antibiotics in a 1 L conical flask and incubated with 
shaking for 16 hours at 37°C. Plasmid DNA was extracted using the Plasmid Maxi kit 
(Qiagen) with minor modifications to enhance DNA yields. Bacterial cells were pelleted 
by centrifugation at 6000 rpm for 15 minutes at 4 °C in a 250 mL centrifuge bottle using a 
JLA-10.5 rotor in an Avanti J-E centrifuge (Beckman Coulter). The pellet was resuspended 
in 15 mL of chilled Buffer P1 by shaking at 37 °C for 10 minutes. Cells were lysed with 15 
mL of Buffer P2 with gentle mixing, and allowed to lyse for 5 minutes, swirling every 2.5 
minutes. The reaction was neutralised with 15 mL of chilled Buffer P3, mixed by repeated 
inversion and incubated on ice for 20 minutes, swirling every 10 minutes. The lysate was 
centrifuged at 9000 rpm for 35 minutes at 4 °C. Qiagen-tip 100 columns were equilibrated 
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with 15 mL of Buffer QBT. The plasmid DNA supernatant was then filtered through a 
folded Kimtech 100 tissue (Sigma) placed inside equilibrated columns. Columns were 
washed twice with 30 mL of Buffer QC, and DNA was eluted into an Oakridge tube using 
15 mL of Buffer QF pre-warmed to 55 °C. DNA was precipitated with 10.5 mL of 
isopropanol and pelleted by centrifugation at 14000 rpm for 30 minutes at 4 °C, using a 
JA-17 rotor. The pellet was then washed with 3.5mL of 70% ethanol and centrifuged again 
at 14000 rpm for 30 minutes at 4 °C. The pellet was allowed to air dry for 10 minutes 
before resuspension in 250 μL of TE overnight at 4 °C. The tube was centrifuged at 1000 
rpm for 5 minutes to collect drops and transferred to a clean microtube. DNA was 
quantified using a NanoDrop spectrophotometer (Thermo Scientific). 
 
2.3.3 Genomic DNA extraction from human cells 
Genomic DNA from FXN-GAA-Luc and FXN-Luc clonal cell lines was isolated by 
standard phenol/chloroform extraction and ethanol precipitation. Cells were lysed in 500 
μL of lysis buffer (0.6% SDS, 100 mM NaCl, 50 mM Tris-HCl pH 8, 20 mM EDTA) 
containing 50 μg/mL RNAse A with gentle shaking for 20 minutes at room temperature. 
The cell lysate was scraped into a 2 mL microtube and incubated overnight at 37 °C. The 
lysate was then incubated with 100 μg/mL of proteinase K overnight at 37 °C. The lysate 
was extracted twice with 500 μL phenol:chloroform (1:1) and twice with 500 μL of 
chloroform, using 1.5 mL phase-lock gel tubes (Eppendorf), mixed by inversion and 
centrifuged at 10000 rpm for 6 minute. After extraction, the lysate was transferred to a new 
microtube. DNA was precipitated with 30 μL of 5 M NaCl and 1.3 mL of absolute ethanol. 
After gently mixing by inversion, the precipitate was chilled on ice for 5 minutes and 
pelleted by centrifugation at 13000 rpm for 30 minutes at 4 °C. The DNA pellet was 
washed with 500 μL of 70% ethanol and centrifuged at 13000 rpm for 20 minutes at 4 °C. 
The pellet was allowed to air-dry briefly and resuspended in 100 μL of TE overnight at 
4°C.  
Genomic DNA from FXN-GAA-MS2-Luc and FXN-MS2-Luc clonal cell lines was 
isolated using Illustra Tissue and Cells GenomicPrep Mini Spin Kit (GE Healthcare), 
according to the manufacturer’s instructions. DNA was quantified using a NanoDrop 
spectrophotometer (Thermo Scientific). 
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2.3.4 Polymerase Chain Reaction (PCR) 
 
2.3.4.1 Standard PCR 
Amplification of DNA fragments for cloning (section 2.3.9), sequencing (section 
2.3.10), homologous recombination (section 2.3.11) and vector integration assessment was 
performed by standard PCR analysis. The integration of pBAC-FXN-Luc, pBAC-FXN-
GAA-Luc, pBAC-FXN-MS2-Luc and pBAC-FXN-GAA-MS2-Luc at the docking site was 
assessed using primers pSV40-F (5’-CCAGTTCCGCCCATTCTC-3’) and Hygro-R (5’-
CAGCTATTTACCCGCAGGAC-3’) and AmpliTaq Gold (Roche). DNA was denatured at 
95 ºC for 10 minutes, followed by 35 cycles of denaturation at 95 ºC for 30 seconds, 
primer annealing at 58 ºC for 30 seconds and extension at 72 ºC for 1 minute, and then a 
final extension at 72 ºC for 8 minutes. For some reactions, the annealing temperature was 
adjusted to provide optimal specificity. Each reaction was carried out in 15 µl containing 1 
µl of DNA (50 ng of genomic DNA or 10 ng of BACs), 1x Buffer, 1.5 mM MgCl2, 0.4 
mM deoxynucleotide triphosphate [dNTP] (Life Tecnologies), 0.05 µM of each primer, 1x 
Q Solution (Qiagen) and 1 U of AmpliTaq Gold (Roche). PCR products were visualised on 
a 1% agarose gel. 
 
2.3.4.2 Amplification of GAA repeats 
PCR amplification of the GAA repeat sequence was carried out on 200 ng of 
genomic DNA using primers 147F and 602R (Montermini et al, 1997a) and Expand Long 
Template DNA DNA Polymerase (Roche) as previously described (Campuzano et al, 
1996; Al-Mahdawi et al, 2004). DNA was denatured at 94 ºC for 2 minutes, followed by 
10 cycles of denaturation at 94 ºC for 10 seconds, primer annealing at 60 ºC for 30 seconds 
and extension at 68 ºC for 45 seconds, and then 20 cycles of denaturation at 94 ºC for 10 
seconds, primer annealing at 60 ºC for 30 seconds and extension at 68 ºC for 1 minute with 
20 seconds increments, and a final extension at 68ºC for 10 minutes. Each reaction was 
carried out in 25 µL containing 1 µL of DNA (200 ng), 1x Buffer 2, 125 µM of each dNTP 
(Life Tecnologies), 0.5 µM of each primer, 1x Q Solution (Qiagen) and 1.5 U of Expand 
Long Template DNA Polymerase (Roche). PCR products were visualised on a 1% agarose 
gel. The GAA repeat sequences were sequenced and digested with MboII (Holloway et al, 
2011) to check for interruptions. 
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2.3.4.3 qPCR 
For copy number determination, genomic DNA from FXN-Luc, FXN-GAA-Luc, 
FXN-MS2-Luc and FXN-GAA-MS2-Luc clonal cell lines was isolated using Illustra Tissue 
and Cells GenomicPrep Mini Spin Kit (GE Healthcare), according to the manufacturer’s 
instructions. The number of transgene copies was determined by real-time PCR, using the 
relative standard curve method. Five-fold dilution standards were prepared to generate a 
standard curve for each primer pair. The upstream region of the GAA repeats in intron 1 of 
the FXN gene was amplified using the primers UpGAA-F and UpGAA-R (Herman et al, 
2006) and normalising data by GAPDH, using the primers GAPDH-F and GAPDH-R 
(Herman et al, 2006). Three independent genomic DNA samples per cell line were 
quantified in triplicate by real-time PCR using the SYBR Green PCR Master Mix (Life 
Technologies). Each 25 μL reaction contained 2 μL of genomic DNA dilution, 1x SYBR 
Green PCR Master Mix and 70 nM of each primer. The assay was performed using the 
StepOnePlus Real-Time PCR system (Life Technologies) with the following protocol: 10 
minutes at 95 °C for enzyme activation, followed by 40 cycles of denaturation at 95 °C for 
15 seconds and primer annealing and extension at 60 °C for 1 minute. Specificity of 
amplification was monitored with a final dissociation stage which generates a melting 
curve. The number of transgene copies was determined by comparison with the acceptor 
cell line HEK FRT as reference sample, which carries three endogenous FXN loci as 
determined by FISH. 
 
2.3.4.4 Small-pool PCR 
Analysis of GAA repeat instability in the FXN-GAA-Luc transgene was performed as 
previously described (Gomes-Pereira et al, 2004a). Eight independent reactions were set 
up for each genomic FXN-GAA-Luc DNA concentration (6-600 pg) in siliconized 
microfuge tubes. PCR amplification of the GAA repeat sequence was performed using 
primers 147F and 602R and Expand Long Template DNA DNA Polymerase (Roche) as 
described in section 2.3.4.2. PCR products were resolved by electrophoresis on 1% agarose 
gels and bands were detected by Southern blotting using DIG High Prime DNA Labeling 
and Detection Starter Kit II (Roche), according to the manufacturer’s instructions, with a 
digoxigenin-labelled (TTC)10 probe. After agarose gel electrophoresis, DNA was 
denatured and transferred onto a hybond-N+ membrane (GE Healthcare). DNA was 
allowed to hybridise to a digoxigenin-labelled (TTC)10 probe at 55 °C overnight. 
Stringency washes were done with 2x SSC containing 0.1% SDS at room temperature for 5 
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minutes and 0.5x SSC containing 0.1% SDS at 60°C for 15 minutes. The membrane was 
blocked in 1x Blocking Solution for 30 minutes before incubation with an anti-digoxigenin 
antibody (1/10000 dilution) for 30 minutes. Chemiluminescent detection was performed 
using the CSPD ready-to-use solution. 
 
2.3.4.5 Colony PCR 
Colony PCR was performed to quickly identify which clones had taken up the 
plasmid of interest during homologous recombination. Individual colonies were picked 
from a petri dish into 50 μL of Milli-Q water in a 96-well plate. Bacteria were lysed by 
heating to 95 °C for 10 minutes and PCR analysis was performed using the AmpliTaq 
Gold (Roche) using the following conditions: DNA was denatured at 95 ºC for 10 minutes, 
followed by 35 cycles of denaturation at 95 ºC for 30 seconds, primer annealing at 58 ºC 
for 30 seconds and extension at 72 ºC for 1 minute, and then a final extension at 72 ºC for 
8 minutes. PCR products were visualised on a 1% agarose gel. 
 
2.3.5 Restriction digestion of plasmid DNA 
Restriction enzymes, buffers and bovine serum albumin (BSA) were purchased from 
New England Biolabs (NEB). A restriction digestion reaction (15 μL) was prepared by 
adding the following reagents to a microfuge tube, on ice: 10 μL DNA from a miniprep (or 
200 ng), 1.5 μL 10x restriction buffer, 0.75 μL 20x BSA, 0.3 μL restriction enzyme (3 
units) and Milli-Q water up to 15 μL. The reaction was incubated at the required 
temperature for 2.5 hours. Small plasmids (<20 kb) were analysed by agarose gel 
electrophoresis (section 2.3.6), whereas BACs were analysed by pulsed-field gel 
electrophoresis (section 2.3.7). 
 
2.3.6 Agarose gel electrophoresis 
Agarose gels were prepared in 1x Tris-borate EDTA (TBE) (Sigma) at a 
concentration of 0.8-2% (w/v). The mix was heated in a microwave until the agarose was 
dissolved. The solution was cooled before the addition of ethidium bromide to a final 
concentration of 0.5 mg/mL. The agarose mix was poured into a gel tray with well combs 
in place. Electrophoresis was performed using a Sub-Cell GT gel electrophoresis system 
(Bio-Rad) with a covering volume of 1x TBE. Sample 6x loading buffer (1.5 g Ficoll 400, 
Orange G dye and Milli-Q water up to 10 mL) was added to the samples prior to loading. 
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A DNA ladder (Life Technologies) was routinely used as a size indicator. The gel was 
photographed using a GelDoc XR transilluminator system (Bio-Rad). 
 
2.3.7 Pulsed-field gel electrophoresis 
Pulsed-field electrophoresis was used to separate DNA fragments larger than 20 kb. 
Samples were run on a 1% agarose gel in 0.5x TBE buffer without ethidium bromide in a 
Bio-Rad CHEF DRII gel running tank containing 2 L of 0.5x TBE buffer. Running 
conditions were: 2 seconds of initial pulse time, 16 seconds of final pulse time, linear 
ramping, voltage of 6V/cm, buffer temperature at 14 °C, running time of 16 hours. The 
Mid-Range PFG II marker (NEB) and 1kb DNA ladder (Life Technologies) were used as 
size markers. Following electrophoresis, the gel was stained in 500 mL of 0.5x TBE buffer 
containing 1 mg/mL of ethidium bromide for 1 hour and photographed using the GelDoc 
XR system. 
 
2.3.8 Purification of DNA fragments from agarose gels 
Agarose gels were prepared in 1x TBE (Sigma) at a concentration of 1% (w/v) and 
electrophoresis performed as described in section 2.3.6. The band of interest was excised 
with the help of a handheld long wave UV illuminator. DNA was purified using the 
GeneClean kit (QBIO-gene) according to the manufacturer’s instructions. 
 
2.3.9 DNA ligation 
Ligations were performed at 16 °C for 3 hours. Each 10 μL reaction contained: 
purified PCR product (in a vector: insert ratio of 1:1, 1:3 or 1:5), 1 μL purified linearised 
vector DNA, 1 μL of 10x T4 DNA ligase buffer, 1 μL of T4 DNA ligase (NEB) and Milli-
Q water up to 10 μL. A negative control reaction contained all components except the 
insert. One microlitre of the ligation reaction was electroporated into electrocompetent 
DH10B E.coli cells, as described in section 2.2.2. Successful cloning was confirmed by 
colony-PCR, restriction enzyme digestions and sequencing. 
 
2.3.10 DNA sequencing 
Sequencing was performed on all plasmids after sequence modifications were 
completed. The region to be sequenced was first amplified by PCR using the standard PCR 
conditions (section 2.3.4.1) or the Expand Long Template protocol for GAA repeats 
(section 2.3.4.2). The PCR product was analysed by agarose gel electrophoresis prior to 
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sequencing. For purification, PCR buffer, salts and dNTPs were removed using 
exonuclease I (NEB) and shrimp alkaline phosphatase (SAP) (Promega). The ExoSAP 
reaction consisted of the following: 3.0 μL PCR product, 1.0 μL 10x SAP buffer, 1.0 μL 
SAP (500U/μL), 0.1 μL Exonuclease I (20U/μL) and 0.9 μL Milli-Q water. Samples were 
incubated at 37 °C for 1 hour and 80 °C for 20 minutes. Sequencing reactions were 
performed according to the BigDye Terminator v3.1 Cycle Sequencing protocol (Applied 
Biosystems). The 10 μL reaction mix consisted of the following: 5.0 μL PCR product (or 
4.0 μL when sequencing GAA repeats), 1.0 μL Primer (10 μM), 1.5 μL 5x BigDye buffer, 
0.5 μL BigDye (or 2.0 μL for GAA repeats) and 1.5 μL Milli-Q water. The sequencing 
reaction was performed using the following program: 96 °C for 1 minute, 30 cycles of 96 
°C for 10 seconds, 50 °C for 5 seconds and 60 °C for 4 minutes. Samples were kept at 4 °C 
until DNA precipitation. DNA was precipitated as follows: 2 μL of 125 mM EDTA and 2 
μL of 3 M sodium acetate were added to each well, followed by addition of 50 μL of 100% 
ethanol. The wells were covered with caps and the mixture vortexed before centrifugation 
at 3000 x g for 30 minutes at 4 °C. The supernatant was discarded and 70 μL of 70% 
ethanol was added to each well. After centrifugation at 1650 x g for 15 minutes at 4 °C, the 
supernatant was discarded and the wells allowed to air dry for 10 minutes protected from 
light. Sequencing was performed on a 3700 DNA Analyzer (Applied Biosystems) 
sequencing platform. 
 
2.3.11 Homologous DNA recombination in E. coli 
The pBAC-FXN-GAA-MS2-Luc was generated from the pBAC-FXN-GAA-Luc 
vector which carries the whole 80 kb FXN locus with exons 1–5b of the FXN gene, an 
insertion of the luciferase gene in exon 5a and a ~310 GAA repeat expansion in intron 1. A 
selection/counter-selection homologous recombination protocol based on Red/ET 
recombination (GeneBridges) was used. Electrocompetent bacteria containing the pBAC-
FXN-GAA-Luc were prepared and transformed with 1 ng of the plasmid pSC101-BAD-
gbaA (as described in section 2.2.2), which expresses the Red/ET recombinase enzymes 
under the control of an arabinose-inducible promoter (Gene Bridges). Since this plasmid 
contains a temperature-sensitive origin of replication, bacteria containing the Red/ET 
plasmid were always grown at 30 °C. Induction of homologous recombination enzymes 
was achieved by the addition of L-arabinose during the preparation of electrocompetent 
bacteria, as described in section 2.2.1, with the exception that 100 mL of LB bacterial 
culture in the appropriate antibiotic were grown at 30 °C with shaking until the optical 
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density reached 0.10-0.13. At this point, 1 mL of 10% of L-arabinose (w/v) was added to 
the culture, which was then incubated at 37 °C until the optical density was in the range 
0.30-0.35. The culture was transferred to a 250 mL centrifuge flask and used to prepare 
electrocompetent cells as described in section 2.2.1. 
Recombination using the rpsL-neo and the pSC101-BAD plasmids was carried out in 
two steps in E. coli according to the manufacturer’s instructions. In the first step, a PCR 
product containing the rpsL-neo cassette flanked by 55 bp homology arms to either side of 
exon 2 was used to insert the cassette. The resulting PCR product was purified using a 
QIAquick PCR purification kit according to manufacturer’s protocol (Qiagen), digested 
with DpnI enzyme for 2 hours at 37 °C to remove any remaining template DNA and 
purified again. Eight microlitres of purified product were then electroporated into 50 μL of 
electrocompetent host cells containing the pBAC-FXN-GAA-Luc and expressing the 
Red/ET recombination proteins. Cultures were plated on LB agar with chloramphenicol 
and kanamycin and colonies were allowed to form at 37 °C overnight. Streptomycin 
sensitivity was also tested. Correct insertion of the rpsL-neo cassette was analysed by 
colony-PCR, PCR and restriction enzyme digestion followed by pulsed-field gel 
electrophoresis. GAA repeat expansion length was assessed by colony-PCR and PCR. 
Before the beginning of the second step of homologous recombination, persistence of 
pRed/ET in successful recombinants was analysed by restriction enzyme digestion. 
Replacement of the rpsL-neo cassette in the second step of recombination by 24 MS2 
Binding Sites in exon 2 was performed as follows. A plasmid containing exon 2 with an 
engineered BamHI restriction site and flanking homology arms (147 bp upstream and 172 
bp downstream of exon 2) was purchased from GeneArt (Life Tecnologies). The 24 MS2 
Binding Sites were excised by BamHI/BglII digestion from pCR4-24XMS2SL-stable 
(Addgene plasmid 31865) (Bertrand et al, 1998) and inserted in exon 2 at the BamHI site 
(Exon2-MBS). The rpsL-neo cassette was replaced with a PCR product containing the 
Exon2-MBS sequence flanked by homology arms, generating pBAC-FXN-GAA-MS2-Luc. 
As previously, 8 μL of purified PCR product were electroporated into 50 μL of 
electrocompetent host cells, containing the pBAC-FXN-rspLneo-Luc and expressing the 
Red/ET recombination proteins. Cultures were plated on LB agar with chloramphenicol 
and streptomycin and incubated overnight at 37 °C. Correct insertion of the 24 MBS 
cassette was confirmed by colony-PCR, PCR, restriction enzyme digestion followed by 
pulsed-field gel electrophoresis, and sequencing. GAA repeat expansion length was 
assessed by colony-PCR and PCR.  
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To generate pBAC-FXN-MS2-Luc, the ~310 GAA repeats in intron 1 in pBAC-FXN-
GAA-MS2-Luc were replaced by the rpsL-neo cassette amplified with primers carrying 58 
bp homology arms to sequences immediately upstream and downstream of GAA repeats. 
The rpsL-neo was then replaced with a PCR product containing 6 GAA repeats amplified 
from the genomic DNA of GM15851 using GAA-F and GAA-R primers (Campuzano et 
al, 1996). Successful construction was confirmed by PCR, restriction enzyme digestion 
followed by pulsed-field gel electrophoresis and sequencing. 
 
2.3.12 Cre-loxP recombination for retrofitting 
Cre-loxP mediated retrofitting of pBAC-FXN-MS2-Luc and pBAC-FXN-GAA-MS2-
Luc vectors to pH-FRT-Hy was performed to insert the Flp-In promoter-less hygromycin 
cassette necessary to generate stable human clonal cell lines and a lacZ gene. For each 
BAC, three 30 μL reaction mixtures were prepared on ice: for reaction 1, 2 μg of each 
BAC, 50 ng of pH-FRT-Hy, 3 μL of Cre buffer, 1 μL of Cre recombinase and Milli-Q 
water; for reaction 2, 1 μg of each BAC, 50 ng of pH-FRT-Hy, 3 μL of Cre buffer, 1 μL of 
Cre recombinase and Milli-Q water; for reaction 3, 1 μg of each BAC, 3 ng of pH-FRT-
Hy, 3 μL of Cre buffer, 1 μL of Cre recombinase and Milli-Q water. Samples were 
thoroughly mixed and briefly centrifuged. Each mixture was then incubated at 37 °C for 1 
hour, followed by inactivation of the enzyme at 70 °C for 5 minutes. After leaving samples 
at room temperature for 10 minutes, the reaction was drop-dialysed against 50 mL of Milli-
Q water for 1 hour, using 0.25 μm membrane filters (Millipore). Each sample was 
electroporated into electrocompetent DH10B bacteria as described in section 2.2.2, and 
plated on a 15 cm LB agar petri dish containing the relevant antibiotics (chloramphenicol 
for the BAC and ampicillin for the pH-FRT-Hy construct). Successful recombinants were 
identified by restriction enzyme digestion and pulsed-field electrophoresis. 
 
2.4 Delivery of DNA into human cells 
 
2.4.1 Lipofection 
DNA was delivered to HEK FRT cells using Lipofectamine and Plus reagent (Life 
Technologies). Briefly, 1x106 cells were seeded per 6 cm dish in DMEM medium 
supplemented with 10% FBS and 100 U/ml penicillin/streptomycin (Life Tecnologies) and 
allowed to adhere overnight. For each 6 cm dish, the following two transfection mixes 
were prepared: (i) tube A, 3200 ng of pBAC-FXN-MS2-Luc or pBAC-FXN-GAA-MS2-Luc 
69 
 
(500 ng when transfecting a small plasmid), 250 μL of Opti-MEM medium and 10 μL of 
Plus reagent; DNA was mixed well prior to addition of Plus reagent; (ii) tube B, 250 µL of 
Opti-MEM medium and 16 μL of Plus reagent.  
The mixtures were incubated for 10 minutes at room temperature and then the 
contents of Tube B were added to Tube A. The DNA:Lipofectamine complexes were 
allowed to form for 30 minutes. Opti-MEM was added for a final volume of 500 μL. The 
mixture was then added dropwise to HEK FRT cells previously washed twice with Opti-
MEM. After 4 hours, cells were washed three times with Opti-MEM to remove 
DNA:Lipofectamine complexes and complete DMEM medium was added. BAC 
transfection efficiency was assessed by X-gal staining (section 2.4.2.1) after 72 hours. 
 
2.4.2 Generation of stable clones by site-specific integration 
Stable clonal cell lines were obtained by transfecting HEK FRT cells with either 
pBAC-FXN-MS2-Luc or pBAC-FXN-GAA-MS2-Luc together with Flp recombinase-
encoding plasmid pOG44 (800 ng, Life Technologies), generating the lines FXN-MS2-Luc 
and FXN-GAA-MS2-Luc, respectively. Cells used as a positive control were co-transfected 
with pH-FRT-Hy (730 ng) and pOG44 (800 ng) and cells used as a negative control were 
transfected with pH-FRT-Hy only. After 48 hours, each 6 cm dish was split into two 10 cm 
dishes. Stable selection was performed with 100 µg/ml hygromycin (Life Technologies). 
Cells were cultured for two weeks, changing the medium regularly to allow healthy clone 
formation. When identifiable, individual clones were picked into 96-well plates and 
allowed to grow up to 12-well plates for freezing and screening. Vector integration at the 
FRT docking site of HEK FRT cells was assessed by PCR, as described in section 2.3.4.1. 
 
2.4.2.1 X-gal staining 
X-gal (5-bromo-4-chloro-3-indolyl-D-galactopyranoside) staining was used to 
determine transfection efficiency of pBAC-FXN-MS2-Luc and pBAC-FXN-GAA-MS2-Luc. 
Cells were washed once in PBS and incubated in fixative solution (5% formaldehyde, 
0.2% glutaraldehyde in PBS) for 10 minutes. Cells were washed twice and incubated with 
1 mg/mL X-gal (Promega) in staining solution (5 mM potassium ferricyanide [K3Fe(CN)6], 
5 mM potassium ferrocyanide [K4Fe(CN)6·3H20], 2 mM MgCl2 in PBS) at 37 °C 
overnight. 
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2.5 Epigenetic analysis 
 
2.5.1 Bisulphite sequencing 
Genomic DNA of the FXN-Luc and FXN-GAA-Luc cell lines was isolated using the 
Illustra Tissue and Cells GenomicPrep Mini Spin Kit (GE Healthcare). Two micrograms of 
DNA was used in the bisulfite conversion reaction using the EpiTect Bisulfite kit (Qiagen), 
according to the manufacturer’s instructions. Nested PCR was performed on bisulfite-
converted DNA using the following primers (Al-Mahdawi et al, 2008): SL1F1 and SL1R1 
(first round PCR) and SL1F2 and SL1R2 (second round PCR) for the FXN promoter 
region; F1G and R1G (first round PCR) and F2G and R2G (second round PCR) for the 
upstream region of the GAA repeats in intron 1 of the FXN gene; NH1F and SLGR2 (first 
round PCR) and NH2F and SLGR1 (second round PCR) for the downstream region of the 
GAA repeats in intron 1 of the FXN gene. In the first round of the nested PCR, 3 µl of 
bisulfite-converted DNA were denatured at 95ºC for 15 minutes, followed by 35 cycles of 
denaturation at 94ºC for 30 seconds, primer annealing at 50ºC for 30 seconds and 
extension at 72ºC for 1 minute and final extension at 72ºC for 10 minutes. In the second 
round of nested PCR, 5 µl of the first round were used with the same termocycling 
conditions. Each reaction was carried out in 25 µL containing 1x PCR Buffer, 125 µM of 
each dNTP (Life Tecnologies), 0.5 µM of each primer, 1x Q Solution (Qiagen) and 1 U of 
HotStart Taq DNA Polymerase (Qiagen). PCR products were cloned into pGEM-T Easy 
vector (Promega) and electroporated into E.coli DH10B (Life Tecnologies). Recombinant 
clones were directly identified through blue/white screening and confirmed by EcoRI 
restriction digestion which releases cloned inserts. A total of 10 colonies were sequenced 
per region and for each cell line using T7 and SP6 primers. 
 
2.5.2 Chromatin Immunoprecipitation 
Analysis of histone modifications in the FXN promoter and regions flanking GAA 
repeats in lymphoblastoid (GM15850 and GM15851), FXN-Luc and FXN-GAA-Luc cell 
lines was performed as previously described (Carey et al, 2009). Lymphoblastoid cell lines 
were treated with DMSO or C5 for 48 hours before crosslinking. Proteins were cross-
linked to DNA by 1% formaldehyde treatment for 4 minutes (GM15850 and GM15851) or 
7 minutes (FXN-Luc and FXN-GAA-Luc cells). Chromatin from lysed cells was sheared by 
sonication to obtain fragments from 100 to 800 bp using a Bioruptor (Diagenode). 
Immunoprecipitation experiments were performed using the Immunoprecipitation Kit with 
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Dynabeads Protein G (Life Technologies), according to the manufacturer’s instructions. 
Chromatin was incubated with one of the following antibodies at 4°C: (i) anti-H3K9ac (07-
352), (ii) anti-H4K8ac (07-328), (iii) anti-H3K9me2 (07-441), (v) anti-H3K9me3 (07-442) 
and (vi) normal rabbit serum (12-370) used as a negative control (all antibodies were 
purchased from Millipore). Samples were treated with 500 mM NaCl, 0.25 mg/mL RNase 
A and 0.25 mg/mL proteinase K and incubated at 65°C overnight to reverse crosslinking. 
After reversing the crosslinking, the amount of FXN DNA immunoprecipitated was 
quantified in triplicate by real-time PCR using the SYBR Green PCR Master Mix (Applied 
Biosystems) and determined using the ΔΔCt method. The immunoprecipitated DNA was 
normalised to 10% of input and taking into consideration the background signal. For the 
analysis of the FXN promoter and the regions upstream and downstream of the GAA 
repeats, primers described by Soragni and colleagues were used (Soragni et al, 2008). 
 
2.6 Analysis of FXN expression 
 
2.6.1 RT-PCR 
Total RNA from HEK FRT, FXN-MS2-Luc and FXN-GAA-MS2-Luc clonal cell lines 
and from the lymphoblastoid-derived cell lines GM15851, GM14519 and GM16209 was 
extracted using RNeasy Mini Kit (Qiagen) and treated with RNase-Free DNase (Qiagen). 
cDNA was synthesized from 1 µg of total RNA using random primers (Life Technologies) 
and SuperScript III Reverse Transcriptase (Life Technologies) in a total volume of 20 µL 
as follows: 1.0 μg of RNA, 1.0 μL of random primers (150 ng), 1.0 μL of dNTP (10 mM) 
and DEPC water up to 13 μL. This mixture was heated to 65 °C for 5 minutes. Next, the 
following reagents were added: 4 μL of 5x first strand buffer, 1 μL of DTT (0.1M), 1 μL of 
RNase OUT and 1 μL of Superscript III Reverse Transcriptase (all Life Technologies). The 
sample was incubated in the thermocycler using the following conditions: 25 °C for 5 
minutes, 55 °C for 60 minutes and 70 °C for 15 minutes. RT-PCR amplification was 
performed as described in section 2.3.4.1 using 5 μL of a 1:10 dilution of cDNA to assess 
transient expression of FXN-MS2-Luc and FXN-GAA-MS2-Luc transgenes in HEK FRT 
cells. GAPDH expression was used as a positive control.  
 
2.6.2 qRT-PCR 
Total RNA from HEK FRT, FXN-MS2-Luc and FXN-GAA-MS2-Luc clonal cell lines 
and from the lymphoblastoid-derived cell lines GM15851, GM14519 and GM16209 was 
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extracted using RNeasy Mini Kit (Qiagen) and treated with RNase-free DNase (Qiagen). 
cDNA was synthesized from 1 µg of total RNA using random primers (Life Technologies) 
and SuperScript III Reverse Transcriptase (Life Technologies) as described in section 
2.6.1. Three independent cDNA samples per cell line were quantified in triplicate by real-
time PCR using the SYBR Green PCR Master Mix (Applied Biosystems) in a reaction 
volume of 25 µL. FXN-MS2-Luc mRNA expression was determined using primers qFXN-
Luc-F (5′-CGGAAAAGATGCTGGAAGTG-3′) and qFXN-Luc-R (5′-AACCAGGGC 
GTATCTCTTCA-3′) normalised by GAPDH (Forward, 5′-GGTCTCCTCTGACT 
TCAACA-3′; Reverse, 5′-AGCCAAATTCGTTGTCATAC-3′; RTPrimer DB, ID: 912). 
FXN mRNA expression was detected using primers FXN-F and FXN-R (Herman et al, 
2006) normalised by β-actin (Forward, 5′-AGCGCGGCTACAGCTTCA-3′; Reverse, 5′-
CGTAGCACAGCTTCTCCTTAATGTC-3′; RTPrimerDB, ID: 2203). 
 
2.7 Analysis of frataxin protein levels 
 
2.7.1 Luciferase assay 
To assay luciferase expression, 1.5x106 cells of FXN-MS2-Luc and FXN-GAA-MS2-
Luc clonal cell lines were used. Cells were seeded in 6-well plates, washed in PBS and 
lysed in Lysis Buffer (25 mM TrisPO4 pH7.8, 2 mM CDTA, 10% Glycerol and 1% Triton-
X 100) for 20 minutes at 4°C. Seventy-five microlitres of lysates were mixed with 100 μL 
of Luciferase Assay Buffer (15 mM MgSO4, 15 mM KPO4 pH 7.8, 4 mM ethylene glycol 
tetraacetic acid [EGTA] pH 7.8, 2 mM adenosine 5′-triphosphate [ATP] and 2mM 
dithiothreitol [DTT]) and 50 μL of D-Luciferin (0.3 mg/mL). The relative light units of 
luciferase of each cell line were determined using the Dynex MLX 96 Well Plate 
Luminometer and were normalised by total protein concentration, determined using 
bicinchoninic acid solution (BCA, Sigma), according with the manufacturer’s instructions. 
 
2.8 Fluorescence in situ hybridisation (FISH) 
 
2.8.1 Probes for DNA FISH 
Human FXN gene was detected in GM15851, GM14519 and GM16209 cells using 
either G248P87590H8 or G248P89980G8 fosmid clones obtained from BACPAC 
Resources Center (Children's Hospital Oakland Research Institute). Probes were labelled 
by nick translation with digoxigenin (Roche). Briefly, 1µg of DNA from each fosmid clone 
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was treated with 200 ng RNase (Sigma) for 30 minutes at 37°C. After RNA removal, each 
probe was mixed with 5 µL of nick translation buffer (0.5 M Tris–HCl pH 8.0, 50 mM 
MgCl2, 0.5 mg/mL BSA), 5 µL of -mercaptoethanol, 5 µL of dNTP mix (0.5 mM 
deoxyadenosine triphosphate [dATP], 0.5 mM deoxyguanosine triphosphate [dGTP], 0.5 
mM deoxycytidine triphosphate [dCTP]), 1 nmol of digoxigenin, 6 units DNAse I (Roche) 
and 10 units of DNA polymerase I (Life Technologies) and incubated for 2 hours at 16°C. 
Unincorporated nucleotides were removed using Illustra G-50 columns (GE Healthcare), 
according to the manufacturer’s instructions. In carrier cells, the expanded allele was 
distinguished from the wild-type allele using biotinylated (GAA)15 or (TTC)15 oligos 
(Biomers). Chromosome 9 was detected using a green XCyting 9 whole chromosome paint 
for HSA9 (MetaSystems). 
 
2.8.2 2D FISH 
DNA FISH was performed on GM14519 carrier cell line as described previously 
with slight modifications (Brown et al, 2008). Cells were fixed in 3:1 methanol–acetic acid 
and treated with 100 μg/mL RNase for 30 minutes at 37°C, washed in 2x SSC, and 
dehydrated. Cells were denatured in 70% formamide/2x SSC at 72°C for 2 minutes and 
dehydrated. Labelled oligos (100 ng) were denatured in FISH hybridization buffer 
(Kreatech) at 90°C for 8 minutes and immediately allowed to cool on ice. Labelled fosmid 
clones (100 ng) were precipitated with 3 µg of human Cot-1 DNA (Life Technologies) and 
20 µg of salmon sperm DNA (Sigma), denatured in FISH hybridization buffer at 90°C for 
8 minutes and were preannealed at 37°C for 8 minutes. Whole chromosome 9 paint (4 µL) 
was denatured at 75°C for 2 minutes and combined with 8 μL of denatured oligo and 
fosmid and applied onto the slide. Slides were hybridised overnight at 37°C. After 
hybridisation, slides were washed in 0.4x SSC/0.3% Igepal for 2 minutes and then 1 
minute at room temperature. Slides were blocked in 3% BSA/4x SSC for 30 minutes, 
biotin was detected with streptavidin Cy3 (Jackson ImmunoResearch Laboratories, 1/200 
dilution), and digoxygenin was detected with sheep anti-digoxigenin FITC (Roche, 1/50 
dilution) followed by rabbit anti–sheep FITC (Vector Laboratories, 1/100 dilution) or 
mouse anti-digoxigenin (Jackson ImmunoResearch Laboratories, 1/100 dilution) followed 
by Alexa Fluor 647 goat anti–mouse IgG (Life Technologies, A-21236, 1/200 dilution) 
when the green whole chromosome 9 paint was used. Cells were mounted in Vectashield 
(Vector Laboratories) with 1 µg/mL 4′,6-diamidino-2- phenylindole (DAPI) counterstain.  
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2.8.3 3D FISH 
3D DNA FISH was performed on GM14519 carrier cell line as described previously 
with slight modifications (Brown et al, 2008). Cells were washed in PBS and allowed to 
settle on poly-L-lysine-treated coverslips for 5 minutes. Cells were fixed in 4% 
paraformaldehyde (PFA)/25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(Hepes) for 15 minutes and permeabilised in 0.5% Triton X-100 (Calbiochem) in PBS for 
10 minutes. RNA was removed with 100 μg/mL RNase in 2x SSC for 1 h at 37°C. Cells 
were denatured in 3 N HCl for 20 minutes, and neutralized in ice-cold PBS. Probes were 
prepared as in the previous section, and slides were hybridised overnight at 37°C. Cells 
were washed two times in 2x SSC at 37°C, once in 1x SSC at room temperature for 30 
minutes, and blocked in 3% BSA/4x SSC for 1 hour. Probes were detected as in the 
previous section. Cells were washes between layers in 4x SSC with 0.05% Tween20. 
Coverslips were mounted in Vectashield with 1 µg/mL DAPI counterstain. 
 
2.8.4 Immuno-FISH 
Immuno-FISH was performed on FXN-MS2-Luc and FXN-GAA-MS2-Luc cells, and 
on the lymphoblastoid cell lines GM14519, GM15851 and GM16209 as described 
previously with slight modifications (Brown et al, 2008). Adherent cells were seeded on 
poly-L-lysine-treated coverslips and allowed to grow overnight. Suspension cells were 
washed in PBS and allowed to settle on poly-L-lysine-treated coverslips for 5 minutes. 
Cells were fixed in 4% PFA/25 mM Hepes for 15 minutes and permeabilised in 0.5% 
Triton X-100 for 10 minutes. Non-specific sites were blocked with 10% FBS. Antibodies 
were prepared in blocking solution. The NL was detected with goat anti-lamin B1 (Santa 
Cruz, sc-6217, 1/200 dilution). Nuclear speckles were detected with mouse anti-SC35 
(Sigma, S4045, 1/1000 dilution). The nucleolus was detected with mouse anti-nucleolin 
(Abcam, ab13541, 1/25 dilution). Secondary antibodies used were Alexa Fluor 647 goat 
anti–mouse IgG (Life Technologies, A-21236, 1/1000 dilution) and Alexa Fluor 647 rabbit 
anti-goat IgG (Life Technologies, A-21446, 1/500 dilution). After protein detection, slides 
were post-fixed in 4% PFA/25mM Hepes at room temperature for 10 minutes. Cells were 
treated with 100 μg/mL RNase for 1 h at 37°C, denatured in 3 N HCl for 20 minutes, and 
neutralized in ice-cold PBS. Probes were prepared as in section 2.8.2, and slides were 
hybridised overnight at 37°C. Cells were washed twice in 2x SSC at 37°C, once in 1x SSC 
at room tempearture, and blocked in 3% BSA/4x SSC. Probes were detected as in section 
2.8.3. 
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2.8.5 RNA FISH 
RNA FISH was performed on HEK FRT and FXN-MS2-Luc cell lines as previously 
described (Chartrand et al, 2000) with minor modifications. Briefly, cells were allowed to 
grow on poly-L-lysine-treated coverslips overnight, washed in PBS and fixed in 4% 
formaldehyde (Electron Microscopy Science) for 10 minutes at room temperature. Cells 
were permeabilised in 0.5% Triton X-100 for 6 minutes and washed in 50% formamide/2x 
SSC for 5 minutes. Cells were hybridised overnight at 37°C with 10 ng Cy3-MS2 DNA 
probe (Hocine et al, 2013) in 40 µL hybridisation mix containing 2x SSC, 3% BSA, 10% 
dextran sulphate (Sigma), 2 mM vanadyl-ribonucleoside complex (New England Biolabs), 
40 µg tRNA (Roche), and 50% formamide. Cells were washed once in 50% formamide/2x 
SSC at 37°C for 10 minutes, once in 2x SSC for 10 minutes at 37°C and once in 2x SSC 
for 5 minutes at room temperature. Cells were washed briefly in PBS and mounted in 
Vectashield with 1 µg/mL DAPI counterstain. 
RNA FISH on GM15851 and GM16209 cell lines was performed as described 
previously (Raj & Tyagi, 2010) with minor modifications. Custom Stellaris FISH probes 
TSS (20 oligos), UpGAA (41 oligos) and DownGAA (41 oligos) were designed to 
hybridise with the regions TSS-exon1, upstream and downstream of the GAA repeats, 
respectively (Table 2.1), according to the manufacturer’s instructions. Cells were washed 
in PBS and allowed to settle on poly-L-lysine-treated coverslips for 5 minutes. Cells were 
fixed in 3.7% formaldehyde/1X PBS for 10 minutes, permeabilised in 70% ethanol at 4°C 
for 1 hour and washed in 10% formamide/2x SSC at room temperature for 5 minutes. 
Hybridisation was performed overnight at 42°C with probes TSS (50 nM), UpGAA (50 
nM) and DownGAA (25 nM) in 100 µL hybridisation buffer containing 100 mg/mL 
dextran sulphate, 10% formamide in 2x SSC. Cells were washed in 10% formamide/2x 
SSC at 42°C for 10 minutes. Cells were washed briefly in PBS and mounted in Vectashield 
with 1 µg/mL DAPI counterstain. 
 
 
 
 
 
 
 
 
76 
 
Table 2.1 Custom Stellaris FISH probes TSS, UpGAA and DownGAA used in RNA FISH experiments. 
Probe # TSS UpGAA DownGAA 
1 acccctgacccaagggagac ctgagaaggagcggggtgag tttttgagacggagtcttgc 
2 aaagcacggagtgcaaccag ccagagaagggagttgcaag gctgggaaatccattttatt 
3 aaatggagagcctgctttgt cagtgtaaatgcaaccggga acttgcctatttttccagag 
4 gcactattcgtgcatttaac cttttccttcggaaagcaga gatctaaggaccatcatggc 
5 caggaagaacttcccagctt tcgcaccgcaggacaaaatg aaatgtctgctttcctagag 
6 gagcagctagaggttagacc tcgcagagaagtgacaagca aatacgtggcagctcagata 
7 caggcactcttctgtggg actagcagataccatctatt acacaactctgctgacaacc 
8 ccctggtggccactggcc cagacacacacattatgtgt cctgggcaacaagagggaaa 
9 cgctgggtgctgcggcga acacacacgctatatacaga tgcagtgagctgagactgag 
10 cgcccgctccgccctcca tgcgcgcaaacacacacaca cttgaacccaggaggcagag 
11 catgctgctccgggtctg aaatattaggtgtgcgcgcg ggaggctgaggcaggagaat 
12 cgcggcgcccgagagtcc ccaggaaagcatttcgttca aattagccgataatcccagc 
13 gccaggaggccggctact gctctgaaagtttcacctcg gcctgaccaacatggagaaa 
14 ctgggccgggctgggtga ctgctgctctagctattctg tgaggttgggagttcgagac 
15 cccgggtgagggtctggg gtcgggtcagtttccaaaag taattccagcactttgggag 
16 aactctgccggccgcggg gtggggcagaatctggaata aaaaactctgctgatggcca 
17 gcggccgcagagtggggc caaggtcacacagctctgcg cctcttgtcattctcctaaa 
18 tgtcggtgcgcaggccac ctcagagaggttaggggaat ccaccaggtaccatctaaaa 
19 ggcgtgcaggtcgcatcg ccctacagaaaacaaagcca aagttgggtgtgtttgtcag 
20 gatacttactgcgcggcg caaaatgggcgtcaccttta tatccagaaacccagtgtcc 
21  tttaatcctcacaccaggtc gtgacagaggttgctaacca 
22  gactttatctatgttattcc tagaaaaaaagaggcccagc 
23  cccaaaggaagaaaggggaa gtgcaagggaactatggaac 
24  ggtcagatatttctttgtac caactcctcaaatacccaag 
25  ctttcaagccgtggcgtaac aattaaacaggatggtggcc 
26  acagccattctttgggtttc aggacagtcagggctttaaa 
27  ttgaggaatcttcctcatcc tgaattttggagaccagggg 
28  cattaaataccatgtcctcc gccttcaagtgaactcagtt 
29  ttccttggcatcttcaagac gtggagaaaagggtggggaa 
30  ctcgtgaaacaccctctacc ctgctttagaagtagatgca 
31  ttcatctcccctaatacatg ccattctgtttctgttgaac 
32  aaatatggcttggacgtggc tgtagaattatgtgtgtggc 
33  gtacaaactccggagagcaa cctggtctcattactgattt 
34  gtgtgggaagtttaagccta caaagtcctgggattacagt 
35  cacaatgtgggccaaataac cttgaactcctgatctcaga 
36  ccaatcccaaagtttcttca agagatggggtttcaccatg 
37  cctaacttttaagcactggc ccatgctgagctagttttta 
38  gccaggaaatccattttcta cgagtagctgggactacagg 
39  aagtgctgagattatgggca aagtgattctcatgcctcag 
40  caggttagtcttgaactccg aaatcttggctcactgcaac 
41  tagatactgggtttcaccat tttgtatgtcacagaatccc 
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2.9 Fluorescence Recovery After Photobleaching (FRAP) 
FRAP experiments were performed using the UltraView Spinning Disk system 
(PerkinElmer) mounted on an IX81 microscope (Olympus) equipped with a 100× 1.3 
numerical aperture (NA) objective, a FRAP unit and an electron multiplying charge-
coupled device (EMCCD) camera (Hamamatsu Photonics) and driven by Volocity 
software (PerkinElmer). HEK FRT and FXN-MS2-Luc cell lines were seeded on collagen-
coated glass-bottom dishes (MatTek) in complete DMEM medium (section 2.1.1) and 
transiently transfected with NES-YFP-MS2-NLS (a kind gift from Y. Shav-Tal) (Ben-Ari 
et al, 2010). For nuclear detection, NucBlue Live reagent was added to the cells 20 minutes 
before imaging. Cells were maintained at 37 °C in a 5% CO2 humidified atmosphere using 
an on-scope incubator and an objective heater (Tokai). Fluorescent spots inside the nucleus 
indicating active FXN-MS2-Luc transcription sites were detected with the YFP channel 
(514 nm laser). The nucleus was detected with the DAPI channel (405 nm laser). z-stacks 
were acquired at 0.25 µm intervals to cover the entire nuclear volume of each cell. Before 
bleaching, three z-stacks of each cell were taken. The active transcription site was bleached 
for 200 ms with the 514 nm laser power set to 100%. Post-bleach recovery z-stacks images 
were acquired with an exposure time of 50 ms every 20 seconds for 20 minutes.  
 
2.10 Imaging acquisition and analysis 
Images of fixed cells were obtained using the DV Elite system based on an Olympus 
IX71 fully motorised widefield deconvolution inverted microscope with a 100x objective 
1.40 NA fitted with a CoolSNAP HQ2 cooled charge-coupled device (CCD) camera 
(Photometrics) driven by SoftWoRx 5.0 software (Applied Precision). Several cell 
positions were chosen randomly and recorded using the motorized stage. z-stacks were 
acquired at 0.2 µm intervals to cover the entire volume of each cell. Distance 
measurements between FISH signals and the nuclear periphery were calculated with 
NEMO software (Iannuccelli et al, 2010). Briefly, a region of interest (ROI) was defined 
around each nucleus using an image stack from the DAPI channel. The software applied 
several segmentation filters (Median 3D, TopHat 3D, mathematical morphology 3D) on 
raw image stacks for object detection. Objects were detected by computing seeds as the 
brightest maximum local pixels above a global threshold, and a local threshold was then 
computed to aggregate neighbouring pixels to the seed. For each cell, the distance of each 
allele to the nuclear periphery was normalised by the local ray between the nuclear centre 
and periphery passing through the FISH signal. For relative positional analysis, image 
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stacks were deconvolved using the SoftWoRx 5.0 software. Association of FISH signals 
with subnuclear domains or chromosome territories was analysed using ImageJ 
(http://imagej.nih. gov/ij/): image stacks were analysed manually and association was 
determined by eye when FXN FISH signals were touching or superimposing the signal 
from a specific subnuclear domain at a given z-section. Images are maximum projections 
of z-stacks covering the signals. Contrast-stretch and gamma adjustments were made using 
Adobe Photoshop CS5 only for display in Figures 5.4B, 5.5D and 5.6A. 
RNA MS2 FISH signals were detected as described previously (Raj et al, 2008) 
using StarSearch software (Levesque & Raj, 2013). Briefly, the program applied Laplacian 
of Gaussian filters in three-dimensions, taking into consideration the size of the fluorescent 
spots to remove the non-uniform background while enhancing particles. After filtering, the 
program calculated the number of spots detected for all possible thresholds. After plotting 
this data, the graph showed a plateau region corresponding to a broad range of thresholds 
over which the spot count did not vary significantly. Spot counts calculated with these 
thresholds matched the number of spots identified by eye. In HEK FRT cells and cells 
from the FXN-MS2-Luc cell lines that did not express the transgene, the plateau region was 
not observed. The DIC channel was used to determine the cell edges. 
In RNA FISH experiments on GM15851 and GM16209 cell lines several cell 
positions were chosen randomly. z-stacks were acquired at 0.2 µm intervals to cover the 
entire volume of each nucleus. Images were analysed using ImageJ. For the analysis of 
nascent RNA FISH signals using the UpGAA probe only, a threshold was defined for both 
cell lines to eliminate non-specific background. RNA fluorescent spots were identified 
either at the nuclear rim or interior using the DAPI channel and their intensity measured 
using the 3D Object Counter plugin (Bolte & Cordelières, 2006). Identification of RNA 
FISH signals using probes TSS, UpGAA and DownGAA was performed as described 
above. In addition to threshold determination, to distinguish true signals from background, 
the downstream signals were scored when co-localised with the upstream signals. Because 
the TSS probe hybridises to exon 1, it could potentially label mature FXN mRNA. 
However, due to its short length spanning, the TSS probe did not generate more than two 
RNA FISH signals per cell. Therefore, all TSS RNA FISH signals were identified as 
nascent transcript accumulating at the transcription sites. 
For live-cell experiments, HEK FRT and FXN-MS2-Luc cell lines were seeded on 
collagen coated glass-bottom dishes (MatTek) in complete DMEM medium and transiently 
transfected with NES-YFP-MS2-NLS (Ben-Ari et al, 2010). For live-cell imaging of 
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transcription sites, cells were imaged in four dimensions (three dimensions over time) 
using the DV Elite system based on an Olympus IX71 microscope with a 100x objective 
1.40 NA fitted with an Evolve EMCCD camera (Photometrics) driven by SoftWoRx 5.0 
software under physiological conditions inside an incubator at 37°C and 5% CO2.  
FRAP image sequences were analysed with Volocity software (PerkinElmer). 
Tracking of fluorescence spots was performed using the manual tracking function on 
Volocity at each time point. Relative intensity of each time point was calculated using 
 
where T0 and T(t) are the average intensity of an arbitrary area in the nucleus before and 
after bleaching, respectively, and I0 and I(t) are the average intensity of the ROI before and 
after bleaching, respectively. The background was subtracted from all measured values. 
The formula accounted for fluorescence loss due to bleaching monitoring, and finally 
fluorescence intensity was normalised to 1 (Dundr & Misteli, 2003). Data from five cells 
per lines were collected in three independent experiments, and the averaged FRAP 
measurements were fitted with exponential curves. The diffusion of MCP-YFP protein 
during FRAP analysis was disregarded as the diffusion rate of free MCP-YFP is very 
rapid, whereas the bound MCP-YFP is associated with high affinity to the mRNA and does 
not detach, diffuse and bind again at the transcription site (Yunger et al, 2010). 
 
  
 
 
 
 
 
CHAPTER 3 
Epigenetic silencing induced by a GAA repeat 
expansion in a human cell model of FRDA 
 
 
The results featured in this Chapter were published in the paper (Annex 1):  
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3.1 Introduction 
The generation of FRDA models has been essential to uncover (i) the molecular 
mechanisms underlying the GAA expansion-mediated gene silencing and instability, (ii) 
the pathophysiology of the disease, (iii) the function of the frataxin protein, (iv) new 
therapeutic targets and (v) potential therapeutic compounds (reviewed in Martelli et al, 
2012; Perdomini et al, 2013; Yandim et al, 2013; Sandi et al, 2014a).  
An ideal FRDA model should have a GAA repeat expansion within the FXN 
genomic context, leading to impairment of FXN transcription. Cellular models should 
recapitulate the tissue-specific disease phenotype and GAA repeat instability. Additionally, 
animal models should recapitulate FRDA biochemical and cellular defects and disease 
progression (Perdomini et al, 2013). So far, none of the available FRDA models meets all 
these criteria, so the use of a specific model depends on the scientific question being 
answered. Here, I will focus on the epigenetic findings from available FRDA cellular and 
animal models used to understand the pathological molecular mechanism caused by 
expanded GAA repeats and to test compounds able to upregulate FXN expression.  
 
3.1.1 FRDA cell models 
Several studies have been conducted using patient-derived lymphoblastoid cells, 
primary fibroblasts or peripheral lymphocytes. Although these cells recapitulate some 
molecular features of FRDA, including the GAA-mediated FXN heterochromatinization 
and decreased levels of FXN mRNA, they do not develop spontaneous phenotypic 
characteristics of the disease (Rotig et al, 1997; Sturm et al, 2005).  
FRDA-iPSC lines have been developed in order to generate patient-specific and 
disease-relevant cell lineages, including neurons and cardiomyocytes. FRDA iPSCs 
recapitulate some of the molecular and genetic aspects of FRDA. The pathological GAA 
repeat expansion in iPSCs decrease the levels of FXN mRNA and frataxin protein, but do 
not lead to a deficit of the activity of ISC proteins (Perdomini et al, 2013). 
 
3.1.2 FRDA mouse models 
GAA-based mouse models were obtained using either a knock-in approach, based on 
homologous recombination, or a YAC transgenic approach.  
Homozygous 230 GAA repeat expansion knock-in mice (KIKI) show a 25% 
decrease in frataxin expression, whereas compound heterozygous knock-in–knockout mice 
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(KIKO) express 25-35% of wild-type frataxin levels (reviewed in Perdomini et al, 2013). 
Although only presenting a mild FRDA phenotype, these models have been useful to 
investigate epigenetic-based FXN upregulating compounds, such as HDAC inhibitors (Rai 
et al, 2008, 2010).  
The human FXN YAC transgenic mouse models express human FXN in a mouse 
FXN-null background: Y47R, contains (GAA)9 repeats, and YG8R and YG22R, which 
initially contained 90-190 and 190 GAA repeats, respectively, now contain 120-220 units 
and 170-260 GAA repeats, respectively (Pook et al, 2001; Al-Mahdawi et al, 2004, 2008; 
Anjomani Virmouni et al, 2014). Both YG8R and YG22R mice express decreased levels 
of human FXN mRNA and frataxin protein in comparison with wild-type or Y47R control 
mice (Al-Mahdawi et al, 2004, 2008; Anjomani Virmouni et al, 2014). Furthermore, both 
YG8R and YG22R mice exhibit a progressive FRDA-like molecular disease phenotype, 
including intergenerational and somatic instability of the GAA repeat expansion (Al-
Mahdawi et al, 2004; Clark et al, 2004) and mild progressive behavioural motor 
coordination deficits when compared with wild-type or Y47R controls (Al-Mahdawi et al, 
2008; Anjomani Virmouni et al, 2014). Recently, a new line designated YG8sR was 
generated from YG8R and contains a single copy of the FXN transgene with ~200 pure 
GAA repeats (Anjomani Virmouni et al, 2015).  
There are also several condicitional FXN knockout models which exhibit severe 
early-onset FRDA-like pathologies, being extremely useful for assessing potential FRDA 
drug therapies acting on the downstream effects of frataxin deficiency (Puccio et al, 2001; 
Martelli et al, 2012).  
 
3.1.3 Epigenetic changes at the expanded FXN allele 
The GAA repeat expansion has been shown to induce epigenetic changes at the FXN 
locus, including DNA methylation and hydroxymethylation, histone deacetylation, and 
histone methylation, which may lead to reduced FXN mRNA levels in FRDA patient cells, 
tissues, cellular and mouse models (Table 3.1).  
Studies have revealed increased DNA methylation of specific CpG sites in the 
upstream region of GAA repeat expansions in FRDA patient lymphoblastoid cell lines, 
FRDA patient tissues and YG8 and YG22 FXN transgenic mice (Greene et al, 2007; Al-
Mahdawi et al, 2008). In particular, three (CpG sites 3, 6 and 13) out of 15 CpG sites were 
found to be usually unmethylated in healthy cells, but highly methylated in FRDA cells. 
One of these residues is located within an E-box whose deletion caused a significant drop 
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in FXN promoter activity in reporter assays (Greene et al, 2007). Furthermore, Al-
Mahdawi and colleagues showed that the increased level of DNA methylation at CpG site 
12 predominantly comprises 5hmC rather than 5mC (Al-Mahdawi et al, 2013). The degree 
of DNA methylation in the upstream GAA repeat region has been shown to correlate with 
the length of the GAA repeats and inversely correlate with FXN expression levels and age 
of disease onset (Castaldo et al, 2008; Evans-Galea et al, 2012).  
 
Table 3.1 Epigenetic changes in FRDA patient cells, tissue, cellular and mouse models (Yandim et al, 
2013; Sandi et al, 2014a). FRDA results were compared to levels obtained on cells or tissues derived from 
healthy individuals. A relatively high level compared to healthy is marked with ‘↑’, low level with ‘↓’. For 
YG8R and YG22R FXN YAC transgenic mice with expanded GAA repeats, levels were compared to Y47 
transgenic mice containing only have 9 GAA repeats. For HEK293T cells, results obtained from engineered 
560 GAA repeats into a GFP intron were compared to a control construct without GAA repeats. 
Chromatin 
change Location 
FRDA tissue, cell, or 
animalmodel References 
5mC ↑  GAA upstream FRDA patient tissues, primary 
lymphocytes, lymphoblasts, FXN 
YAC transgenic mice 
Greene et al, 2007; Al-Mahdawi et al, 
2008; Evans-Galea et al, 2012. 
5hmC ↑  GAA upstream FRDA patient tissues Al-Mahdawi et al, 2013. 
H3K4me2/3 ↓ FXN promoter/exon 1 Lymphoblasts Punga & Bühler, 2010; Kim et al, 
2011; Kumari et al, 2011. 
GAA upstream  Lymphoblasts Kim et al, 2011; Kumari et al, 2011. 
GAA downstream Lymphoblasts Kim et al, 2011; Kumari et al, 2011. 
H3K9me2/3 ↑ FXN 5’ UTR/promoter  Primary fibroblast, lymphoblasts De Biase et al, 2009; Kim et al, 2011. 
GAA upstream Lymphoblasts, FXN YAC 
transgenic mice, KIKI mice 
Herman et al, 2006; Al-Mahdawi et 
al, 2008; Rai et al, 2008; Punga & 
Bühler, 2010; Kim et al, 2011; 
Kumari et al, 2011; Chan et al, 2013. 
GAA downstream FRDA patient tissues, FXN YAC 
transgenic mice, lymphoblasts 
Herman et al, 2006; Al-Mahdawi et 
al, 2008; Punga & Bühler, 2010; Kim 
et al, 2011; Kumari et al, 2011; Chan 
et al, 2013. 
H3K27me3 ↑ FXN 5’ UTR/promoter  Primary fibroblasts, lymphoblasts De Biase et al, 2009; Kim et al, 2011. 
GAA upstream Lymphoblasts Kim et al, 2011; Chan et al, 2013. 
GAA downstream Lymphoblasts De Biase et al, 2009; Kim et al, 2011. 
H3K36me3 ↓ GAA upstream Lymphoblasts Punga & Bühler, 2010; Kim et al, 
2011; Kumari et al, 2011. 
GAA downstream Lymphoblasts Punga & Bühler, 2010; Kim et al, 
2011; Kumari et al, 2011. 
H3K79me2 ↓ GAA upstream Lymphoblasts Kim et al, 2011. 
GAA downstream Lymphoblasts Kim et al, 2011. 
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H4K20me3 ↑ GAA upstream Lymphoblasts Kim et al, 2011. 
GAA downstream Lymphoblasts Kim et al, 2011. 
H3K9ac ↓ FXN promoter FRDA patient brain tissue, 
lymphoblasts 
Al-Mahdawi et al, 2008; Kumari et 
al, 2011. 
GAA upstream FRDA patient tissues, 
lymphoblasts, HEK GFP-GAA560, 
FXN YAC transgenic mice, KIKI 
mice 
Herman et al, 2006; Al-Mahdawi et 
al, 2008; Soragni et al, 2008; Kumari 
et al, 2011. 
GAA downstream FRDA patient tissues, 
lymphoblasts, HEK GFP-GAA560, 
FXN YAC transgenic mice 
Herman et al, 2006; Al-Mahdawi et 
al, 2008; Soragni et al, 2008; Kumari 
et al, 2011. 
H3K14ac ↓ FXN promoter FRDA patient tissues Al-Mahdawi et al, 2008. 
GAA upstream Lymphoblasts, HEK GFP-GAA560, 
KIKI mice 
Rai et al, 2008; Soragni et al, 2008; 
Kumari et al, 2011. 
GAA downstream Lymphoblasts, HEK GFP-GAA560 Soragni et al, 2008; Kumari et al, 
2011. 
H4K5ac ↓ FXN promoter Lymphoblasts Kumari et al, 2011. 
GAA upstream Lymphoblasts, HEK GFP-GAA560, 
KIKI mice 
Herman et al, 2006; Rai et al, 2008; 
Soragni et al, 2008; Kumari et al, 
2011. 
GAA downstream FRDA patient tissues, HEK GFP-
GAA560, FXN YAC transgenic 
mice, lymphocytes 
Herman et al, 2006; Rai et al, 2008; 
Soragni et al, 2008; Kumari et al, 
2011. 
H4K8ac ↓ GAA upstream Lymphoblasts, FRDA patient 
tissues, HEK GFP-GAA560, KIKI 
mice 
Herman et al, 2006; Al-Mahdawi et 
al, 2008; Rai et al, 2008; Soragni et 
al, 2008; Kumari et al, 2011. 
GAA downstream Lymphoblasts, FRDA patient 
tissues, HEK GFP-GAA560 
Herman et al, 2006; Soragni et al, 
2008; Kumari et al, 2011. 
H4K12ac ↓ FXN promoter Lymphoblasts Herman et al, 2006. 
GAA upstream Lymphoblasts, FRDA patient 
tissues, FXN YAC transgenic mice 
Herman et al, 2006; Al-Mahdawi et 
al, 2008. 
GAA downstream Lymphoblasts, FRDA patient 
tissues, FXN YAC transgenic mice 
Herman et al, 2006; Al-Mahdawi et 
al, 2008. 
H4K16ac ↓ FXN promoter Lymphoblasts Rai et al, 2008; Kumari et al, 2011. 
GAA upstream Lymphoblasts, FRDA patient 
tissues, FXN YAC transgenic mice, 
KIKI mice 
Herman et al, 2006; Al-Mahdawi et 
al, 2008; Rai et al, 2008; Kumari et 
al, 2011. 
GAA downstream Lymphoblasts, FRDA patient 
tissues, FXN YAC transgenic mice, 
KIKI mice 
Herman et al, 2006; Al-Mahdawi et 
al, 2008; Rai et al, 2008; Kumari et 
al, 2011. 
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Hypoacetylation of several lysine residues of histones H3 and H4 (e.g. H3K14ac, 
H4K5ac, H4K12ac) and di- and trimethylation of H3K9 were first identified at the regions 
flanking the GAA repeat expansion in FRDA patient-derived lymphoblastoid cells 
(Herman et al, 2006). These epigenetic markers, usually associated with silenced 
heterochromatin, have since been confirmed in various models, including patient 
lymphoblast and fibroblast cell lines, iPSCs derived from FRDA patient cells, iPSC-
derived neurons, patient autopsy tissues, YG8 and YG22 FXN YAC transgenic mice, KIKI 
mice and cellular models containing integrated transgenes with long GAA repeats (Greene 
et al, 2007; Al-Mahdawi et al, 2008; Rai et al, 2008; Soragni et al, 2008; De Biase et al, 
2009; Ku et al, 2010; Punga & Bühler, 2010; Kim et al, 2011; Kumari et al, 2011; Sandi et 
al, 2011; Chan et al, 2013). Whether GAA-mediated heterochromatin is also present at the 
FXN promotor is still a matter of debate, but a few studies indicate that the FXN promoter 
region of FRDA patient cells show reduced levels of certain marks of active chromatin, as 
well as reduced occupancy of CTCF and increased levels of FAST1 at the 5’ UTR (De 
Biase et al, 2009; Kumari et al, 2011). Increased expression of FAST1 in FRDA mouse 
fibroblasts (Sandi et al, 2014b) and reduced CTCF binding at the 5’ UTR region of the 
FXN gene in FRDA cerebellum tissue (Al-Mahdawi et al, 2013) have also been reported. 
Given the GAA-mediated heterochromatin at expanded FXN loci, HDAC inhibitors 
emerged as potential candidates to prevent deacetylation of histones, and thus restore 
euchromatin and increase FXN transcription. A first screening of commercially available 
HDAC inhibitors was performed on healthy and FRDA patient-derived lymphoblastoid 
cells, identifying compound 4b which was able to increase both FXN mRNA and protein 
levels in patient cells (Herman et al, 2006). Subsequently, three derivatives (compounds 
106, 136 and 109) were tested on KIKI mice (Rai et al, 2010), FXN YAC transgenic mice 
(Sandi et al, 2011) and neuronal cells derived from FRDA iPSCs (Soragni et al, 2014). 
Compound 109 yielded the most promising results. Similarly, the sirtuin protein 
deacetylase inhibitor nicotinamide (vitamin B3) also increased FXN mRNA levels in 
FRDA cells and FXN YAC transgenic mice (Chan et al, 2013). 
Cellular models used for high-throughput screening of compounds capable of FXN 
upregulation usually contain engineered reporter FXN constructs. A stable cell line 
containing a partial sequence of FXN intron 1 with 145 GAA repeats fused to a GFP 
reporter was used for screening of compounds that could increase transcription through the 
GAA repeat region (Grant et al, 2006). Another cell line containing a GFP reporter 
minigene with 560 GAA repeats inserted in an intron recapitulated the molecular hallmarks 
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of the expanded FXN locus, such as reduced mRNA and protein levels, patterns of 
chromatin modifications around the repeats, and repeat instability (Soragni et al, 2008). 
HDAC inhibitors were able to increase expression of the reporter gene. Additionally, a 
stable human cell line containing a FXN-EGFP fusion construct with the entire normal 
human FXN gene in a BAC clone was generated to screen a chemical library of FDA-
approved compounds and natural extracts (Li et al, 2013).  
 
3.1.4 Aims of this Chapter 
Expanded GAA repeats lead to heterochromatin-mediated dysfunction of the FXN 
gene. In order to better understand the underlying pathogenesis and ultimately to design 
effective therapies for FRDA, it is important to generate cellular models that recapitulate 
the repressive hallmarks of the disease while providing efficient ways to quantify FXN 
expression. Here, I describe the characterisation and epigenetic analysis of the first model 
that allows a direct comparison of the effect of normal or expanded GAA repeats on FXN 
expression within the genomic context of the FXN locus. 
 
3.2 Results 
I performed all experiments and analysed the results featured in this section, unless stated 
that an experiment had been previously perfomed in the laboratory. 
 
3.2.1 Characterisation of the FXN-Luc and FXN-GAA-Luc cell lines 
The FXN-GAA-Luc and FXN-Luc human cell lines were previously generated in the 
laboratory to allow a direct comparison of the effect of normal and expanded GAA repeats 
on FXN gene expression. These lines contain BAC vectors carrying the 80 kb FXN locus, 
which had been previously modified by homologous recombination to insert either a ~310 
GAA repeats expansion (pBAC-FXN-GAA-Luc) or 6 GAA repeats (pBAC-FXN- Luc), 
with an insertion of a Luciferase gene in exon 5a, respectively (Fig. 3.1A). Because the 
native FXN promoter and all introns and regulatory sequences required for FXN expression 
are present in the each vector, physiologically relevant FXN expression levels can be 
achieved (Gomez-Sebastian et al, 2007). FISH analysis has previously revealed that each 
cell line possesses the vector integrated at the same location on chromosome 1p. 
I assessed vector copy number in FXN-Luc and FXN-GAA-Luc cells by real-time 
PCR, using as reference the HEK FRT acceptor cell line (Fig. 3.1B), which carries three 
endogenous FXN loci previously detected by FISH. These stable cell lines carried a single 
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copy of each vector in the same integration site located on chromosome 1p (Fig. 3.1B and 
C). Confirmation of the size and purity of the GAA repeat expansion was achieved by 
PCR, MboII digestion and sequencing (Fig. 3.1D-F). Sequencing was performed from both 
sides of the GAA expansion. I confirmed the presence of 213 GAA repeats on the GAA 
strand and 125 GAA repeats on the TTC strand, thereby achieving an overlap of at least 28 
GAA repeats and ensuring that the whole GAA expansion was sequenced. No interruptions 
were found in the expanded GAA sequence. To further confirm its purity, I performed a 
MboII digestion of the PCR product containing the GAA repeats, according to a previously 
described method (Fig. 3.1E) (Holloway et al, 2011). MboII recognises and cleaves a 
GAAGA sequence. Complete digestion confirmed the purity of the GAA expansion in the 
FXN-GAA-Luc cell line. 
Expansion of GAA repeats causes intergenerational and age-related somatic 
instability in FRDA patients cells and tissues (De Biase et al, 2007a, 2007b) and also in 
mice tissues (Al-Mahdawi et al, 2004; Clark et al, 2007). FXN-GAA-Luc cells were 
continuously sub-cultured for 3 months to analyse the degree of the GAA repeat-length 
variation over time. Instability of the GAA repeat expansion was assessed by PCR (Fig. 
3.1G) and small-pool PCR (Fig. 3.1H). PCR analysis of the GAA repeat sequence in the 
FXN-GAA-Luc cell line did not show any difference in size between time points (Fig. 
3.1G). I next performed a small-pool PCR analysis to detect uncommon GAA repeat 
expansion variants that could be present only in a small proportion of cells. However, this 
too confirmed GAA repeat stability in FXN-GAA-Luc cells (Fig. 3.1H). Taken together, 
these data suggest that the GAA repeat expansion in the FXN-GAA-Luc transgene is stable.  
The ~310 GAA repeat expansion in FXN-GAA-Luc cells was previously shown to 
reduce FXN-Luc mRNA levels by 37% and protein levels by 42%, indicating that the GAA 
repeat expansion induces FXN repression as seen in FRDA. 
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Figure 3.1 Characterisation of the FXN-GAA-Luc and FXN-Luc cell lines. (A) Schematic representation 
of the pBAC-FXN-MS2-Luc and pBAC-FXN-GAA-MS2-Luc vectors. Each vector carries either six or ~310 
GAA repeats in intron 1, respectively, and a luciferase sequence preceded by a GSGSG peptide linker in 
exon 5a, immediately before the stop codon. Expression results in a FXN-luciferase fusion protein. (B) 
Single-copy clones were determined by real-time PCR using UpGAA primers normalised by GAPDH. Data 
were relative to HEK FRT, which contains three endogenous copies. Data are mean ± SEM (n = 3). (C) Site-
specific vector integration in single-copy FXN-MS2-Luc and FXN-GAA-MS2-Luc clones was confirmed by 
PCR using primers targeting the PSV40 promoter and the hygromycin cassette. (D) Insertion and sizing of 
GAA repeats was determined by PCR analysis. (E) The purity of the GAA repeat expansion was analysed by 
MboII digestion after PCR amplification of the repeats. The resulting fragments of 208 bp and 248 bp 
contained only the regions flanking the GAA repeats, indicating the GAA repeat sequence was not 
interrupted. (F) The ~310 GAA repeats were sequenced for sizing and purity analysis. A section of the 
sequencing data is shown. (G-H) GAA repeat instability in FXN-GAA-Luc cells after continuous sub-culture 
for 3 months. (G) Analysis by PCR did not show any repeat instability. (H) For small-pool PCR, eight 
independent reactions were set up from a starting DNA concentration of 150 pg. The ~310 GAA repeats were 
stable in FXN-GAA-Luc cells. NTC, no template control. 
90 
 
3.2.2 Epigenetic characterisation of FXN-Luc and FXN-GAA-Luc cell lines 
Expanded GAA repeats can induce FXN silencing via a heterochromatin-mediated 
mechanism of repression (Saveliev et al, 2003; Herman et al, 2006; Chan et al, 2013). 
Epigenetic changes around expanded GAA repeats have been identified, which include 
increased DNA methylation at specific CpG sites upstream of the GAA repeats (Greene et 
al, 2007; Al-Mahdawi et al, 2008; Castaldo et al, 2008; Evans-Galea et al, 2012) and 
reduced acetylation of histones H3 and H4 accompanied by increased levels of methylated 
histones H3K9me2 and H3K9me3 in regions flanking GAA repeats (Herman et al, 2006; 
Al-Mahdawi et al, 2008; Kim et al, 2011; Kumari et al, 2011). The FXN promoter in 
patient-derived cells and tissues shows a less permissive configuration for transcription 
initiation when compared with healthy cells (Al-Mahdawi et al, 2008; Kumari et al, 2011; 
Chutake et al, 2014; Groh et al, 2014).  
I optimised the ChIP technique (Fig. 3.2) to test for the presence of repressive 
epigenetic hallmarks at the FXN-GAA-Luc transgene. Key steps included (i) determination 
of appropriate crosslinking time, (ii) adjustment of sonication time to yield sheared 
chromatin fragments with sizes ranging from 200-800 bp, (iii) using antibodies that bind 
their target with high affinity, and (iv) quantification of purified DNA by real-time PCR 
(Carey et al, 2009). 
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Figure 3.2 Workflow of Chromatin Immunoprecipitation (ChIP). ChIP is used to study interactions 
between specific proteins or modified forms of proteins and a genomic DNA region, such as the presence of 
histones with post-translational modifications at specific genomic locations. Formaldehyde crosslinks 
proteins to DNA. Nuclei are isolated and crosslinked chromatin is then sonicated to generate smaller DNA 
fragments. Immunoprecipitation (IP) with the desired antibodies is performed. The precipitated protein-DNA 
is then purified, treated with a protease, and analysed real-time PCR. 
 
Proteins were crosslinked to chromatin to analyse histone modifications at three FXN 
regions, namely the promoter and the regions upstream and downstream of GAA repeat 
expansion. The best sonication conditions yielded fragments with sizes 200-800 bp and 
were obtained after treating 5x106 FXN-GAA-Luc cells (10x dilution) with 1% 
formaldehyde for 7 minutes and performing 24 cycles of sonication (Fig. 3.3A). 
Immunoprecipitation of histones bound to DNA was performed using antibodies specific 
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for the human acetylated histones H3K9 and H4K8 and di- and trimethylated histone 
H3K9. Crosslinking was then reversed and DNA was quantified by real-time PCR. This 
analysis revealed a decrease in histone acetylation and an increase in histone methylation 
across the three regions in the FXN-GAA-Luc cell line when compared with FXN-Luc cells 
(Fig. 3.3B), as previously reported in FRDA patient brain tissue and patient-derived cell 
lines (Herman et al, 2006; Al-Mahdawi et al, 2008; Kim et al, 2011; Kumari et al, 2011).  
I then analysed CpG methylation by bisulphite sequencing as reported in previous 
studies (Al-Mahdawi et al, 2008). Genomic DNA from FXN-GAA-Luc and FXN-Luc cells 
was bisulphite-treated to deaminate unmethylated cytosines in order to produce uracils in 
DNA. In this process, methylated cytosines are protected from the conversion to uracils. 
The FXN promoter and regions flanking the GAA repeats were amplified by PCR using 
bisulphite-specific primers and then sequenced to determine the locations of unmethylated 
cytosines and 5-methylcytosines at single-nucleotide resolution (Fig. 3.4A). The FXN 
promoter region did not present any of the 59 CpG sites methylated in either cell line. In 
line with these results, Greene et al (2007) also reported a lack of any DNA methylation in 
the promoter region of either healthy or FRDA patient-derived cells. However, depending 
on the type of samples analysed, the promoter has shown (i) incomplete methylation at 
specific CpG sites in the heart tissue of healthy controls, but complete methylation of those 
CpG sites in FRDA (Al-Mahdawi et al, 2008), and also (ii) no observed significant 
difference between healthy and FRDA clinical samples in the promoter region with CpG 
sites being largely unmethylated (Evans-Galea et al, 2012). In the region upstream of the 
expanded GAA repeats, I found increased DNA methylation at CpG sites 4 and 5 (Fig. 
3.4B), in agreement with previously published methylation data from FRDA patients (Al-
Mahdawi et al, 2008; Evans-Galea et al, 2012). Data for CpG 6 differ from the results 
previously found in patients (Al-Mahdawi et al, 2008; Greene et al, 2007), but are in 
agreement with methylation data from the brain of FRDA mice (Al-Mahdawi et al, 2008). 
In the region downstream of the GAA repeats, an increase in DNA methylation was 
observed at CpG sites 1, 2 and 7 (Fig. 3.4B).  
Overall, since the FXN-Luc and FXN-GAA-Luc cell lines share the same integration 
site and only differ by the presence of an expansion of ~310 GAA repeats, these data 
suggest that the GAA expansion is causing the observed changes in histone 
acetylation/methylation and DNA methylation and inducing a closed chromatin 
configuration which may be linked to FXN-GAA-Luc repression. 
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Figure 3.3 Histone modifications on the FXN locus. (A) Optimization of chromatin shearing was 
performed in FXN-GAA-Luc cells. Serial dilutions were made starting with 50x106 cells and diluting 10x and 
20x. Twelve and 24 cycles of sonication of 30 seconds “ON” and 30 seconds “OFF” were performed after 
crosslinking proteins to the DNA for 5, 7 and 10 minutes. Crosslinking was reversed overnight. (B) 
Schematic representation showing the location of primers used for DNA quantification by real-time PCR 
(top). ChIP was performed on FXN-Luc and FXN-GAA-Luc cells using antibodies specific for the human 
acetylated histones H3K9 and H4K8 (middle) and di- and trimethylated histone H3K9 (bottom). Analysis of 
histone modifications in the promoter and regions flanking GAA repeats showed a decrease in H3K9ac and 
H4K8ac levels and an increase in H3K9me2 and H3K9me3 levels in FXN-GAA-Luc cells. Data are mean ± 
SEM from two independent IPs and each IP was quantified in triplicate. *P < 0.05, **P < 0.01, ***P < 
0.001, as determined by unpaired two-tailed Student’s t-test. 
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Figure 3.4 DNA methylation analysis of the FXN locus. (A) Schematic representation showing the 
location of the bisulphite-specific primers used in this analysis (top). Genomic DNA of the FXN-Luc and 
FXN-GAA-Luc cell lines was bisulphite-converted and the promoter and regions flanking the GAA repeats 
were amplified by nested-PCR (middle). PCR products were cloned and a total of 10 colonies were 
sequenced per region and for each cell line. A section of the sequencing data is shown (bottom). CpG sites 
are identified in red boxes. (B) The promoter region did not show any CpG methylation in either cell line. 
FXN-GAA-Luc cells showed an increased in DNA methylation at CpG sites 4 and 5 upstream of the GAA 
expansion and at CpG sites 1, 2 and 7 downstream of GAA repeats.  
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3.2.3 C5 restores histone acetylation levels around the GAA repeat expansion 
Treatment with the HDAC inhibitors nicotinamide and 2-aminobenzamide 
compounds 106, 136, and 109 have been previously shown to upregulate FXN expression 
in FRDA patient cells (Xu et al, 2009; Chan et al, 2013) and mouse models (Rai et al, 
2010; Sandi et al, 2011). The FXN-Luc and FXN-GAA-Luc cell lines allow the rapid 
quantification of FXN expression and are a useful tool for the identification of compounds 
able to increase frataxin protein levels. The GAA-expanded reporter model was used in the 
laboratory to screen a library of novel small molecules with potential HDAC inhibitor 
function and led to the identification of one molecule (C5) which upregulates FXN 
expression in FRDA patient primary cells. 
To assess whether C5 acts as an HDAC inhibitor on the FXN gene and is able to 
reverse the GAA-mediated FXN silencing, I incubated FRDA patient-derived 
lymphoblastoid cells with C5 at 20 mM for 48 h and analysed histone acetylation at the 
FXN gene by ChIP (Fig. 3.5). The best sonication conditions yielded fragments with sizes 
200-800 bp and were obtained after treating 2.5x106 cells (20x dilution) with 1% 
formaldehyde for 4 minutes and performing 24 cycles of sonication (Fig. 3.5A). Analysis 
of H3K9 and H4K8 acetylation was performed at the FXN promoter and regions upstream 
and downstream of GAA repeats (Fig. 3.5B). Patient-derived cells showed a reduction in 
histone acetylation at the regions flanking the GAA expanded repeats when compared with 
healthy cells, in line with previous reports (Herman et al, 2006; Kim et al, 2011; Kumari et 
al, 2011), but not in the FXN promoter. However, reduced levels of some marks of active 
chromatin at the FXN promoter, but not others, have been reported previously (Kim et al, 
2011; Kumari et al, 2011). When FRDA patient cells were incubated with C5, the FRDA 
histone acetylation was restored to healthy levels in the upstream and downstream regions 
of the GAA repeats, suggesting that C5 acts either directly or indirectly in inhibiting 
HDAC activity. Taken together, these data suggest C5 upregulates FXN expression by 
restoring normal histone acetylation around the GAA repeats. 
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Figure 3.5 Effect of C5 on a FRDA patient-derived cell line. (A) Optimisation of chromatin shearing was 
performed using GM15850 cells. Serial dilutions were made starting with 50x106 cells and diluting as 
follows: 1x, 5x, 10x, 20x, 50x and 100x. Twelve and 24 cycles of sonication of 30 seconds “ON” and 30 
seconds “OFF” were performed for each cell line after crosslinking proteins to the DNA for 4 minutes. 
Crosslinking was reversed overnight. (B) Schematic representation showing the location of primers used for 
DNA quantification by real-time PCR (top). C5 increases H3K9 and H4K8 histone acetylation in FRDA 
lymphoblastoid cells (GM15850) to normal levels observed in healthy cells (GM15851) in the regions 
flanking the GAA repeats. Cells were incubated with C5 at 20 mM for 48 hours and ChIP was performed 
using antibodies specific for H3K9ac and H4K8ac. Data are mean ± SEM from three independent IPs and 
each IP was quantified in triplicate. 
 
3.3 Discussion 
Expanded GAA repeats lead to FXN mRNA deficiency and subsequent reduced 
levels of frataxin protein in FRDA. To understand the underlying pathogenesis and 
ultimately to design effective therapies for FRDA, it is important to generate cellular 
models that recapitulate the repressive hallmarks of the disease. All existing cell models 
present advantages and disadvantages (reviewed in Perdomini et al, 2013). As human 
primary neurons and cardiomyocytes cannot be obtained, the most relevant available cells 
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for studying the pathological mechanisms in FRDA are patient-derived fibroblasts and 
lymphocytes. These cells contain two FXN alleles with the entire genomic locus carrying 
expanded GAA repeats in their native chromatin environment. Although the mutation 
reduces FXN expression in these cells, expanded GAA repeats are relatively stable 
(Sharma et al, 2002) and the pathological biochemical phenotype is absent (Sturm et al, 
2005). FRDA patient skin fibroblasts have been reprogrammed into iPSCs (Ku et al, 2010; 
Liu et al, 2011; Hick et al, 2013), which have been differentiated into neurons and 
cardiomyocytes (Liu et al, 2011; Hick et al, 2013). These iPSCs exhibit GAA repeat 
instability and reduced levels of FXN mRNA and protein, but do not show biochemical 
defects (Hick et al, 2013). Differentiated neurons and cardiomyocytes present 
mitochondrial dysfunction (Hick et al, 2013). However, differentiation protocols are not 
efficient and yield a mixed population of cells. 
The FXN-Luc and FXN-GAA-Luc reporter cell lines are the first models that allow a 
direct comparison of the effect of normal or expanded GAA repeats on FXN expression 
within the genomic context of the FXN locus. A few reporter cell models carrying 
expanded GAA repeats have been described previously. However, these models only carry 
expanded GAA repeats within a GFP reporter gene lacking any FXN gene sequence 
(Soragni et al, 2008; Ditch et al, 2009) or only contain a small portion of intron 1 (Grant et 
al, 2006). The FXN-GAA-Luc and FXN-Luc cell lines carry the whole FXN locus with its 
native promoter, introns, exons and all elements required for physiological transgene 
expression. Furthermore, the cell model was generated by site-specific recombination to 
promote the integration of a single copy of pBAC-FXN-Luc or pBAC-FXN-GAA-Luc into 
a specific FRT (Flp recombinase target) site in chromosome 1 of HEK FRT cells, 
generating highly comparable cell lines only differing in the number of GAA repeats. A 
previous FXN genomic reporter system has been described previously; however, this 
system does not contain expanded GAA repeats (Sarsero et al, 2003; Li et al, 2013). 
RNA/DNA hybrids (R-loops) have been previously shown to form on the FXN-GAA-
Luc transgene (Groh et al, 2014). R-loops impair RNAPII elongation and trigger epigenetic 
changes, such as H3K9me2 repressive marks through recruitment of G9a 
methyltransferase (Groh et al, 2014). 
Similar to other cellular models, the FXN-GAA-Luc reporter model exhibits 
limitations. Due to the difficulty in engineering large GAA repeat expansions, the FXN-
GAA-Luc cells contains only an expansion of ~310 GAA repeats, which does not cause a 
severe phenotype as seen in FRDA patient cells. Nevertheless, ~310 GAA repeats cause 
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FRDA with a late age of onset at ~30 years old (Bidichandani et al, 2000). Because the 
endogenous FXN gene is present in the FXN-GAA-Luc cell line, the FRDA biochemical 
defects cannot be analysed. Moreover, this cell model does not show time-depended GAA 
repeat instability. However, in this regard, it would be interesting to assess the expression 
levels of the MMR proteins MSH2, MSH3, MSH6 or PMS2 and analyse their effect in 
inducing GAA expansions or contractions in these cells, like in other cell models (Ku et al, 
2010; Du et al, 2012) and mouse models (Ezzatizadeh et al, 2012; Bourn et al, 2012). 
The presence of ~310 GAA repeats reduces FXN-GAA-Luc mRNA and protein levels 
via a heterochromatin-mediated silencing mechanism. I show that the GAA repeat 
expansion decreases histone acetylation and increases histone methylation at the FXN 
promoter and regions upstream and downstream of the GAA repeats, in accordance with 
previous reports (Herman et al, 2006; Al-Mahdawi et al, 2008; Kim et al, 2011; Kumari et 
al, 2011). Furthermore, FXN-GAA-Luc cells show increased CpG methylation upstream 
and downstream of the GAA repeat expansion when compared with FXN-Luc cells. 
Upstream of the GAA repeats, I observe increased DNA methylation at CpG sites 4 and 5, 
in accordance with previous data obtained using post-mortem brain and heart tissues from 
FRDA patients (Al-Mahdawi et al, 2008) and peripheral blood and buccal cells from 
FRDA patients (Evans-Galea et al, 2012). The results for CpG site 6 are different from 
methylation data from FRDA patients (Al-Mahdawi et al, 2008; Greene et al, 2007), but 
are in agreement with data from brain tissue of FRDA mice (Al-Mahdawi et al, 2008). In 
the region downstream of the GAA repeats, I observed increased methylation at CpG sites 
1, 2 and 7, whereas the rest of the CpG sites were completely methylated. Unlike these 
findings, analysis of DNA methylation in cells (Evans-Galea et al, 2012) and tissues (Al-
Mahdawi et al, 2008) from FRDA patients reported a general hypomethylation in this 
region. A methylation pattern similar to the findings in FXN-GAA-Luc has been reported 
inYG8 mice, which do not present hypomethylation downstream of GAA repeats (Al-
Mahdawi et al, 2008). Since the results shown here are different from data obtained from 
FRDA patients (Evans-Galea et al, 2012), who carry large GAA expansions (618.1 ± 
230.7), but are similar to the findings in YG8 mice which carry shorter GAA repeats (190 
+ 90 GAA repeats), it is tempting to speculate that this variation in CpG methylation could 
be related to the size of the GAA expansion. To explain how shorter repeat expansions 
cause changes in DNA methylation, Al-Mahdawi and colleagues suggested that large GAA 
expansions increase the distance of the downstream region from a putative methylation 
centre at the 5′ end of the Alu sequence, located upstream of GAA repeats, thus generating 
99 
 
hypomethylation of the region downstream of GAA repeats when compared with healthy 
individuals. However, a shorter GAA expansion would decrease such distance, thereby 
leading to hypermethylation downstream of GAA repeats (Al-Mahdawi et al, 2008). 
Recently, HDAC inhibitors have been tested as a potential therapy for FRDA. These 
compounds successfully increased FXN expression in FRDA lymphoblastoid cells and 
primary lymphocytes, KIKI mice and YG8R mice (Herman et al, 2006; Rai et al, 2008, 
2010; Sandi et al, 2011; Chan et al, 2013). The FXN-Luc and FXN-GAA-Luc cell lines 
allow the rapid quantification of FXN transgene expression and are a useful tool for the 
identification of compounds able to increase frataxin protein levels. C5 was identified in 
the laboratory using this cell model. Subsequently, this compound was shown to upregulate 
FXN expression in FRDA patient primary cells by remodelling the chromatin configuration 
around the GAA repeats. 
Data presented in this Chapter demonstrates that genomic reporter models of FRDA 
recapitulate the GAA repeat-mediated FXN repression and the epigenetic hallmarks of 
FRDA. Therefore, these models are an excellent tool to study the molecular mechanisms 
underlying FRDA as well as providing a platform for the screening of FXN upregulating 
compounds. 
 
  
 
 
 
 
 
 
 
CHAPTER 4 
Visualisation of the effect of a GAA repeat 
expansion on FXN gene nuclear localisation and 
expression at single-cell resolution 
 
 
 
  
The results featured in this Chapter were published in the paper (Annex 2): 
 
Silva AM, Brown JM, Buckle VJ, Wade-Martins R and Lufino MM (2015) Expanded 
GAA Repeats Impair FXN Gene Expression and Reposition the FXN Locus to the Nuclear 
Lamina in Single Cells. Hum. Mol. Genet. 24(12):3457-71. 
 
Author contributions: 
A.M.S, J.M.B., V.J.B., R.W.-M. and M.M.L. conceived and designed the experiments; 
A.M.S performed the experiments and analysed the data; A.M.S wrote the manuscript; 
A.M.S, J.M.B., V.J.B., R.W.-M. and M.M.L. revised the manuscript. 
 
 
102 
 
4.1 Introduction 
Gene expression is dependent on the spatial and structural organisation of genes 
inside the nucleus and a wide range of proteins involved in transcriptional regulation. 
Standard methods to study gene expression – such as northern blotting, qRT-PCR and 
microarrays – rely on the detection of transcripts from samples containing millions of cells. 
These steady-state population-level measurements are useful if a considerable proportion 
of the cell population is actively expressing. However, if the sample is small and/or the 
target is present in low copies not reaching a detectable threshold, changes in expression 
levels can go unnoticed. Single-cell analyses in various systems have revealed a 
considerable cell-to-cell variation in gene expression, and this heterogeneity can be 
attributed to the stochastic nature of transcription (Levsky & Singer, 2003; Coulon et al, 
2013). Given that averaged gene expression levels in cell populations do not reflect the 
behaviour of individual cells, methods that can detect and quantify mRNA molecules in 
single cells are needed. In this introduction, I will highly the experimental advantages of 
studying transcriptional kinetics at the single-cell level. 
 
4.1.1 In situ hybridisation (ISH) 
ISH commonly uses nucleic acid probes that are complementary to target RNA 
sequences to reveal the intracellular location of mRNAs in fixed cells (reviewed in Weil et 
al, 2010). Improvements due to technical advances typically revolve around the type of 
probe and labelling used to detect the signal. Initially, radiolabelled cDNA probes 
complementary to the appropriate target were used (Harrison et al, 1973). Although 
quantitative, detection offered low spatial resolution and the technique was laborious and 
time-consuming. Later, it became conventional to use probes containing modified bases 
that allowed the conjugation of various haptens or fluorophores. Detection could be 
performed indirectly through enzymes that catalyse chromogenic or fluorogenic reactions 
or directly by fluorescent microscopy (Raap et al, 1995). Indirect detection is highly 
sensitive due to signal amplification but the location of signal is not precisely determined. 
In contrast, probes labelled directly with a few fluorophores maintain spatial resolution, but 
sensitivity is relatively poor. High sensitivity is of paramount importance because the 
majority of mRNAs are often present at less than ten copies per cell (Lockhart & Winzeler, 
2000). 
Improvements in RNA FISH methodology were made to increase sensitivity and to 
allow the detection of single mRNAs (Femino, 1998). In this method, five 50-mers 
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oligonucleotide probes labelled with 5 fluorochromes per molecule are hybridised to each 
mRNA target and are easily visible as a fluorescent spot via fluorescence microscopy. The 
authors were able to determine the rates of transcription initiation and termination and 
RNA processing by targeting the probes to the β-actin mRNA. However, these probes are 
prone to hybridisation variability and self-quenching due to the presence of multiple 
fluorophores in the same oligonucleotide. 
To overcome these issues, Raj and colleagues targeted mRNA molecules with 48 
different oligonucleotides singly labelled with Alexa 594 flurophores. This method 
generates uniform signals that can be computationally identified to determine accurate 
mRNA counts, allowing simultaneous detection of single molecules of multiple mRNAs in 
single cells (Raj et al, 2008). 
 
4.1.2 mRNA imaging in living cells  
Important data regarding transcription and mRNA localisation have been harnessed 
from RNA FISH experiments in fixed cells. However, they show static snapshots of 
dynamic processes that may only be occurring in a subset of cells. Visualising specific 
mRNAs in living cells requires techniques to fluorescently tag mRNAs to monitor their 
dynamics over time. 
RNA FISH can also be used in living cells, but it has its limitations (review in 
Sheinberger & Shav-Tal, 2013). Cells can tag short single stranded DNA oligonucleotides 
in the nucleus for rapid degradation, and the inability to properly wash away unbound 
probe leads to high background. Improvements have been made by designing degradation-
resistant molecular beacons consisting of short oligonucleotide probes with a fluorophore 
and a quencher on opposite ends. They are delivered to cells in a quenched fluorescent 
state and only fluoresce when specifically hybridised to their mRNA target (Vargas et al, 
2005). This reduces background and allows single-molecule resolution. Limitations 
include (i) probe delivery via microinjection, electroporation or streptolysin O 
permeabilisation, which can be challenging to living cells; (ii) inefficient probe 
hybridisation due to RNA-protein binding or to secondary RNA structures; and (iii) the 
need for multiple binding sites to generate a detectable signal.  
A substantial advance in mRNA imaging was achieved using the MS2 system which 
allows the direct fluorescent tagging of mRNAs due to the specific interaction between the 
bacteriophage MS2 coat protein (MCP) and a unique RNA hairpin sequence (MS2-binding 
site (MBS)) (Bertrand et al, 1998). When the MBS is transcribed, it forms stem-loops that 
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are bound by dimers of MCP (Fig. 4.1). Inserting the MBS in tandem and co-expressing 
the MCP fused to a fluorescent protein (MCP-FP) enables time-lapse imaging of 
transcription and mRNA kinetics in living cells. This method also has its limitations: (i) the 
number of loops inserted into an mRNA needs to be carefully considered as to not increase 
the size of the RNA substantially, but still result in signal amplification; (ii) it identifies 
only mRNA molecules that contain the MBS originated from exogenous gene constructs; 
(iii) the right location for the MBS insertion is subjective; and (iv) the expression levels of 
the MCP-FP have to be adjusted to achieve a good signal-to-noise ratio and avoid 
aggregates in cells expressing the MCP-FP without the target RNA (Yunger et al, 2013). 
 
Figure 4.1 The MS2 system allows real-time imaging of RNA synthesis at a single-cell level. In this 
system, when a gene carrying the DNA sequence derived from the bacteriophage MS2 (MBS) is transcribed, 
the MBS folds into stem-loops that are bound with high affinity by the MCP. Co-expression of the MBS-
gene construct with the MCP fused to a fluorescent protein (MCP-YFP) generates a nascent RNA reporter 
system. Sharp fluorescent spots inside the nucleus indicate active transcription sites above the unbound 
MCP-YFP background. 
 
Similar systems exist that use the same principle of coat proteins binding hairpin 
sequences. The U1A mRNA system is limited to non-mammalian cells. It uses the human 
U1A protein, a component of the spliceosomal U1 small nuclear ribonucleoprotein, and a 
specific RNA hairpin (Brodsky & Silver, 2002). Simultaneous imaging of two mRNA 
species is possible by using the binding of the phage PP7 coat protein (PCP) to its RNA 
hairpin (Hocine et al, 2013), or the λ-phage N-protein–boxB system (Lange et al, 2008), in 
parallel with the MS2 system.  
 
4.1.2.1 The MS2 system: improvements and applications 
Several studies have used the MS2 system to study different aspects of mRNA 
dynamics in several models, for example transcription kinetics were examined in 
mammalian cells (Janicki et al, 2004; Darzacq et al, 2007; Yunger et al, 2010; Ben-Ari et 
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al, 2010), E. coli (Golding et al, 2005), Dictyostelium (Chubb et al, 2006; Muramoto et al, 
2012) and yeasts (Zenklusen et al, 2008); the dynamic movement of mRNA-protein 
complexes was monitor in either the nucleoplasm (Shav-Tal et al, 2004) or the cytoplasm 
(Fusco et al, 2003) of mammalian cells; mRNA localisation was analysed in yeasts 
(Bertrand et al, 1998), mice (Lionnet et al, 2011) and Drosophila melanogaster (Zimyanin 
et al, 2008). 
The first studies of transcription in live mammalian cells combined the lacO-lacI and 
the MS2 systems together with fluorescent labelling of the protein product (Janicki et al, 
2004; Darzacq et al, 2007; Ben-Ari et al, 2010). Using this highly sensitive system 
composed of a 200 copy transgene array, the authors were able to correlate changes in 
chromatin structure with the progression of transcriptional activation and protein 
production in single living cells. Photobleaching and photoactivation of MCP-FP bound to 
nascent mRNAs provided sensitive RNAPII elongation measurements. Polymerases 
elongated at 4.3 kb/min and entered a paused state for unexpectedly long times. 
Using models with transgenes in tandem amplifies the mRNA fluorescent signal to 
highly detectable levels. Given the variability in gene expression due to the probability of a 
gene being switched on and off, these models provide only an averaged transcriptional 
output from many copies of the same gene and cannot yield a true picture of the 
endogenous state of single-copy genes. A major concern when imaging single genes that 
are expressing is whether the signal will be detectable in the nucleus of mammalian cells, 
given that the signal-to-noise ratio is much lower compared with using multiple genes. 
Integration of the MBS into specific single-copy genes of Dictyostelium revealed the 
pulsatile nature of transcription, where the frequency, intensity and duration of pulses were 
measured (Chubb et al, 2006). Each gene displayed its own transcriptional signature. 
While developmental genes showed a binary pulsing behaviour controlled at the level of 
transcription initiation, housekeeping genes strongly modulate pulsing strength during 
development allowing integration of global physiological cues reaching the cell 
(Muramoto et al, 2012). 
A cell and a mouse model have been generated to follow and quantify expression of 
single genes in mammalian cells. Yunger and colleagues generated comparable stable 
clonal cell lines containing single copies of either the human cyclin D1 gene driven by its 
promoter or a CMV promoter using HEK-293 cells with a single FRT genomic locus for 
Flp-In homologous recombination (Yunger et al, 2010). The endogenous promoter had 
alternating periods of gene activity as seen in transcriptional bursting, and RNA FISH data 
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confirmed cell-to-cell variability in mammalian cells (Raj et al, 2006). In contrast, the viral 
promoter had higher and constant expression.  
The first mammalian transgenic animal for imaging mRNAs in living tissue was a 
knock-in mouse containing the MBS inserted into the 3ʹ UTR of the β-actin mRNA, 
allowing its imaging in every cell of the animal (Lionnet et al, 2011). The ability to detect 
an active β-actin allele was confirmed by RNA FISH and by MCP-FP labelling. 
Subsequently, a transgenic mouse expressing MCP-GFP was crossed with the β-actin–
MBS mouse, generating mice with an MS2 tag on both β-actin alleles and expressing the 
MCP. This mouse model allowed for the first time the global fluorescent labelling of an 
endogenous mRNA in all cells and tissues of an organism (Park et al, 2014). 
Besides the traditional labelling of single mRNA molecules using the MS2 system, 
improvements and other applications can be performed (Fig. 4.2). By using two systems in 
parallel, for instance MS2 and PP7, two different mRNA species or two regions of the 
same mRNA can be detected (Hocine et al, 2013). To improve signal-to-noise ratio, the 
bimolecular fluorescence complementation system can be used. This system uses coat 
proteins fused to split fluorescent protein that only become fluorescent when bound to the 
mRNA stem-loops (Wu et al, 2014). In addition, the interactions of coat proteins with 
mRNAs can be used to alter their intracellular localisation (Katz et al, 2012), perform 
affinity purification, tethering proteins to the mRNA (Long et al, 2000), and 
simultaneously detect mRNAs and their protein products (Haim-Vilmovsky et al, 2011).  
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Figure 4.2 Traditional and novel uses of MS2-like systems to investigate mRNA biology. (A) Binding of 
MCP-GFP to the MBS allows single-molecule mRNA imaging. (B) Using two different labelling systems, 
two mRNAs (top) or two different parts of the same mRNA are tagged, thereby allowing the imaging of two 
different mRNAs in the same cell or the analysis of RNA dynamics, such as transcription, nuclear export and 
degradation. (C) To reduce background fluorescence, two different labelling systems (MS2 and PP7) can be 
used. Each RNA-binding protein (MCP and PCP) is fused to one half of a split fluorescent protein (YFP). 
Signal is obtained when both MCP and PCP are bound to the mRNA and the YFP becomes functional. (D) 
The tethering of an mRNA to a specific cellular location or structure is carried out by fusing MCP to a 
protein (in this case, vinculin) with specific subcellular localisation. (E) In RNA affinity purification, the 
MCP is fused to a unique epitope — for example, streptavidin-binding protein (SBP) — which mediates the 
affinity purification of the RNA together with protein complexes that might bind to it by using streptavidin 
and biotin beads. (F) A specific protein (for example, the transporter She3) can be tethered to an mRNA 
through the MCP, allowing the analysis of the RNA-protein interaction. (G) Simultaneous localisation of the 
mRNA and its protein product can be achieved by fusing the gene to an mCherry gene and cloning the MBS 
into its 3′ UTR (adapted from Buxbaum et al, 2015). 
 
4.1.3 Aims of this Chapter 
Recent studies show that expanded GAA repeats trigger R-loop formation (Groh et 
al, 2014) and locally recruit HP1 (De Biase et al, 2009), G9a methyltransferase (Groh et 
al, 2014) and HDACs (Herman et al, 2006; Chan et al, 2013), causing epigenetic changes 
that contribute to FXN transcriptional dysregulation. However, these studies only provide 
the probable state of the FXN gene as these observations come from experiments in which 
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the outputs of bulk cell cultures are averaged. A dissection of the silencing mechanism in 
FRDA in situ, in which FXN localisation and expression are quantified at single-cell level, 
is crucial to improve our understanding of the underlying pathogenesis and ultimately to 
design effective therapies for FRDA. 
Here, I developed a novel human cell model to visualise and analyse FXN repression 
in both fixed and living single cells using the MS2 system. I show that GAA-expanded 
repeats decrease the number of FXN mRNA molecules, slow transcription, and increase 
FXN localisation at the NL. 
 
4.2 Results 
 
4.2.1 Construction of pBAC-FXN-MS2-Luc and pBAC-FXN-GAA-MS2-Luc vectors 
by homologous recombination 
The pBAC-FXN-Luc and pBAC-FXN-GAA-Luc genomic DNA reporter vectors – 
previously used in the generation of the FXN-Luc and FXN-GAA-Luc cell lines described 
in Chapter 3 – were modified to develop a cell model that enables real-time visualisation of 
FXN mRNA to investigate the link between FXN localisation and expression at the single-
cell level. These BAC vectors carry the whole 80 kb FXN locus with its native promoter, 
including exons 1 to 5b and all regulatory elements necessary to achieve physiologically-
relevant FXN expression, a luciferase reporter gene in exon 5a and the presence of either 6 
GAA repeats (pBAC-FXN-Luc) or a ~310 GAA repeat expansion (pBAC-FXN-GAA-Luc) 
in intron 1. A two-step selection/counter-selection homologous recombination approach in 
E. coli (Zhang et al, 2000) was used to insert 24 repeats of the MBS into exon 2 in a 
precise and specific manner (Fig. 4.3). This allows fluorescent labelling of the transgenic 
FXN mRNA and quantification of the effect of the expansion on FXN transcription when 
co-expressed with the MCP-YFP fusion protein. Given that the mature human frataxin 
protein is encoded by amino acids 81-210 (Schmucker et al, 2008), the MBS was inserted 
upstream of the cleavage site, allowing the production of a mature frataxin-luciferase 
fusion protein without the MBS. 
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Figure 4.3 Experimental outline for vector construction of pBAC-FXN-GAA-MS2-Luc and pBAC-
FXN-MS2-Luc using a selection/counter-selection homologous recombination approach in E.coli. 
(Step 1 and 4) The E. coli strain, carrying the BAC to be modified, is transformed with pRedET, which 
mediates recombination. pRedET expresses the λ- phage redγβα operon under the control of the arabinose-
inducible pBAD promoter. (Step 2 and 5) pRedET is induced by addition of L-arabinose and a temperature 
shift from 30°C to 37°C. After induction, cells are electroporated with the linear rpsL-neo counter-
selection/selection cassette (PCR product) flanked by homology arms (hm). Red/ET recombination inserts 
rpsL-neo into the target locus. Only colonies carrying the modified BAC are kanamycin resistant and 
streptomycin sensitive. pRedET persists in cells grown at 30°C. (Step 3 and 6) pRedET is induced by L-
arabinose and a temperature shift from 30 °C to 37 °C. After induction, cells are electroporated with the PCR 
product containing the MBS (step 3) or (GAA)6 (Step 6), flanked by homology arms. Red/ET recombination 
replaces the rpsL-neo cassette by the non-selectable DNA. Only colonies which lost the selection/counter-
selection cassette are streptomycin resistant. pBAC-FXN-GAA-MS2-Luc was generated from pBAC-FXN-
GAA-Luc (steps 1-3). pBAC-FXN-GAA-MS2-Luc was used to generated pBAC-FXN-MS2-Luc (steps 4-6). 
110 
 
The pBAC-FXN-GAA-MS2-Luc was engineered from the pBAC-FXN-GAA-Luc 
vector. In the first step, a PCR product containing the rpsL-neo cassette flanked by 55 bp 
homology arms to either side of exon 2 was used to insert the cassette (Fig. 4.4A). After 
purification, the PCR product (Fig. 4.4B) was transformed into bacteria containing the 
pBAC-FXN-GAA-Luc construct. Successful recombinants were resistant to 
chloramphenicol (from the BAC vector) and kanamycin (from rpsL-neo), but sensitive to 
streptomycin (from rpsL-neo) (Fig. 4.4.C). Correct insertion of the rpsL-neo cassette was 
confirmed by colony-PCR (Fig. 4.4D), PCR (Fig. 4.4E) and restriction enzyme digestion 
followed by pulsed-field gel electrophoresis (Fig. 4.4G). Preservation of the GAA repeat 
expansion was assessed by colony-PCR and PCR (Fig. 4.4D and F). Before the beginning 
of the second step of homologous recombination, persistence of pRed/ET in successful 
recombinants was analysed by restriction enzyme digestion (Fig. 4.4H). 
The replacement of the rpsL-neo cassette in the second step of recombination by 24 
MBS in exon 2 was performed as follows. A plasmid containing exon 2 with an engineered 
BamHI restriction site and long flanking homology arms (147 bp upstream and 172 bp 
downstream of exon 2) was used to increase the efficiency of recombination. The 24 MBS 
were excised by BamHI/BglII digestion from pCR4-24XMS2SL-stable (Bertrand et al, 
1998) and inserted in exon 2 at the BamHI site (Exon2-MBS) (Fig. 4.5). The rpsL-neo 
cassette was replaced with a PCR product containing the Exon2-MBS sequence flanked by 
homology arms, generating pBAC-FXN-GAA-MS2-Luc (Fig. 4.6). Successful 
recombinants were resistant to chloramphenicol (from the BAC vector) and streptomycin 
(from replacing rpsL-neo). Correct insertion of the 24 MBS cassette was confirmed by 
colony-PCR, PCR, restriction enzyme digestion followed by pulsed-field gel 
electrophoresis, and sequencing. Preservation of the GAA repeat expansion was assessed 
by colony-PCR and PCR (Fig 4.6D-F). 
To generate pBAC-FXN-MS2-Luc, the ~310 GAA repeats in intron 1 of pBAC-FXN-
GAA-MS2-Luc were replaced by the rpsL-neo cassette amplified with primers carrying 58 
bp homology arms to sequences immediately upstream and downstream of GAA repeats 
(Fig. 4.7). The rpsL-neo was then replaced with a PCR product containing 6 GAA repeats 
amplified from the genomic DNA of a healthy-derived lymphoblastoid cell line 
(GM15851) (Fig. 4.8). Successful construction was confirmed by colony-PCR, restriction 
enzyme digestion followed by pulsed-field gel electrophoresis, and sequencing.  
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Figure 4.4 Insertion of rpsL-neo into exon 2 of the FXN-GAA-Luc gene by homologous recombination. 
(A) Schematic representation of insertion of the rpsL-neo cassette into exon 2 of the FXN-GAA-Luc. The 
rpsL-neo cassette was amplified by PCR using long primers containing homology sequences (hm) to exon 2 
in pBAC-FXN-GAA-Luc. (B) The PCR product containing the rpsL-neo cassette flanked by 55 bp homology 
arms to either side of exon 2 was purified and transformed into bacteria containing the pBAC-FXN-GAA-Luc 
construct. (C-D) Fifty colonies were tested for: resistance to chloramphenicol and kanamycin (C – top) and 
sensitivity to streptomycin (C –bottom); presence of left (D – top) and right rpsL-neo junctions (D – middle) 
and full size of the GAA repeat expansion (D – bottom) by colony-PCR (only results from the first 25 
colonies screened are shown). Arrows indicate successful recombinants with all the correct elements. (E-G) 
Ten successful recombinants were further tested by PCR of the left, right junctions and whole rpsL-neo (E) 
and presence of ~310 GAA repeats (F), BAC integrity was analysed by NotI and BsiWI digestion (G) C- is 
pBAC-FXN-GAA-Luc. (H) Persistence of pRed/ET was analysed by EcoRI digestion. 
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Figure 4.5 Construction of Exon2-MBS for homologous recombination. (A) Schematic representation of 
Exon2-MBS construction. pExon2-BamHI carries FXN exon 2 with an engineered BamHI restriction site and 
flanking homology arms (147 bp upstream and 172 bp downstream of exon 2) containing 3’ FXN intron 1 
and 5’ intron 2, respectively, for subsequent homologous recombination. The 24 MBS were excised by 
BamHI/BglII digestion from pCR4-24XMS2SL-stable and inserted in exon 2 at the BamHI site (Exon2-
MBS). (B) To insert the MBS cassete into the BamHI site of pExon2-BamHI, pExon2-BamHI was linearised 
by BamHI digestion and the MBS was excised from pCR4-24XMS2SL-stable by BamHI/BglII digestion. (C) 
Successful insertion of the MBS cassette was confirmed by colony-PCR. (D) Correct orientation of the MBS 
cassette was confirmed by colony-PCR. Several bands appear as the reverse primer binds to the repeated 
sequence of the MBS only when the insert is in the correct orientation. Arrows are positive colonies. 
 
Cre-loxP mediated retrofitting of pBAC-FXN-MS2-Luc and pBAC-FXN-GAA-MS2-
Luc vectors to pH-FRT-Hy was performed as previously described (Lufino et al, 2007). 
The pH-FRT-Hy plasmid contains the Flp-In promoter-less hygromycin cassette necessary 
to generate stable human clonal cell lines by site-specific integration of BAC vectors using 
the Flp-In system and a lacZ gene (Fig 4.9A). Successful recombinants were confirmed by 
restriction enzyme digestion followed by pulsed-field gel electrophoresis (Fig. 4.9B). 
Finally, the integrity of all BAC constructs was confirmed by PCR and restriction 
enzyme digestion followed by pulsed-field gel electrophoresis, specifically the presence of 
all exons and full length GAA repeats and MBS sequences (Fig. 4.10). 
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Figure 4.6 Replacement of the rpsL-neo cassette by 24 MBS in the second round of homologous 
recombination. (A) Schematic representation of insertion of 24 MBS into exon 2 of the pBAC-FXN-GAA-
Luc. The rpsL-neo cassette was replaced by a PCR product with 24 MBS flanked by long homology arms 
containing exon 2, 3’ FXN intron 1 and 5’ intron 2. (B) Amplification of Exon2-MBS by PCR was optimised 
to obtain the full PCR product for homologous recombination. Arrow indicates the optimal annealing 
temperature. (C) Two strategies for homologous recombination were followed: Exon2-MBS fragment was 
obtained by PCR following optimised conditions as in (A) and BstZ17I digestion. Fragments were purified 
and transformed into bacteria containing the pBAC-FXN-GAA-rspLneo-Luc construct obtained in Figure 4.4. 
(D) One thousand and five hundred colonies resistant to chloramphenicol and streptomycin were tested for 
the presence of the left MBS junction by colony-PCR (left). Positive colonies were then tested for the full 
length MBS (middle) and GAA repeats (right) by colony-PCR. Arrow indicates the only successful 
recombinant (colony 5.33) with all the correct elements. BAC, pBAC-FXN-GAA-Luc; C-, pBAC-FXN-GAA-
rspLneo-Luc. (E) Colony 5.33 was further tested by PCR of the left, right junctions and whole MBS, and 
presence of ~310 GAA repeats. (F) BAC integrity was analysed by NotI and BsiWI digestion.  
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Figure 4.7 Insertion of rpsL-neo into intron 1 of the FXN-GAA-MS2-Luc gene to generate FXN-MS2-
Luc by homologous recombination. (A) Schematic representation of insertion of the rpsL-neo cassette into 
intron 1 of the FXN-GAA-Luc. The rpsL-neo cassette was amplified by PCR using long primers containing 
homology sequences (hm) to the regions flanking the GAA repeat sequence in pBAC-FXN-GAA-Luc. (B) 
The PCR product containing the rpsL-neo cassette flanked by 58 bp homology sequences to the regions 
immediately upstream and downstream of GAA repeats was purified and transformed into bacteria 
containing the pBAC-FXN-GAA-MS2-Luc construct. (C) Forty-eight colonies were tested for resistance to 
chloramphenicol and kanamycin (top) and sensitivity to streptomycin (bottom). Red arrows indicate a colony 
resistant to streptomycin which probably carries a mutated rpsL-neo cassette. The remaining colonies carry a 
functional rpsL-neo cassette. (D) Presence of left (left), right rpsL-neo junctions (middle) and full size rpsL-
neo cassette. (right) was analysed by colony-PCR. (E) BAC integrity was analysed by NotI and BsiWI 
digestion. BAC is pBAC-FXN-GAA-MS2-Luc. 
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Figure 4.8 Replacement of the rpsL-neo cassette by 6 GAA repeats in the second round of homologous 
recombination. (A) Schematic representation of insertion of 6 GAA repeats into intron 1 of the FXN-GAA-
MS2-Luc to generate FXN-MS2-Luc. The rpsL-neo cassette was replaced by a PCR product with 6 GAA 
repeats flanked by long homology arms. (B) The PCR product containing 6 GAA repeats flanked by 
homology sequences to the regions immediately upstream (195 bp) and downstream (225 bp) of GAA 
repeats. The fragments were purified and transformed into bacteria containing the pBAC-FXN-rspLneo-MS2-
Luc construct obtained in Figure 4.7. (C) Colonies resistant to chloramphenicol and streptomycin were tested 
for the presence of GAA repeats (top) and full length MBS (bottom) by colony-PCR. Positive colonies were 
then tested for the full length MBS (middle) and GAA repeats (right) by colony-PCR. BAC, pBAC-FXN-
GAA-MS2-Luc. (D) BAC integrity was analysed by NotI, BsiWI, AatII, NruI and PvuI digestion.  
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Figure 4.9 Cre-loxP mediated retrofitting of pBAC-FXN-MS2-Luc and pBAC-FXN-GAA-MS2-Luc 
vectors to pH-FRT-Hy. (A) pBAC-FXN-MS2-Luc and pBAC-FXN-GAA-MS2-Luc were retrofitted with pH-
FRT-Hy, which contains a FRT site, a promoter-less hygromycin cassette and a lacZ gene, by Cre-mediated 
recombination between loxP sites. (B) Integration of a single copy of pH-FRT-Hy produces a 19.35 kb 
fragment after NotI digestion. 
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Figure 4.10 Confirmation of successful construction of the pBAC-FXN-MS2-Luc and pBAC-FXN-
GAA-MS2-Luc vectors from pBAC-FXN-Luc and pBAC-FXN-GAA-Luc. (A) Schematic representation 
of the pBAC-FXN-MS2-Luc and pBAC-FXN-GAA-MS2-Luc vectors. Each vector carries either six or ~310 
GAA repeats in intron 1, respectively, an array of 24 MBS in exon 2 and expresses a FXN-luciferase fusion 
protein. For stable cell line generation, vectors were retrofitted with pH-FRT-Hy to insert a promoter-less 
hygromycin cassette. (B) Insertion and sizing of GAA repeats and MBS cassette by PCR analysis. (C) BAC 
integrity was confirmed by NotI and AatII digestion followed by pulsed-field gel electrophoresis. (D) 
Presence of all exons in the constructs was analysed by PCR. 
 
4.2.2 Transient expression of the FXN-MS2-Luc constructs 
Quantification of the effect of ~310 GAA repeats on FXN-GAA-MS2-Luc expression 
was achieved by transient expression in HEK 293 cells. Successful transfection of pBAC-
FXN-MS2-Luc and pBAC-FXN-GAA-MS2-Luc was confirmed by LacZ staining (Fig. 
4.11A). Expression throughout each transgene was analysed by RT-PCR using primers 
hybridising with the MBS and Luciferase sequences (Fig. 4.11B). Exogenous transcript 
was detected in both pBAC-FXN-MS2-Luc and pBAC-FXN-GAA-MS2-Luc transfected 
118 
 
cells when compared with untransfected HEK cells, demonstrating that the insertion of the 
MBS cassette does not disrupt transcription of the transgene and confirming the 
physiological relevance of these constructs. The effect of the ~310 GAA repeat expansion 
in the pBAC-FXN-GAA-MS2-Luc construct was analysed by qRT-PCR and Luciferase 
assay, yielding a similar transgene repression as obtained with the pBAC-FXN-GAA-Luc 
(Chapter 3) (Lufino et al, 2013). FXN-GAA-MS2-Luc mRNA levels were reduced by 49% 
(Fig. 4.11C) and frataxin protein levels by 45% (Fig. 4.11D) when compared with the 
pBAC-FXN-MS2-Luc construct. 
 
Figure 4.11 Transient expression of the FXN-MS2-Luc vectors in HEK293 cells. (A) Successful 
transfection of pBAC-FXN-MS2-Luc and pBAC-FXN-GAA-MS2-Luc into HEK 293 cells was confirmed by 
LacZ staining. (B) Vector expression was analysed by RT-PCR using two different sets of primers 
hybridising upstream and downstream of the MBS, and from exon 4 to 5a-luciferase. GAPDH mRNA 
expression was used as control. (C-D) Expanded GAA repeats caused a significant reduction in FXN-GAA-
MS2-Luc mRNA (C) and protein (D) levels, as determined by unpaired two-tailed Student’s t-test (*P < 0.05, 
**P < 0.01). Data are mean ± SEM (n = 3). 
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4.2.3 Imaging optimisation 
Single-cell detection of mRNAs synthesised from an MBS-tagged allele can be 
performed by imaging fixed or living cells. In fixed cells, RNA FISH is performed using a 
probe that hybridises to the MBS sequence, allowing detection and quantification of single 
mRNA molecules transcribed from the transgene. In live-cell imaging, nascent mRNA 
molecules are detected in vivo as they are synthesised by the RNAPII and as the MBS is 
bound by MCP-YFP fusion proteins, allowing time-lapse and transcription kinetics studies 
(Yunger et al, 2010, 2013). 
A positive control (pHGCX-Ex2-MS2) was engineered to optimise the RNA FISH 
and imaging conditions in fixed cells. To generate pHGCX-Ex2-MS2, the PCR product 
containing the Exon2-MBS sequence – described in the previous section to insert the MBS 
cassette into pBAC-FXN-GAA-MS2-Luc – was inserted in the multiple cloning site of the 
pHGCX vector. The resulting pHGCX-Ex2-MS2 construct encoded an Exon2-MS2-GFP 
fusion protein expressed under the control of a CMV promoter (Fig 4.12). HEK 293 cells 
were transiently transfected with pHGCX-Ex2-MS2 while using the pHGCX plasmid as a 
negative control. GFP expression in both conditions allowed visual identification of all 
cells carrying either plasmid using a widefield epifluorescent microscope (Fig. 4.13). 
Transcription of CMV-Ex2-MS2-GFP was analysed by RNA FISH using a probe 
hybridising to the MBS sequence. Single mRNA molecules were identified as sharp 
signals above non-specific MS2 fluorescence HEK cell background only in cells 
containing the pHGCX-Ex2-MS2 plasmid. 
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Figure 4.12 Construction of pHGCX-Ex2-MS2 as a positive control for MS2 RNA FISH. 
(A) Schematic representation of insertion of Ex2-MBS into the multiple cloning site (MCS) of pHGCX to 
generate pHGCX-Ex2-MS2, which encodes an Exon2-MS2-GFP fusion protein expressed under the control 
of a CMV promoter. (B) pHGCX was linearised by EcoRV digestion and Exon2-MBS was excised from 
pEx2-MBS by BstZ17I digestion. Fragments were ligated and transformed into E. coli. (C) Successful 
insertion of the MBS cassette was confirmed by colony-PCR. (D) Insertion and correct orientation of Ex2-
MBS was confirmed by BamHI/BsrGI digestion. Arrows indicate insert in the correct orientation. 
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Figure 4.13 MS2 imaging optimisation in fixed HEK 293 cells. Detection of CMV-Ex2-MS2-GFP mRNA 
molecules by RNA FISH. MS2-tagged mRNA molecules were identified as sharp dots above background of 
non-specific fluorescence using an MS2-Cy3 probe (pseudocoloured red in merged image) in HEK 293 cells 
transfected with pHGCX-Ex2-MS2. GFP expression (pseudocoloured green) allowed identification of 
transfected cells. pHGCX was used as a negative control since no MS2-tagged mRNA was expressed. Nuclei 
were identified by DAPI staining (psudocoloured blue). Images are maximum intensity projections of z-
stacks covering the signals. Scale bar 2 µm.  
 
To optimise live-cell imaging conditions, HEK FRT cells were transiently co-
transfected with the MCP-YFP and either pBAC-FXN-MS2-Luc or pBAC-FXN-GAA-MS2-
Luc. Two version of the MCP-YFP were used: MCP-YFP-NLS and NES-YFP-MS2-NLS. 
The original MCP-YFP contains a nuclear localisation signal (NLS) resulting in the 
nuclear sequestration of unbound fluorescent coat protein molecules in the nucleus, and 
thus reduction of the cytoplasmic background signal. This facilitates single mRNA 
detection in the cytoplasm, which is specially suitable for studies of cytoplasmic 
localisation and dynamics of mRNAs (Bertrand et al, 1998; Fusco et al, 2003), but may 
obstruct mRNA detection in the nucleus because the background is too strong. To improve 
signal-to-noise ratio, the NES-YFP-MS2-NLS (referred throughout the text as MCP-YFP) 
containing a nuclear export signal (NES) to balance out the NLS was used, resulting in a 
low background throughout the whole cell and allowing nuclear events to be monitored 
(Ben-Ari et al, 2010). Expression of this improved MCP-YFP protein in cells containing 
the MBS-tagged RNA led to the fluorescent labelling and detection of active transcription 
sites in real-time via specific binding between the MCP-YFP protein and the MBS-RNA 
stem-loops (Fig. 4.14). Within the cell population carrying either pBAC-FXN-MS2-Luc or 
pBAC-FXN-GAA-MS2-Luc, some cells presented bright spots in the nucleus that could be 
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followed over time (Fig. 4.14; movie 1 and 2). Cells expressing only the MCP-YFP protein 
did not present any nuclear spots. 
 
 
Figure 4.14 Live-cell imaging optimisation in HEK FRT cells. Live-cell fluorescence movie frames taken 
at indicated times showing nascent FXN transcripts in living HEK FRT cells after transient co-transfection of 
pBAC-FXN-MS2-Luc and pBAC-FXN-GAA-MS2-Luc vectors with MCP-YFP. HEK FRT cells transfected 
with only MCP-YFP were a negative control. Cells were captured as 3D stacks every 2 minutes, for 4 hours. 
Arrows indicate transcription spots. Images are maximum intensity projections of 3D stacks. Scale bar 5 µm. 
 
4.2.4 Generation of stable FXN-MS2-Luc cell lines 
Several stable human clones of FXN-MS2-Luc and FXN-GAA-MS2-Luc were 
generated by transfecting HEK FRT cells with either pBAC-FXN-MS2-Luc or pBAC-FXN-
GAA-MS2-Luc, respectively. The Flp-In recombination system uses the Flp recombinase 
and site-specific recombination to promote the integration of pBAC-FXN-MS2-Luc or 
pBAC-FXN-GAA-MS2-Luc into a specific FRT site in chromosome 1 of HEK FRT cells 
(Fig. 4.15A). These stable cell lines carried a single copy of each vector in the same 
integration site (Fig. 4.15B-E), allowing a direct single-allele comparison of normal and 
expanded FXN loci. I selected FXN-MS2-Luc clone 2 and FXN-GAA-MS2-Luc clone 22 
(referred to throughout the text as FXN-MS2-Luc and FXN-GAA-MS2-Luc, respectively) 
for the following studies, as these best represented the average reduction in FXN mRNA 
(Fig. 4.16A) and protein levels (Fig. 4.16B) in screened clones. The ~310 GAA repeat 
expansion in the FXN-GAA-MS2-Luc cell line recapitulates the characteristic FXN gene 
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repression seen in FRDA by altering the FXN epigenetic landscape (Chapter 3) and 
reducing FXN mRNA levels by 62% and frataxin protein levels by 52% (Fig. 4.16).  
 
 
Figure 4.15 FXN-MS2-Luc and FXN-GAA-MS2-Luc cell models to study FXN localisation and 
expression. (A) Schematic representation of the pBAC-FXN-MS2-Luc and pBAC-FXN-GAA-MS2-Luc 
vectors integrated in an FRT site in chromosome 1 of HEK FRT cells. (B) Single-copy clones were identified 
by real-time PCR using UpGAA primers normalised by GAPDH. Data are relative to HEK FRT, which 
contains three endogenous copies. Data are mean ± SEM (n = 3). (C) Site-specific vector integration in 
single-copy FXN-MS2-Luc and FXN-GAA-MS2-Luc clones was confirmed by PCR using primers targeting 
the PSV40 promoter and the hygromycin cassette. (D-E) Insertion and sizing of GAA repeats (D) and MBS 
cassette (E) was determined by PCR analysis in pBAC-FXN-MS2-Luc, pBAC-FXN-GAA-MS2-Luc, single-
copy FXN-MS2-Luc and FXN-GAA-MS2-Luc clones. (C-E) Vertically sliced images are juxtaposed lanes that 
were non-adjacent in the same agarose gel. 
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Figure 4.16 Expression of FXN-MS2-Luc mRNA and protein in FXN-MS2-Luc cell lines. (A) FXN-MS2-
Luc mRNA expression was determined by qRT-PCR using qFXN-Luc primers in single-copy clones (left). 
One-way analysis of variance (ANOVA) with Tukey's multiple comparisons test showed a significant 
reduction in FXN-GAA-MS2-Luc mRNA levels (****P < 0.0001). Data are mean ± SEM (n = 3). The 
average of FXN-MS2-Luc mRNA expression in all single-copy clones (right) showed a significant reduction 
in FXN-GAA-MS2-Luc mRNA levels, as determined by unpaired Student’s t-test (**P < 0.01). Data are mean 
± SEM (n = 3). (B) Luciferase assay showed a significant reduction in FXN-MS2-luciferase protein levels in 
FXN-GAA-MS2-Luc cells. Data were expressed as relative light units (RLU) and normalised to total cell 
protein (left). Data are mean ± SEM (n = 3). **P < 0.01, ***P < 0.001, ****P < 0.0001, as determined by 
One-way ANOVA with Tukey's multiple comparisons test. The average of FXN-MS2-Luciferase protein 
levels in all single-copy clones (right) showed a significant reduction in FXN-GAA-MS2-Luc, as determined 
by unpaired Student’s t-test (*P < 0.05). Data are mean ± SEM (n = 3). 
 
4.2.5 GAA repeat expansion increases FXN-GAA-MS2-Luc positioning at the NL 
FXN transgene localisation in FXN-MS2-Luc and FXN-GAA-MS2-Luc lines was 
determined by immunofluorescence in situ hybridisation (Immuno-FISH), using co-
localised probes for the vector backbone and FXN loci to distinguish the transgene from 
the three additional endogenous FXN loci present in each clone (Fig. 4.17A). The FXN 
transgene was found at the NL in ~44% of FXN-GAA-MS2-Luc cells compared to only 
~10% of FXN-MS2-Luc cells. Treatment with the HDAC inhibitors nicotinamide and 
compound 106 – previously shown to upregulate FXN expression and increase histone 
acetylation levels and DNAse I accessibility at the expanded FXN locus in FRDA patient 
cells (Xu et al, 2009; Chan et al, 2013) – repositioned only FXN-GAA-MS2-Luc away from 
the NL (Fig. 4.17B), but increased transgene FXN mRNA levels in both cell lines (Fig. 
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4.17C), suggesting a complex interplay between FXN repression and intranuclear 
localisation. 
 
Figure 4.17 The expanded GAA repeat FXN transgene associates with the NL more frequently in an 
FXN-GAA-MS2-Luc cell model. (A) 3D Immuno-FISH detection of FXN-MS2-Luc and FXN-GAA-MS2-
Luc association with the NL (pseudocoloured white in merged image). Transgenes were identified by co-
localisation of FISH signals from FXN loci (green) and the vector backbone (red) in FXN-MS2-Luc and FXN-
GAA-MS2-Luc cells (left). Nuclei were identified by DAPI staining (blue). Arrows show endogenous (white) 
and transgene (red) alleles. Comparison of the proportion of transgenes contacting the NL showed a 
significant difference in FXN-MS2-Luc and FXN-GAA-MS2-Luc cells (right) (****P < 0.0001, as determined 
by Fisher's two-tailed exact test, n = 140 cells per condition). Data are mean ± SEM from two independent 
FISH experiments. Association of FISH signals with the NL was analysed using ImageJ: image stacks were 
analysed manually and association was determined by eye when FXN FISH signals were touching or 
superimposing the NL signal at a given z-section. Images are maximum projections of z-stacks covering the 
signals. Scale bar 2 µm. (B) Treatment with nicotinamide (10 mM) or compound 106 (10 µM) for 48 hours 
significantly decreased FXN-GAA-MS2-Luc interaction with NL (**P < 0.01, ***P < 0.001, ****P < 0.0001, 
as determined by Fisher's two-tailed exact test, n = 140 cells per condition). Data are mean ± SEM from 2-3 
independent FISH experiments. (C) FXN-MS2-Luc mRNA expression after incubation with HDACi for 48 
hours was determined by qRT-PCR using qFXN-Luc primers. Data were normalised to GAPDH mRNA 
levels. Results are relative to FXN-MS2-Luc DMSO. Two-way ANOVA with Sidak’s correction test showed 
a significant difference in the two cell lines when comparing with the DMSO control of each line (*P < 0.05, 
**P < 0.01). Data are mean ± SEM from three independent experiments. 
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4.2.6 GAA-expanded repeats decrease the number of FXN mRNA molecules and 
slow transcription kinetics in single FXN-GAA-MS2 cells 
To further understand FXN repression, the transcriptional output of individual 
transgenic FXN alleles in FXN-MS2-Luc and FXN-GAA-MS2-Luc cells was analysed by 
RNA FISH using a probe hybridising to the MBS sequence as optimised in section 4.2.3. 
Single FXN-MS2-Luc mRNA molecules were identified as sharp signals above non-
specific fluorescence HEK cell background in accordance with previous studies 
demonstrating single-molecule resolution of this technique (Fig. 4.18A and C) (Fusco et al, 
2003; Raj et al, 2008; Yunger et al, 2010). The insertion of the MBS in exon 2 led to the 
identification of all fluorescence spots as mature FXN mRNA molecules, considering 
transcription sites were not distinguishable. No difference was detected in the percentage 
of cells expressing the transgene (Fig. 4.18B). FXN-GAA-MS2-Luc cells contained ~5 ± 2 
mRNAs per cell, and FXN-MS2-Luc cells contained ~9 ± 4 mRNA per cell (Fig. 4.18C), 
therefore ~310 GAA repeats reduce the number of mature mRNA molecules by 44% at 
single-cell level. This quantification is in agreement with oligonucleotide array assays 
previously showing the majority of mRNAs are present at <10 copies per cell (Lockhart & 
Winzeler, 2000).  
I then followed the kinetic behaviour of FXN-MS2-Luc and FXN-GAA-MS2-Luc 
transcription using four-dimensional time-lapse imaging and fluorescence recovery after 
photobleaching (FRAP) (Yunger et al, 2010). Nascent transcripts were detected as 
fluorescent spots as they were bound by MCP-YFP fusion protein and visualised in real-
time. Active transcription sites were detected in both cell lines over long periods of time 
using a widefield fluorescent microscope, albeit in only a subset of cells. Given the 
constant expression of FXN-MS2-Luc and FXN-GAA-MS2-Luc, no pulsing activity was 
detected (Fig. 4.19; Movie 3 and 4). 
Recovery of fluorescence indicates new transcripts are actively synthesised at the 
transcription site (Fig. 4.20A; Movie 5 and 6). FRAP curves showed that the time required 
to reach steady state after photobleaching was different between the two cell lines. FXN-
MS2-Luc cells showed half-time of recovery (t1/2) = 12.90 s with full recovery = 120 s (Fig. 
4.20B and Movie 5), whereas FXN-GAA-MS2-Luc cells showed slower kinetics t1/2 = 48.10 
s with full recovery = 260 s (Fig. 4.20B; Movie 6). Since I found no difference in FXN 
mRNA stability in FXN-GAA-MS2-Luc and FXN-GAA-MS2-Luc cells (Fig. 4.20C) (Punga 
& Bühler, 2010), RNA FISH and FRAP data indicate that the GAA expansion decreases 
the amount of FXN-GAA-MS2-Luc mRNA molecules by impeding RNAPII transcription 
127 
 
initiation and/or elongation. However, I could not distinguish between the two events given 
the placement of the MBS in exon 2, where the FRAP readout is obtained. 
 
Figure 4.18 The GAA repeat expansion reduces FXN-GAA-MS2-Luc transcriptional output in fixed 
FXN-GAA-Luc cells. (A) RNA FISH spot intensity histogram of FXN-MS2-Luc (left) and FXN-GAA-MS2-
Luc (right) showing all measurements resulting in a Gaussian distribution with a mean that represents the 
most likely fluorescence signal of a single molecule. The lower tail of this distribution represents noise due to 
aggregates of the MS2 FISH probe and the high-value tail represents mRNA aggregations. RNA particles 
contained only single copies of FXN-MS2-Luc RNA in FXN-MS2-Luc cell lines (n = 34). Curves show a one-
component Gaussian fit. (B) Proportion of FXN-MS2-Luc and FXN-GAA-MS2-Luc cells (n = 63 cells per 
line) with ≥1 RNA FISH signals were identical. Data are mean ± SEM from two independent FISH 
experiments. (C) Quantification of FXN-MS2-Luc mRNA molecules in FXN-MS2-Luc and FXN-GAA-MS2-
Luc cells by RNA FISH. FXN-MS2-Luc mRNA molecules were identified as sharp dots (arrows) above 
background of non-specific fluorescence using an MS2-Cy3 probe (red in merged images) in FXN-MS2-Luc 
(top images) and FXN-GAA-MS2-Luc (bottom images) cells. Non-linear regression curve fit comparison 
showed a significant difference between the distribution of FXN-MS2-Luc mRNA molecules in FXN-MS2-
Luc and FXN-GAA-MS2-Luc cells (P < 0.0001, (F = 33.31, d.f. = 3, 21), n = 63 cells per line) (right). Images 
are maximum projections of Z stacks covering the signals. Scale bar 2 µm. 
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Figure 4.19 Real time visualisation of FXN-MS2-Luc and FXN-GAA-MS2-Luc transcription. Nascent 
FXN-MS2-Luc (top) and FXN-GAA-MS2-Luc (bottom) mRNA were detected as fluorescent spots as 
transcripts were bound by MS2-YFP fusion protein. Exposure: 30 ms; cells were captured as 3D stacks every 
2.5 minutes, for 50 minutes. The displayed images are maximum-projected z-stacks taken at indicated times. 
Scale bar 5 µm. 
 
To elucidate the link between FXN localisation and repression, I analysed the 
fluorescence intensities of active transgenes in living FXN-MS2-Luc and FXN-GAA-MS2-
Luc cells. The fluorescence intensity of transcription sites was significantly lower when 
transgenes were expressed at the nuclear periphery (NP) compared to the interior in both 
FXN-MS2-Luc and FXN-GAA-MS2-Luc cells (Fig. 4.20D). This indicates that both FXN 
transgenes express when localised at the NP, although they do so at lower levels. When 
compared to active FXN-MS2-Luc transgenes, spot intensity of FXN-MS2-GAA-Luc 
transgenes was significantly lower only in the nuclear interior. Taken together with data 
from Fig. 4.17A, these data suggest that expanded GAA repeats increase FXN-GAA-MS2-
Luc positioning at the NL, where expression levels are reduced when compared to the 
nuclear interior or with FXN-MS2-Luc expression levels in the nucleoplasm.  
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Figure 4.20 The GAA repeat expansion reduces FXN-GAA-MS2-Luc transcriptional output and 
impedes transcription in living FXN-GAA-Luc cells. (A) Live-cell fluorescence movie frames taken before 
and at indicated times after photobleaching of the transcription site. Scale bar 2 µm. (B) FRAP recovery 
curves and fitted exponential curves show a difference in transcription kinetics (P = 0.0048, (F = 4.434, d.f. = 
3, 210), n = 5 cells per line). (C) Degradation of FXN-MS2-Luc mRNA was analysed by qRT-PCR using 
qFXN-Luc primers in FXN-MS2-Luc and FXN-GAA-MS2-Luc cells after treatment with Actinomycin D for 
24 hours. Data were normalised to β-actin mRNA. Comparison of fitted exponential decay curves shows no 
difference between the two cell lines (P = 0.5979, (F = 0.6351, d.f. = 3, 32). FXN-MS2-Luc mRNA half-life 
was ~4h. Data are mean ± SEM (n = 3). (D) Quantification of fluorescence intensities of active transgenes in 
living FXN-MS2-Luc and FXN-GAA-MS2-Luc cells. Spot intensity of active FXN transgenes above MS2-
YFP background was significantly lower in the nuclear interior in FXN-GAA-MS2-Luc cells when compared 
to FXN-MS2-Luc cells (***P < 0.001), and significantly lower when alleles were expressing at the periphery 
than in the nuclear interior in the two cell lines, as determined by one-way ANOVA with Sidak’s multiple 
comparisons test (****P < 0.0001, *P < 0.05, n = 15 cells per line). 
 
4.3 Discussion 
NL-associated chromatin at the NP is mostly transcriptionally inactive and enriched 
in repressive histone modifications, such as H3K9me2 and H3K27me3 (Kind & van 
Steensel, 2010). Although it is still unclear if gene positioning affects transcription, 
chromatin remodelling is sufficient to induce nuclear reorganisation (Therizols et al, 
2014). It is generally assumed that GAA expansion–mediated epigenetic changes in FXN 
locus can reduce FXN mRNA levels in averaged cell samples though a poorly understood 
mechanism. Working for the first time at the single-cell level, the work described in this 
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Chapter identifies the NL as a novel player in FXN transcriptional impairment. I show that 
expanded GAA repeats increase FXN positioning at the NL, where HDACs can 
deacetylase histones and help repress gene activity. A marked increase in FXN-GAA-MS2-
Luc positioning at the NL with a proportional reduction in the number of FXN-GAA-MS2-
Luc mRNA molecules suggests that expanded transgene localisation at the NL leads to 
FXN impairment and silencing. The mechanism of retention at the NL of these expanded 
repeat structures is highly sensitive to HDAC inhibition. FXN transcription from both 
normal and expanded transgenes is upregulated by restoring acetylation by similar 
amounts, yet results in significant movement from the NL of only the expanded alleles. 
However, the expanded alleles are unable to achieve the same level of upregulation as their 
normal counterparts. This could be the result of a different extent of histone acetylation 
achieved by normal and expanded alleles following treatment with HDAC inhibitors, 
which could be caused by reduced accessibility of compacted FXN alleles. However, the 
observed difference in FXN upregulation could also imply that other structural changes 
such as R-loop formation contribute to transcriptional dysregulation and that the trigger 
event is induced by structural and epigenetic changes to the DNA followed by an increased 
likelihood of retention at the NL. 
Using the MS2 system, I show that active FXN-GAA-MS2-Luc alleles present 
impaired transcription kinetics in living single cells. It would be possible to further dissect 
the FXN impairment by using the dual-labelling system with MS2 and PP7 cassettes in 
different regions of the expanded FXN locus. Alternatively, isogenic cell clones in which 
the FXN-GAA-MS2 transgene is always integrated into the same genomic FRT site, but 
containing the MS2 cassette in different locations throughout the gene could be generated 
to compare different RNAPII transcription rates. 
Variability in gene expression has been linked to dynamic changes in the state of 
chromatin taking place locally at the gene locus, leading to a probabilistic promoter switch 
between active and inactive state (Coulon et al, 2013). Time-lapse experiments did not 
reveal bursting activity either in the normal or expanded transgene. Given that FXN 
expression is essential for life (Cossée et al, 2000), it could be speculated that the 
constitutive expression of the FXN locus observed here may resemble that of housekeeping 
genes, where polymerases fire individually (Coulon et al, 2013). 
Further studies in healthy and FRDA patient-derived cells discussed in Chapter 5, 
will elucidate the link between expanded FXN positioning at the NL and GAA-mediated 
transcriptional repression. 
  
 
 
 
 
 
 
 
CHAPTER 5 
FXN gene nuclear localisation and expression in 
healthy, carrier and FRDA patient-derived cells 
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5.1 Introduction 
Expanded DNA repeats can have a broader impact on nuclear structure and induce an 
abnormal association of expanded genes or mRNA with certain nuclear compartments. For 
example, in DM1, patient-derived fibroblasts exhibit altered localisation of the nuclear 
envelope proteins emerin and lamins A/C and B1 with concomitant increased size and 
altered shape of nuclei (Rodríguez et al, 2015). Moreover, there is evidence of nucleoli 
distortion in DM1 fibroblasts (Rodríguez et al, 2015). Another study reports that CUG- 
expanded DMPK mRNA foci accumulate at the periphery of nuclear speckles, blocking a 
stage in the mRNA export pathway (Holt et al, 2007). In C9ORF72-related FTD/ALS, 
patient cells present nucleolar stress due to the binding of nucleolin, an essential protein of 
the nucleolus, to the GGGGCC repeat-containg RNA transcripts (Haeusler et al, 2014).  
During recent years, the epigenetic changes occurring at the expanded FXN locus, 
such as increased DNA methylation at specific CpG sites (Greene et al, 2007; Al-Mahdawi 
et al, 2008; Castaldo et al, 2008; Evans-Galea et al, 2012), reduced histone acetylation 
(H3/H4ac) and increased levels of methylated histones H3K9me2 and H3K9me3 (Herman 
et al, 2006; Al-Mahdawi et al, 2008), have become the target of potential therapies for 
FRDA. In this Chapter, I aim to uncover a higher level of regulation of FXN repression by 
analysing the interactions of the expanded FXN locus with nuclear components required 
for expression activation or silencing within the nuclear organisation.  
 
5.1.1 Nuclear organisation  
The eukaryotic nucleus is a membrane-bound organelle that separates gene 
transcription from protein translation in the cytoplasm. Within the interphase nucleus, 
chromosomes occupy discrete and non-random territories. In flat-ellipsoidal nuclei, e.g. 
fibroblasts, there is a correlation between the location of chromosome territories (CTs) and 
the size of chromosomes, with larger chromosomes positioned towards the nuclear interior 
and smaller chromosomes sitting close to the NP (Bolzer et al, 2005). However, gene 
content seems to play a major role in CT determination. In spherical nuclei, e.g. 
lymphoblasts, gene-rich chromosomes occupy a more central position, whereas gene-poor 
chromosomes are at the NP (Boyle et al, 2001). 
Studies indicate that the radial positioning of a gene within the nucleus correlates 
with its transcriptional output, but whether a gene is transcribed due to its position, or its 
position is determined by its transcriptional state, is the subject of current research (Dillon, 
2008; Takizawa et al, 2008b; Ferrai et al, 2010a; Therizols et al, 2014). Gene expression 
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usually takes place in the nucleoplasm where distinct, but highly dynamic specialised 
nuclear compartments exist (reviewed in Spector, 2006; Zhao et al, 2009; Qureshi & 
Mehler, 2010). These heterogeneous structures can dynamically assemble and disassemble, 
associate with specific genomic loci, interact with chromatin, move, and undergo other 
changes to support cellular processes. Live-cell imaging shows that chromatin movements 
are generally constrained around the nucleoli and NP and more mobile in the nucleoplasm 
(Chubb et al, 2002), where chromosome intermingling occurs via extended chromatin 
loops (Branco & Pombo, 2006) and genes can interact with various nuclear bodies, 
including but not limited to transcription factories, nuclear speckles, paraspeckles, Cajal 
bodies, promyelocytic leukemia (PML) nuclear bodies and nucleoli (Fig. 5.1). 
 
 
Figure 5.1 Nuclear organisation. Illustration of the mammalian nucleus showing the spatial organisation of 
nuclear compartments.  
 
5.1.1.1 Nuclear compartments involved in gene expression 
Multiple transcription factories can be observed within the nucleus and are composed 
of many active RNA polymerases and associated transcription factors where nascent RNA 
is synthesised (Iborra et al, 1996). Active genes were shown to be dynamically relocated 
and simultaneously transcribed by a shared transcription factory (Osborne et al, 2004). 
Two types of transcription factories have been described: “poised transcription factories” 
and “active transcription factories” depending on the phosphorylation state of RNAPII, 
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leading to the idea that association of genes with poised factories can rapidly induce gene 
activation in response to specific stimuli (Ferrai et al, 2010b).  
Nuclear speckles act as storage/assembly/modification compartments that can supply 
splicing factors to active transcription sites. These highly dynamic structures are enriched 
in components of the pre-mRNA splicing machinery, including small nuclear 
ribonucleoprotein particles (snRNPs), spliceosome subunits, and other non-snRNP protein 
splicing factors. Speckles can be detected throughout the nucleoplasm as 20-50 irregular 
shapes varying in size close to active transcription sites (reviewed in Spector & Lamond, 
2011). Active genes have been found surrounding nuclear speckles (Shopland et al, 2003; 
Brown et al, 2006). For example, the active allele of the monoallelically expressed glial 
fibrillary acidic protein (GFAP) gene was shown to associate with speckles in 70% of 
cells, while the inactive allele did not (Takizawa et al, 2008a). Furthermore, clustering of 
coordinately expressed erythroid genes can be found at the same nuclear speckle (Shopland 
et al, 2003; Brown et al, 2008). Although there is a tight correlation between expressing 
genes and nuclear speckles, this association is not mandatory for transcription and pre-
mRNA splicing. 
Paraspeckles are discrete ribonucleoprotein bodies implicated in the regulation of 
mRNA nuclear export. These structures form around the long non-coding RNA NEAT1 
and contain the protein complexes PSF/SFPQ, P54NRB/NONO and PSPC1 in a 
transcription-dependent manner (Fox et al, 2002). Although not actively involved in 
transcription, paraspeckles may form in association with active genes and coordinate gene 
expression by ensuring the nuclear retention of certain mRNAs (reviewed in Bond & Fox, 
2009). For example, the hyperedited CTN-RNAs escape nuclear export and are efficiently 
retained in the nucleus, where the majority localise to the paraspeckles. Under stress 
conditions, CTN-RNA is post-transcriptionally cleaved to produce protein-coding mCAT2 
mRNA and rapidly exported into the cytoplasm (Prasanth et al, 2005). 
Cajal bodies are involved in pre-mRNA splicing, pre-rRNA processing, histone pre-
mRNA 3′ end processing, and telomere maintenance implicating them in the biogenesis of 
RNA-processing complexes. They have also been implicated in the biogenesis of several 
classes of spliceosomal snRNPs and are enriched in RNA polymerase subunits, specific 
basal transcription factors, RNA processing factors, and p80/coilin protein. Their number 
and size vary throughout the cell cycle and are responsive to cell stress and levels of gene 
transcription (reviewed in Qureshi & Mehler, 2010; Dundr, 2012). 
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PML bodies are heterogeneous macromolecular protein complexes composed of 
PML protein and a variety of other proteins, including Sp100, SUMO-1, Daxx, pRB, p53, 
and BLM, suggesting a role in the regulation of many cellular processes, such as control of 
cell proliferation, DNA repair, apoptosis, and viral infection. These structures have also 
been shown to associate with gene-dense, transcriptionally active chromatin regions, 
including the major histocompatibility complex class I gene cluster region and the p53 
gene locus, for which PML bodies were proposed to modulate chromatin architecture and 
transcription (reviewed in Bernardi & Pandolfi, 2007). A stably integrated gene locus was 
shown to interaction with PML bodies in living cells, but ongoing transcription appeared 
independent of PML body association (Tsukamoto et al, 2000). Furthermore, analysis of 
multiple genomic regions showed that PML bodies associated with genomic regions with 
high transcriptional activity, but did not directly regulate transcription of these genes 
(Wang et al, 2004). The exact molecular mechanism leading to PML-mediated 
transcriptional regulation needs further elucidation. 
The nucleolus forms around chromosomal loci of tandemly repeated rDNA gene 
clusters (called the NORs – nucleolus organiser regions) and is the site of rRNA 
transcription, processing, and ribosome subunit export (McStay & Grummt, 2008). Active 
NORs present an open chromatin conformation and are transcribe by RNAPI. On inactive 
NORs, rDNA appears in a heterochromatic state indistinguishable from the surrounding 
heterochromatin (called perinucleolar heterochromatin), and lack associated RNAPI and 
RNAPI–specific factors.  
 
5.1.1.2 Nuclear compartment involved in gene repression 
Heterochromatin containing repressed genes is usually found surrounding the 
nucleolus and the NP.  
The nucleolus was discussed in the previous section as a transcription factory 
involved in ribosomal biogenesis. However, the perinucleolar heterochromatin surrounding 
the nucleolus is composed of satellite DNA that surrounds NORs, and silent rDNA 
clusters. Furthermore, there is evidence that the perinucleolar heterochromatin can 
establish and maintain silencing of non-rDNA-related genomic regions (McStay & 
Grummt, 2008). For example, in 80-90% of nuclei of synchronised female mouse 
fibroblasts, following X chromosome pairing, the inactive X chromosome is targeted to the 
perinucleolar region and establishes Xist ncRNA-dependent contacts with the nucleolus 
(Zhang et al, 2007). 
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Genomic DNA interactions with the NP can actively contribute to gene repression 
(Finlan et al, 2008; Reddy et al, 2008; Zullo et al, 2012). However this is not a general 
phenomenon (Finlan et al, 2008; Kumaran & Spector, 2008), rather is gene-specific, and 
may depend on multiple parameters such as transcription factor accessibility, promoter 
strength, existence of insulator elements and pre-existing chromatin marks, which may 
counteract the mechanisms underlying transcription repression. The NL tends to be in 
contact with heterochromatin and is associated with markers of gene repression, such as 
enrichment in histone modifications H3K9me2 and H3K27me3 and depletion of activating 
histone marks and RNAPII occupancy (reviewed in Kind & van Steensel, 2010). This 
nuclear compartment is further discussed in section 5.1.2.  
 
5.1.2 Gene regulation at the NP 
Breakthrough studies suggested that the intranuclear position of a gene could affect 
its expression after measuring the radial position of a locus and analysing the association of 
low gene-density and late-replicating regions with the NP (Croft et al, 1999; Boyle et al, 
2001; Chubb et al, 2002; Bolzer et al, 2005). 
Different components of the NP have distinct roles in transcriptional regulation. The 
nucleus and cytoplasm communicate via channels in the nuclear envelope, called nuclear 
pore complexes, which promote bidirectional exchange of proteins, RNAs and 
ribonucleoproteins. In animal cells, the inner nuclear membrane (INM) is structurally 
supported by the NL, a meshwork of intermediate filament proteins composed of lamins 
and lamin-associated proteins. Localisation to nuclear pores can be correlated with 
decondensed chromatin and transcriptional activation of genes, while the NL is associated 
with heterochromatin and linked to the repression of genes and repetitive sequences (Kind 
& van Steensel, 2010; Padeken & Heun, 2014). 
Several studies support that the NP, and in particular the NL, represents a repressive 
environment for gene expression. Most genes whose activity is linked to differentiation 
and development transition from a peripheral nuclear position to the nuclear interior upon 
their activation. Examples include IgH and β-globin during B cell and erythroid cell 
differentiation, respectively (Kosak et al, 2002; Ragoczy et al, 2006), and genes of the 
hoxB cluster during development (Chambeyron & Bickmore, 2004). By analysing the two 
alleles of the monoallelically expressed GFAP gene within the same nucleus, Takizawa 
and colleagues showed that the active allele is generally found more internally when 
compared with its inactive counterpart (Takizawa et al, 2008a). 
138 
 
However, studies artificially targeting genomic regions to the NP showed conflicting 
results. In one approach, tethering of a reporter gene to emerin, a protein of the INM, 
resulted in its transcriptional repression (Reddy et al, 2008). Finlan and colleagues tethered 
human chromosomes to LAP2β, another protein of the INM, and showed that this could 
reversibly repress the expression of some endogenous genes, but not others (Finlan et al, 
2008). Finally, in a third approach, a genetic locus was targeted to the NL in living 
mammalian cells, allowing visualisation of transcription in real-time at the NP upon 
transcriptional induction (Kumaran & Spector, 2008). Varying effects may be due to 
experimental differences, but may also reflect different microenvironments and chromatin 
heterogeneity at the NP. However, these studies indicate that, although the NP is generally 
considered a transcriptionally repressive environment, microdomains of the INM/NL that 
are transcriptionally permissive may exist (Zhao et al, 2009). 
 
5.1.2.1 The NL as a repressive compartment 
Mammalian cells express four main lamins: A and C, which are splicing variants 
encoded by the LMNA gene; and B1 and B2 encoded by the LMNB1 and LMNB2 genes, 
respectively. Lamin filaments are important for the assembly, structure, shape, and 
mechanical stability of the nucleus. They also play a role in the regulation of chromatin 
organisation and gene expression. Several transmembrane proteins are also part of the NL. 
INM proteins containing the LEM domain (Lap2β, Emerin and MAN1) interact with a 
range of transcriptional regulators. MAN1 interacts with R-Smads, germ-cell-less (GCL), 
Barrier to autointegration factor (BAF) and BCL-2 associated transcription factor (BTF). 
Emerin interacts with BAF, BTF, GCL, HDACs, the nuclear corepressor (NCoR) complex 
and with β-catenin. Lap2β binds lamin B, chromatin, GCL and HDACs (reviewed in 
Wilson & Foisner, 2010). 
Genome-NL interactions were mapped using the DamID technology, in which 
genomic regions that are in molecular contact with the NL become adenine methylated (a 
modification unknown to higher eukaryotes) due to expression of a fusion protein 
consisting of E. coli DNA adenine methyltransferase (Dam) and Lamin B1 (Guelen et al, 
2008). Mammalian genomes contain about 1100–1400 lamina-associated domains (LADs), 
which are regions of ~0.1–10 Mb that specifically associate with the NL. LADs are 
relatively gene-poor, have a repressive chromatin signature, are often demarcated by 
specific sequence elements, such as binding sites for the insulator protein CTCF, and are 
transcriptionally inactive (Fig. 5.2). 
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Figure 5.2 Illustration of genome-NL interactions in mammalian cells. Chromatin associated with the NL 
is marked by specific histone modification, such as H3K9me2 and H3K27me3, and is mostly composed of 
inactive genes. LADs are bordered by CTCF and possibly by other proteins. NL and nuclear pore complexes 
(NPCs) form different microenvironments. ONM, outer nuclear membrane; LBR, Lamin B receptor (adapted 
from Kind & van Steensel, 2010).  
 
The mechanisms that promote LAD-NL interactions are still poorly understood. 
Recent studies suggest that specific DNA sequences can be recognised by NL-associated 
DNA-binding proteins. Analysis of two mouse LADs showed enrichment in (GA)n repeats. 
The transcriptional repressor cKrox could bind this repeated motif and tether them to the 
NL by forming a complex with HDAC3 and Lap2β (Zullo et al, 2012). However, (GA)n 
repeats may not be globally enriched in LADs, indicating that other NL-targeting 
sequences may exist (Guelen et al, 2008). In mammals, constitutive LADs, which are 
present in all cell types, are characterised by long stretches of DNA of high A/T content 
(Meuleman et al, 2013). 
Not only DNA sequence, but also local chromatin properties can provide recognition 
sites to NL interactions. In human cells, LAD-NL interactions are linked to transcriptional 
repression and H3K9me2, and are regulated by the H3K9 methyltransferase G9a (Kind et 
al, 2013). Both H3K9me2 and H3K9me3 were found to be involved in the NL-targeting of 
the human beta-globin locus (Bian et al, 2013). Furthermore, treatment with HDAC 
inhibitors can dissociate mammalian genes from the NP and upregulate their expression 
(Finlan et al, 2008). 
140 
 
It seems that whether the association of a locus with the NL favours, represses or 
does not affect transcription will depend on the chromatin environment of the locus, how it 
is recruited to the NL and how it is positioned relative to various nuclear neighbourhoods 
(Takizawa et al, 2008b). 
 
5.1.3 Aims of this Chapter 
Reporter transgenes are a powerful tool to reveal mechanisms of gene expression, 
however the local environment of the integration site may influence their expression 
(Akhtar et al, 2013), interfere with their nuclear positioning and their ability to sit outside 
of their CTs and contact with sequences from other chromosomes (Brown et al, 2006, 
2008).  
The FXN-MS2-Luc cell lines (Chapter 4) are an invaluable tool to study the interplay 
between FXN localisation and expression at the single-cell level. However, FXN-MS2-Luc 
and FXN-GAA-MS2-Luc transgenes are integrated in chromosome 1. In this Chapter, I 
analyse the nuclear localisation of GAA expanded FXN alleles in their native chromatin 
environment in chromosome 9, and how their position relative to nuclear compartments is 
able to impact on FXN repression. Furthermore, I analyse whether GAA expansion-
mediated relocation of the FXN locus to the NL plays a role in FRDA. Here, I investigate 
the link between expanded FXN positioning at the NL and GAA-mediated transcriptional 
repression in FRDA patient-derived cells. Finally, I elucidate the effect of the mutation at 
the initiation and elongation stages of FXN transcription at single-cell resolution. 
 
5.2 Results 
 
5.2.1 Expanded FXN alleles localise preferentially close to the NP in carrier cells 
I first analysed FXN localisation in its native genomic environment in carrier-derived 
lymphoblastoid cells (GM14519) carrying 9 and 1285 GAA repeats in each FXN allele, 
respectively. Each carrier cell exhibited a 55% reduction in mRNA compared to healthy 
cells (Fig. 5.3). Co-detection of a DNA probe for FXN with a (GAA)15 or (TTC)15 oligo 
signal allowed discrimination of the expanded allele and a direct intracellular comparison 
of the normal and the expanded FXN allele, with distance measurements for each allele to 
the NP by 2D (Fig. 5.4A) and 3D (Fig. 5.4B) FISH (Meaburn & Misteli, 2008; Takizawa 
et al, 2008a). I found the expanded FXN allele localised preferentially closer to the NP 
than the normal allele.  
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Figure 5.3 FXN mRNA expression in healthy, carrier and FRDA patient-derived cells. FXN mRNA 
expression was determined by qRT-PCR using FXN primers. Data were normalised to β-actin. *P < 0.05, 
**P < 0.01, as determined by one-way ANOVA with Tukey's multiple comparisons test. Data are mean ± 
SEM (n = 3). 
 
5.2.2 FXN gene positioning relative to nuclear subdomains in carrier cells  
To further analyse the observed difference in nuclear positioning, I then assessed 
FXN association with specific nuclear subdomains known to either (i) suggest the 
transcriptional status of a gene, such as nuclear SC35-enriched speckles and CTs, or (ii) 
interact with heterochromatin, such as the nucleolus and the NL (Shopland et al, 2003; 
Chambeyron & Bickmore, 2004; Brown et al, 2006; Zhang et al, 2007; Reddy et al, 2008; 
Zhao et al, 2009). FXN never looped out of chromosome 9 nuclear territory in 2D FISH 
experiments (Fig. 5.5A), demonstrating that this does not account for the observed 
difference in nuclear localisation. I found no evidence suggesting the expanded and normal 
FXN alleles associated differently with nuclear speckles (Fig. 5.5B) or with 
heterochromatin surrounding nucleoli (Fig. 5.5C). However, when I analysed FXN 
positioning at the NL, I found an increased number of expanded FXN alleles contacting 
with the NL when compared with the normal allele (Fig. 5.5D). Taken together, these data 
suggest GAA repeat expansions increase FXN positioning at the NL in carrier-derived 
cells.  
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Figure 5.4 Expanded FXN alleles localise closer to the NP in carrier cells. Each allele was detected with a 
DNA probe for FXN (green in merged image) and the expanded allele was identified by co-localisation with 
a (GAA)15 or (TTC)15 oligo signal (red) (left). Nuclei were identified by DAPI staining (blue). Arrows 
indicate normal (white) and expanded (red) alleles. (A) 2D FISH analysis showed that the expanded FXN 
allele (1285+50 GAA repeats) localised preferentially closer to the NP than the wild-type (WT) (9 GAA 
repeats) (*P = 0.0153, as determined by Wilcoxon matched-paired two-tailed test; data are mean ± SEM 
from three independent hybridisations, n = 147). (B) 3D FISH analysis confirmed the results obtained by 2D 
FISH (*P = 0.0254, as determined by Wilcoxon matched-paired two-tailed test; data are mean ± SEM from 
three independent hybridisations, n = 107). (A-B) Distance measurements between FISH signals and the NP 
were measured and normalised by the local ray between the nuclear centre and periphery passing through the 
FISH signal (right). Images are maximum projections of Z stacks covering the signals. Scale bar 2 µm. 
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Figure 5.5 Expanded FXN allele preferentially sits at the NL in carrier cells. Each allele was detected 
with a DNA probe for FXN (green in merged image) and the expanded allele was identified by co-
localisation with a (GAA)15 or (TTC)15 oligo signal (red) (left). Nuclei were identified by DAPI staining 
(blue). Arrows indicate normal (white) and expanded (red) alleles. (A) FXN (white) did not loop out of 
chromosome 9 territories (green) in 2D FISH experiments. Data are mean ± SEM, n =136 cells from three 
independent hybridisations. (B) 3D Immuno-FISH detection of FXN (green) association with nuclear SC35-
enriched speckles showed no significant difference between alleles, as determined by Fisher's two-tailed 
exact test (P = 0.4942, n = 86 cells from two independent hybridisations). (C) 3D Immuno-FISH detection of 
FXN association with the nucleoli showed no significant difference between alleles, as determined by Fisher's 
two-tailed exact test (P = 0.3607, n = 156 cells from two independent hybridisations) (D) 3D Immuno-FISH 
detection of FXN association with the NL (pseudocoloured white). Comparison of the proportion of alleles 
contacting with the NL revealed the mutation induced a significant increase in co-localisation with the NL, as 
determined by Fisher's two-tailed exact test (***P = 0.0005). Data are mean ± SEM from two independent 
hybridisations (n = 166). Images are maximum projections of z-stacks covering the signals. Association of 
FISH signals with subnuclear domains or chromosome territories was analysed using ImageJ: image stacks 
were analysed manually and association was determined by eye when FXN FISH signals were touching or 
superimposing the signal from a specific subnuclear domain at a given z-section. Scale bar 2 µm. 
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5.2.3 NL is a key player in FXN transcriptional impairment and silencing 
I next analysed FXN localisation at the NL in healthy (GM15851) and patient-
derived cells (GM16209) using Immuno-FISH (Fig. 5.6A). The patient cell line contains 2 
FXN alleles carrying 800 GAA repeats each and was chosen to avoid differing behaviour 
of each locus due to different repeat size. Eight-hundred GAA repeats decreased mRNA 
levels by ~83% (Fig. 5.3). The distribution of cells with FXN FISH signals contacting with 
the NL was significantly different in the 2 cell lines (Fig. 5.6B). I found one or both FXN 
alleles localised at the NL in a small proportion of healthy cells (~37% and ~14%, 
respectively), with ~49% of cells containing both FXN alleles in the nucleoplasm. In 
contrast, the majority of FRDA cells presented both or one allele contacting with the NL 
(~43% and ~36%, respectively), with only 21% of FRDA cells containing both FXN alleles 
in the nucleoplasm. When data were analysed at allele level instead of cell level, ~60% of 
expanded FXN alleles were found at the NL compared to only ~33% of normal FXN alleles 
(Fig.5.6B). These data suggest the GAA expansion increases the probability of an allele to 
be found at the NL in FRDA cells, in agreement with results obtained with FXN-GAA-
MS2-Luc (Fig. 4.17A) and carrier cells (Fig. 5.5D). 
To further dissect FXN repression, I analysed nascent FXN RNA synthesis at a 
single-cell level, using probes hybridising with the upstream region of the GAA repeats 
(Fig. 5.6C). Figure 5.6D shows ~46% of healthy cells contained 2 FXN alleles expressing, 
and ~30% and ~24% of cells with either one or no expressing FXN alleles, respectively. I 
found a higher proportion of FRDA cells (51%) containing both FXN alleles not 
expressing, followed by ~27% and ~22% of cells with either one or both FXN alleles 
expressing, respectively. Analysing these data at allele level instead of cell level, I found 
~61% of normal FXN alleles were active compared to only ~35% of expanded FXN alleles 
(Fig. 5.6D). These data suggest the mutation increases the probability of an allele being 
silenced. Collectively, data from Figures 4.17A, 4.18C, 4.20D, 5.5D, 5.6B and 5.6D 
indicate a clear link between expanded FXN positioning at the NL and GAA-mediated 
transcriptional repression. Furthermore, these results confirm the existence of biological 
variability within cell populations and highlight the importance of single-cell studies 
(Levsky & Singer, 2003).  
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Figure 5.6 GAA repeat expansion increases FXN localisation at the NL, reduces the number of active FXN alleles and 
downregulates transcription from active FXN in FRDA cells. (A) 3D Immuno-FISH detection of FXN loci association with 
the NL in healthy (top images) and patient-derived (bottom images) cells. Each allele was detected with a DNA probe for FXN 
(green in merged image), and the NL was detected with an antibody for Lamin B1 (white). Nuclei were identified by DAPI 
staining (blue). Arrows indicate alleles. Association of FISH signals with the NL was analysed using ImageJ: image stacks were 
analysed manually and the association was determined by eye when FXN FISH signals were touching or superimposing the 
signal from the NL at a given z-section. (B) Histogram (left) showing the distribution of cells with FXN FISH signals contacting 
with the NL was significantly different in the two cell lines, as determined by Chi-squared test (P < 0.0001, χ2 = 63.056, d.f. = 
2). When data were analysed at allele level instead of cell level (right), the proportion of FXN alleles positioned at the NL is 
significantly different when comparing the localisation of the expanded and normal FXN alleles (****P < 0.0001, as determined 
by Fisher’s two-tailed exact test). (C) Schematic representation showing the relative position to TSS and labelling of the DNA 
oligo probe set used in nascent RNA FISH experiments. (D) Nascent RNA FISH detection of FXN expression in healthy and 
patient-derived cells (top). Each allele was detected with a mix of 41 DNA oligos hybridizing with the region upstream of the 
GAA repeats (pseudocoloured red in merged image). Histogram (bottom left) showing the distribution of cells with RNA FXN 
FISH signals was significantly different in the two cell lines, as determined by Chi-squared test (P < 0.0001, χ2 = 75.424, d.f. = 
2). When data were analysed at allele level instead of cell level (bottom right), the proportion of active FXN alleles is 
significantly different when comparing the expanded and normal FXN alleles (****P < 0.0001, as determined by Fisher’s two-
tailed exact test). Data are mean ± SEM from three independent hybridizations (n = 187–202 cells). (E) Nascent RNA FISH 
detection of FXN expression in healthy and patient-derived cells (top) showing different signal intensities of internal versus 
peripheral nascent RNA loci. Detection was performed as described in (D). Box plot (bottom) showing the RNA FISH spot 
intensity of active FXN alleles above the threshold was significantly lower in the interior and at the periphery in FRDA versus 
healthy nuclei (****P < 0.0001) and significantly lower when alleles were expressing at the periphery than in the nuclear 
interior in the two cell lines, as determined by one-way ANOVA with Tukey’s multiple comparisons test (****P < 0.0001, n = 
245 signals). Images are maximum projections of z-stacks covering the signals. Scale bar: 2 µm. 
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To further elucidate the interplay between the repressive environment at the NL and 
FXN repression, I analysed RNA FISH spot intensities from active FXN alleles in Figure 
5.6D as an indication of the quantity of transcript being synthesized at each transcription 
site relative to its interior or peripheral nuclear position (Fig. 5.6E). The signal variability 
of the technique was assessed by comparing RNA FISH intensities between replicates. 
Spot intensities were comparable among replicates (Fig. 5.7A) and background intensity 
was not significantly different in nuclei of healthy and FRDA patient cells (Fig. 5.7B). I 
found that FXN RNA FISH spot intensity was significantly lower when FXN alleles were 
expressed in the NP compared to the interior in both healthy and FRDA cells. This 
indicates the NP was not incompatible with FXN expression, since FXN RNA FISH signals 
could be seen at the periphery in both healthy and FRDA cells, albeit at lower intensities. 
Strikingly, RNA FISH spot intensity in FRDA cells was significantly lower than in healthy 
cells both in the interior and at the periphery. When collectively considering the data in 
Figures 5.5D, 5.6B and 5.6D, several factors seem to combine to diminish transcription 
from the expanded FXN gene. The expanded FXN gene has a significantly increased 
likelihood of being positioned at the periphery (Figs. 5.5D and 5.6B) and markedly 
reduced probability of being transcribed at all (Fig. 5.6D). Crucially, when transcription 
does occur at the expanded GAA-FXN locus, it is at a significantly reduced level both in 
the nucleoplasm and especially at the periphery (Fig. 5.6E). The NP can therefore be seen 
as a generally less supportive environment for FXN transcription, but the combined effect 
of GAA expansion with peripheral relocation results in a catastrophic reduction in 
transcriptional output. 
 
Figure 5.7 Nascent FXN RNA FISH spot intensities in healthy and FRDA patient cells. (A) FXN RNA 
FISH spot intensities of active FXN alleles in Figure 4E were compared among replicates and shown no 
significant differences, as determined by one-way ANOVA. Data are mean ± SEM from three independent 
hybridisations (n = 245 signals). (B) FXN RNA FISH background intensity was not significantly different in 
nuclei of healthy and FRDA patient cells, as determined by unpaired two-tailed Student’s t-test. Data are 
mean ± SEM from three independent hybridisations (n = 245 signals). 
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5.2.4 Expanded GAA repeats impair preferentially FXN transcription initiation in 
single FRDA cells 
To analyse the effect of the GAA expansion at the initiation and elongation stages of 
FXN transcription at single-cell resolution, probes hybridising with the promoter after the 
transcription start site (TSS) and regions upstream and downstream of GAA repeats were 
included in the RNA FISH analysis (Figs. 5.8A and B). Healthy FXN alleles showed the 
expected decrease in transcription elongation throughout the analysed regions (Fig. 5.8C 
and D), confirming previous qRT-PCR analysis (Kim et al, 2011; Groh et al, 2014). 
However, when compared to healthy alleles, expanded FXN alleles showed a ~19% 
decrease in RNA levels at the TSS site, demonstrating a marked reduction in FXN 
transcription initiation (Fig. 5.8C). A ~20% decrease at the region upstream of GAA 
repeats and a ~22% decrease at the downstream region of GAA repeats were also 
observed. I then normalised the data in Figure 5.8C to exclude the effect of (i) transcription 
initiation at the TSS and (ii) elongation through the regions upstream of GAA repeats, and 
found that expanded FXN alleles showed a small but significant decrease in FXN mRNA 
synthesis only downstream and not upstream of the GAA repeat expansion when compared 
with the same regions in healthy alleles (Fig. 5.8D), demonstrating that transcription 
elongation through expanded GAA repeats is also affected. Taken together, these data 
indicate GAA repeat expansions diminish FXN mRNA synthesis predominantly by 
impairing FXN transcription initiation, but also by impairing elongation through the 
expansion. 
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Figure 5.8 GAA repeat expansion disrupts transcription initiation and elongation in FRDA cells. 
(A) Schematic representation showing the relative position to TSS and labelling of the 3 DNA oligo probe 
sets used to detect transcription initiation and elongation in RNA FISH experiments. (B) FXN RNA FISH 
detection of transcription initiation after the TSS (probe set in green) and elongation through the regions 
upstream (pseudocoloured red) and downstream (pseudocoloured white) of the GAA repeats. Nuclei were 
identified by DAPI staining (blue). Arrows indicate alleles. Images are maximum projections of Z stacks 
covering the signals. Scale bar 2 µm. (C) Data were normalised to the TSS of healthy cells. When compared 
to the same region in healthy alleles, expanded FXN alleles showed a ~19% decrease at the TSS, a ~20% and 
a ~22% decrease at the regions upstream and downstream of GAA repeats, respectively. This data 
demonstrates GAA repeat expansions reduce FXN transcription initiation by 19% and elongation downstream 
of expanded GAA repeats by 3% (*P = 0.0119, **P = 0.003, ****P < 0.0001, as determined by Fisher's two-
tailed exact test, n = 218-226 cells per line). Data are mean ± SEM from three independent FISH 
experiments. (D) Data of each line in (C) were normalised to their TSS, thus excluding the effect of 
transcription initiation (left) and elongation through the region upstream of GAA repeats (right). Expanded 
FXN alleles show a significant difference in the region downstream of the GAA repeats when comparing 
with the same region in healthy alleles (*P < 0.05, **P < 0.01, as determined by two-way ANOVA with 
Sidak's multiple comparisons test). Data are mean ± SEM from three independent FISH experiments. 
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5.3 Discussion 
Nuclear organisation and chromatin structure are important for the regulation of gene 
expression and, if altered, may cause disease. The genome is organised in a non-random 
manner and gene expression is regulated in specific and spatially defined sites, where 
transcription activation or repression are favoured (Misteli, 2007). In FRDA, GAA 
expansion-mediated transcriptional dysregulation occurs due to the generation of unusual 
DNA structures and epigenetic changes that induce a non-permissive chromatin 
configuration for FXN expression. In this Chapter, I used a carrier-derived cell line as a 
model to determine where GAA expanded FXN alleles are found in the nucleus at single-
cell resolution, and how their location may contribute to FXN repression.  
The observed 55% reduction in FXN mRNA in carrier cells reflects the 
transcriptional impairment of the expanded FXN when compared with the healthy allele. 
By comparing the radial position of the expanded and normal FXN, I showed that the 
expanded FXN allele occupies a different intranuclear position from the normal allele. A 
possible explanation could be that, given the expanded FXN heterochromatic state is 
coupled with gene repression, the normal FXN allele can unfold out of its chromosome 9 
territory while being transcribed. However, neither FXN alleles sit outside of chromosome 
9 territory, irrespective of their different local chromatin condensation and transcriptional 
status. Active genes can sit inside their CTs and transcribe from within domains of closed 
chromatin (Gilbert et al, 2004; Scheuermann et al, 2004). Looping out of the territory of a 
chromosome is dependent of several features of the chromatin surrounding a gene, such as 
gene density, chromatin fibre structure, transcriptional activity across the region, and 
location on the chromosome (Brown et al, 2006; Gilbert et al, 2004). The FXN locus is 
located on chromosome 9q21.11, an A/T-rich and gene-poor G-dark band close to the 
centromere (Fig. 5.9). Sitting within the CT may be a reflection of the surrounding 
chromatin context of the FXN locus rather than its transcriptional activity. Furthermore, a 
possible disruption of the localisation of chromosome 9 territory due to the presence of the 
expanded FXN allele was not readily perceptive given (i) the two chromosomes were 
indistinguishable, and (ii) the subtle movement of the expanded FXN locus when compared 
to the normal FXN allele. Moreover, the heterochromatinised GAA expansion is minute 
when compared with the whole CT and unlikely to affect the total positioning of a 
chromosome normally located peripherally. 
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Figure 5.9 Chromosome location of the FXN locus. Ideogram of the G-banding pattern of chromosome 9 
at the 850 band resolution. The FXN locus is located at 9q21.11, an A/T-rich and gene-poor G-dark band 
(taken from the NCBI Human Genome resource site). 
 
Active genes can be found associated with nuclear speckles (Shopland et al, 2003; 
Brown et al, 2006), which are distributed predominantly throughout the nucleoplasm and 
less frequently at the NP. Moreover, gene-rich chromosome bands contact more often with 
speckles than gene-poor G-dark bands. The fact that the FXN gene is on a gene-poor G-
dark band of chromosome 9, with its territory located towards the NP in lymphoblast cells 
(Boyle et al, 2001) may explain the reduced association of the FXN locus with nuclear 
speckles. 
The NL and the nucleolus are surrounded by repressive chromatin and genes located 
in their proximity are often transcriptionally inactive. Distance measurements between the 
FXN locus and the nuclear centre or periphery place the expanded FXN locus towards the 
NP and the normal allele towards the nuclear interior. FXN alleles did not contact with the 
heterochromatin surrounding nucleoli differently. In contrast, I found the expanded FXN 
allele sitting at the NL more often than the normal allele in carrier cells. This is supported 
by my previous findings indicating that expanded GAA repeats increase the contact of the 
transgene with the NL in FXN-GAA-MS2-Luc cells (Chapter 4) and demonstrates that FXN 
repositioning occurs irrespective of its chromatin environment. 
Gene repositioning is dependent on breakdown and reformation of the nuclear 
envelope during mitosis, with chromatin domain position being established early in G1 
(Thomson et al, 2004). The variation found in expanded FXN repositioning to the NL in 
carrier cells may reflect the use of unsynchronised carrier cells in this study. 
I next analysed the link between FXN localisation at the NL and FXN silencing in 
FRDA. I observed the same abnormal repositioning to the NL in FRDA patient cells and 
showed that this tightly correlates with a marked decrease in the number of actively 
expressing FXN alleles. Furthermore, those few active expanded FXN alleles located at the 
NL express at a significantly lower level than the alleles located in the interior of the 
nucleus. 
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Due to limited resolution of light microscopy, FISH experiments shown here cannot 
distinguish whether the expanded FXN allele establishes a functional molecular interaction 
with the NL that leads to FXN repression, or if it is merely in its proximity. However, 
lamina-associating sequences are enriched in an extended GA dinucleotide sequence which 
acts as an INM and NL-anchoring motif and is associated with HDACs and transcriptional 
repressors (Zullo et al, 2012). Studies suggest that GAA repeat expansions induce an 
enrichment of HP1 (De Biase et al, 2009), G9a methyltransferase (Groh et al, 2014) and 
HDACs class I (Herman et al, 2006) and III (Chan et al, 2013) on the FXN locus. 
Consistently, histones in LADs are hypoacetylated, indicating a high local HDAC activity. 
Furthermore, several NL components interact with HDACs, including Lap2β and Emerin 
(Kind & van Steensel, 2010). The results from Chapter 4, showing a significant movement 
from the NL of only the expanded FXN alleles after treatment with HDAC inhibitors, 
supports that the NL represses FXN expression partly by deacetylation of histones. The NP 
is also enriched in HP1, which may contribute to NP targeting due to its interaction with 
the LaminB receptor (Ye et al, 1997).  
A second histone modification that appears to be involved in gene regulation at the 
NL is H3K9me2. Peripheral siting of chromatin after mitosis is largely determined by a 
stochastic mechanism and directly linked to cellular or allelic variation in H3K9me2 levels 
where G9a methyltransferase acts as a regulator of NL contacts (Kind et al, 2013).  
Guenther and colleagues showed that most genes considered inactive, because they 
produce no detectable transcript, still experience transcription initiation, indicating a post-
initiation regulation (Guenther et al, 2007). Detection of FXN nascent transcript at single-
cell resolution showed that both normal and expanded FXN alleles have a decrease in 
transcription elongation throughout the locus, indicating that occasionally the RNAPII may 
initiate transcription with no production of a full-length transcript. However, here I 
showed that expanded GAA repeats impair expression predominantly at the initiation stage 
of transcription. Interestingly, there are genes, such as clusters of silent olfactory receptor 
genes, that do not experience transcription initiation and do not contain nucleosomes 
enriched in H3K4me3 (Guenther et al, 2007). These clusters form heterochromatic foci 
where expression is repressed and frequently associate with the NL (Peric-Hupkes et al, 
2010). 
  
 
 
 
 
 
 
 
CHAPTER 6 
General discussion and future directions 
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In FRDA, expanded GAA repeats in intron 1 of the FXN gene reduce steady-state 
FXN mRNA levels through a poorly understood mechanism. GAA expansion-mediated 
transcriptional dysregulation is thought to occur due to the generation of unusual DNA 
structures surrounding the GAA repeats, such as triplexes or sticky DNA (Sakamoto et al, 
1999; Bidichandani et al, 1998), R-loops (Grabczyk et al, 2007; Groh et al, 2014) and 
heterochromatin (Saveliev et al, 2003; Herman et al, 2006), which interfere with RNAPII 
elongation (Punga & Bühler, 2010; Kim et al, 2011). Although not universally accepted, 
some reports show that these epigenetic changes also spread upstream towards the FXN 
promoter, inducing a non-permissive chromatin configuration for transcription initiation, 
altering nucleosome positioning and preventing insulator protein CTCF binding (De Biase 
et al, 2009; Kumari et al, 2011; Chutake et al, 2014; Groh et al, 2014). In order to better 
understand the underlying pathogenesis and ultimately to design effective therapies for 
FRDA, it is important to generate cellular models that recapitulate the repressive hallmarks 
of the disease while providing efficient ways to quantify FXN expression. 
The FXN-GAA-Luc, FXN-Luc, FXN-GAA-MS2-Luc and FXN-MS2-Luc reporter cell 
lines, described in this Thesis, have been specifically designed to allow a direct single-
allele comparison of the effect of normal or expanded GAA repeats on FXN expression 
within the genomic context of the FXN locus. This was achieved by: i) using the whole 
FXN locus with its native promoter, introns, exons and all elements required for 
physiological transgene expression; and ii) integrating a single copy of each BAC vector 
into a specific FRT site in chromosome 1 of HEK FRT cells to exclude confounding 
effects on FXN expression due to random site of integration. However, the FXN-Luc and 
FXN-MS2-Luc models have been generated with distinct purposes. In the FXN-GAA-Luc 
cell lines, the presence of ~310 GAA repeats recapitulates the GAA repeat-mediated FXN 
repression and the epigenetic hallmarks of FRDA. Therefore, the FXN-GAA-Luc model is 
an excellent tool to study the molecular mechanisms underlying FRDA as well as 
providing a platform for the screening of FXN upregulating compounds. However, studies 
using the FXN-GAA-Luc model, similar to other FRDA reporter systems studies to date, 
only provide the probable state of the FXN gene as observations come from experiments in 
which the outputs of bulk cell cultures are averaged. Consequently, the FXN-GAA-MS2-
Luc model was generated to dissect the silencing mechanism of FRDA in situ, allowing the 
visualization and analysis of FXN localization and repression in both fixed and living 
single cells using the MS2 system.  
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Through these experiments, I demonstrate that the GAA expansion-mediated 
impairment of FXN expression is the result of a complex interplay of multiple factors 
contributing to different extents to decreased FXN transcriptional activity (Fig. 6.1). 
Among these factors I identify the NL, a location known to be a generally repressive 
environment, as a novel major player in FXN silencing in FRDA. Using a variety of 
cellular models and a multidisciplinary approach, I found a marked increase in expanded 
FXN positioning at the NL and a concomitant reduction in the number of active FXN 
alleles, suggesting that FXN localised at the NL leads to FXN silencing. I have also 
identified a small proportion of expanded FXN alleles sitting at the NL which are 
transcriptionally active, however these show significantly reduced expression when 
compared with alleles in the nuclear interior. 
In my work, I observed two distinct events affecting FXN expression. First, I 
observed that the GAA repeat expansion impairs FXN transcription regardless of FXN 
localisation in the nuclear interior or periphery. Second, although the proportion of normal 
and expanded FXN alleles positioned at the NL is remarkably different, I found that the NL 
reduces the expression of both normal and expanded FXN at the NP to a similar extent, 
demonstrating that the repressive action of the NL is irrespective of a GAA expansion. 
This leads to a consideration of the order of molecular events occurring at the expanded 
FXN locus. One of the initial steps in FXN repression is the binding of nascent FXN 
mRNA to the GAA repeat expansion as the gene is being transcribed, a feature shared with 
the CGG repeat expansion disease FRAXA (Groh et al, 2014; Colak et al, 2014). These 
RNA/DNA hybrids (R-loops) have been previously shown to form on both transgenic and 
endogenous expanded FXN loci in FXN-GAA-Luc and FRDA patient-derived 
lymphoblastoid cell lines, respectively, used in this study (Groh et al, 2014). R-loops 
impair RNAPII elongation and trigger epigenetic changes, such as H3K9me2 repressive 
marks through recruitment of G9a methyltransferase (Groh et al, 2014). The effects of 
inhibition of HDACs were interesting in this regard. FXN transcription from both normal 
and expanded alleles is upregulated by increased acetylation by similar amounts, yet I 
observe a significant movement away from the NL of only the expanded alleles. The 
mechanism of retention at the NL of these expanded repeat structures is therefore highly 
sensitive to HDAC inhibition. However, the expanded alleles are unable to achieve the 
same level of upregulation as their normal counterparts. This could be the result of a 
different extent of histone acetylation achieved by normal and expanded alleles following 
treatment with HDAC inhibitors, which could be caused by reduced accessibility of 
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compacted FXN alleles. However, the observed difference in FXN upregulation could also 
imply that other structural changes such as R-loop formation contribute to transcriptional 
dysregulation and that the trigger event is induced by structural and epigenetic changes to 
the DNA followed by an increased likelihood of retention at the NL. Further experiments 
to clarify the order of events could involve cell treatment with other compounds, for 
example DNA sequence-specific polyamides to destabilise triplexes, RNase H1 to resolve 
R-loops, and G9a inhibitors to interfere with FXN retention at the NL. Treatment with 
polyamides (Burnett et al, 2006) and RNAse H1 (Groh et al, 2014) have previously 
resulted in upreagulation of FXN expression in FRDA lymphoblastoid cells. Recent studies 
using the G9a inhibitor BIX-01294 showed a significant reduction in the levels of 
H3K9me2 chromatin mark, but no effect on FXN mRNA levels (Punga & Bühler, 2010; 
Groh et al, 2014). 
 
Figure 6.1 Model of GAA repeat-mediated FXN repression and the repressive role of NL in FXN 
transcriptional impairment. The euchromatic state of normal FXN alleles allows physiological levels of 
expression (a). Expanded GAA repeats trigger R-loop formation and locally recruit HP1 (De Biase et al, 
2009), G9a methyltransferase (Groh et al, 2014) and class I (Herman et al, 2006) and III (Chan et al, 2013) 
HDACs, causing epigenetic changes that contribute to transcriptional dysregulation (b). These GAA 
expansion-mediated structural and epigenetic changes may lead to FXN relocation to the NL—a location 
known to be a generally repressive environment and enriched in HDAC and histone methyltransferase 
activity—where further repression (c) and silencing (d) occur. ONM, outer nuclear membrane; INM, inner 
nuclear membrane; CM, cell membrane. 
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It seems plausible that, once a locus adopts an abnormal DNA structure and becomes 
modified by specific markers, it is more likely to be retained at the NL after mitosis 
(Schooley et al, 2012). There are several mechanisms that could be involved. Genome 
contacts with the NL during interphase are generally dynamic, but confined to a narrow 
zone near the NL. Peripheral siting of chromatin after mitosis is largely determined by a 
stochastic mechanism and directly linked to cellular or allelic variation in H3K9me2 levels 
where G9a methyltransferase acts as a regulator of NL contacts (Kind et al, 2013). The NP 
is enriched in heterochromatin and the presence of HP1, whose binding is promoted by 
methylation at lysine 9, may help to regulate the post-mitotic binding of INM proteins 
(Schooley et al, 2012). There are also spatial considerations. The FXN locus is located 
between two LADs — NL-interacting chromosome regions demarcated by the insulator 
protein CTCF that present heterochromatic histone modifications and low expression 
levels—in lung fibroblasts (Guelen et al, 2008) and various neural cell types (Peric-Hupkes 
et al, 2010). LAD topology has yet to be assessed in the lymphoblastoid cell lines used in 
this study, but as different cell types present remarkable LAD similarities (Peric-Hupkes et 
al, 2010), it is tempting to speculate that FXN is also in an interLAD in lymphoblastoid 
cells. Given the severe depletion of CTCF in the 5’ UTR of the expanded FXN in FRDA 
(De Biase et al, 2009), I speculate that the boundary between FXN and the LAD located 
upstream is inefficient, leading to the inclusion of expanded FXN inside the LADs and 
increased proximity to the NL, possibly through recruitment of NL-associated HDACs and 
G9a methyltransferase (Groh et al, 2014). It would be interesting to explore the LAD 
layout over this region using the DamID technology (Guelen et al, 2008) in FRDA versus 
healthy individuals, and whether interruption of the boundary CTCF elements can allow 
consolidation of the two flanking LADs. A further spatial contribution could be that even 
normal FXN can stochastically contact the NL, considering the intranuclear mobility of 
chromatin (Chubb et al, 2002) and the FXN native location on the usually peripheral 
chromosome 9. Indeed I observe that transcription from the normal allele is downregulated 
to an equivalent degree when located at the NP. FXN retention may result in a molecular 
interaction with the NL, as lamina-associating sequences are enriched in a GAGA motif 
which is bound by the transcriptional repressor cKrox associated with HDAC3 and INM 
Lap2β (Zullo et al, 2012). It would be interesting to knockdown cKrox in FRDA patient 
cells and analyse whether expanded FXN alleles at the NL relocalise to the nuclear interior. 
These events in turn could act through a positive feedback mechanism by mediating further 
impairment or silencing since the NL is enriched in HDAC and histone methyltransferase 
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activity. Given the shared features of DNA repeat expansions, I hypothesize that the NL 
may play a role in heterochromatin-mediated transcriptional dysregulation in other repeat-
expansion diseases and it would be interesting to interrogate the nuclear location of other 
repeat expansion loci.  
Although I show a marked degree of repression at the NP, one striking finding is that 
of transcriptionally active FXN alleles sitting at the NL, confirming what others have 
shown that the NP creates a repressive environment, but is not incompatible with 
expression (Finlan et al, 2008; Kumaran & Spector, 2008). These findings support the 
existence of NL heterogeneous microdomains composed of nuclear pore complexes and 
different lamin subtypes (Kind & van Steensel, 2010) able to impact differently on gene 
expression. 
It is widely accepted that expanded GAA repeats cause FXN mRNA deficiency via 
RNAPII elongation impairment. I demonstrate that expanded GAA repeats predominantly 
disrupt FXN transcription initiation at single-cell resolution, providing strong confirmation 
that the transcriptional repressive effect of the GAA repeat expansion can spread towards 
the FXN promoter (Kumari et al, 2011; Chutake et al, 2014).  
It remains undetermined how far the GAA-mediated repression can span. Indeed, 
non-coding triplet repeat expansions can mediate gene repression of other genes in cis 
(Klesert et al, 1997; Thornton et al, 1997). There is evidence suggesting that PIP5K1B is 
downregulated in FRDA lymphocytes and fibroblasts (Bayot et al, 2013). The PIP5K1B 
locus is located ~26 kb upstream of FXN and encodes phosphatidylinositol 4-phosphate 5-
kinase β type I, an enzyme functionally linked to actin cytoskeleton dynamics. This gene is 
highly expressed in the brain, but also in the heart and lungs to a lesser extent (Volpicelli-
Daley et al, 2010), thus partially overlapping with tissues where FXN is expressed 
(Campuzano et al, 1996). Two other genes, PRKACG and TJP2, are located immediately 
upstream and downstream of the FXN locus, respectively, and show no differences in 
expression in FRDA patient cells (Bayot et al, 2013). Recently, the most extensive 
genome-wide map of chromosomal interactions revealed that kidney, lung and liver 
disease-associated polymorphisms in the PIP5K1B and TJP2 loci interact with the FXN 
promoter in a lymphoblastoid cell line (GM12878), suggesting that these elements may 
potentially influence FXN regulation, either positively or negatively (Mifsud et al, 2015). 
Information on the FXN locus interaction in trans is not yet available. However, it would 
be interesting to analyse the expanded FXN localisation in FRDA-relevant tissues, such as 
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cardiomyocytes and sensory neurons, and assess expression levels of potential spatial 
FXN-interacting genes.  
Recently, a report showed that R-loops formed by the CGG expanded repeat in 
FRAXA reduces FMR1 expression via recruitment of the Polycomb group (PcG) 
complexes to the FMR1 locus (Kumari & Usdin, 2014). The PcG protein complexes are 
present in silenced genes and include Polycomb repressive complexes 1 and 2 (PRC1 and 
PRC2) (Di Croce & Helin, 2013). Interestingly, recent microarray data from neuronal cells 
(derived from FRDA patient iPSCs) revealed that the gene encoding the Polycomb group 
ring finger 2 (PCGF2) is downregulated after treatment with HDAC inhibitor 109, a potent 
inducer of FXN gene expression (Soragni et al, 2015). PCGF2 is a component of PRC1. 
PRC2 catalyses the trimethylation of H3K27, which acts as the docking site for PRC1 (Di 
Croce & Helin, 2013). Due to enrichment of the repressive hallmark H3K27me3 at the 
expanded FXN locus (De Biase et al, 2009; Kim et al, 2011; Chan et al, 2013), future work 
may explore whether the PcG proteins may also play a role in FXN silencing in FRDA.  
Here, I have focused on the nuclear location of and transcription from the expanded 
FXN gene at the single-cell level. I find an increased retention of the expanded FXN gene 
at the NL. I show that a higher proportion of expanded FXN alleles are inactive when 
compared with normal alleles and I have demonstrated reduced transcription from the 
expanded alleles that are active. I provide a single-cell quantification showing that 
expanded GAA repeats impair expression predominantly at the initiation stage of 
transcription, but also block RNAPII elongation. It is the combination of these factors 
which together reduce the levels of frataxin protein to cause disease. This Thesis provides 
new mechanistic insights into the molecular causes of FRDA which may extend to other 
genetic diseases mediated by repeat expansions within regions of non-coding DNA. 
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